



(51) International Patent Classification:

C07K 5/02 (2006.01) C07F 5/02 (2006.01)

C07D 211/60 (2006.01)

(21) International Application Number:

PCT/IB2019/052616

(22) International Filing Date:

29 March 2019 (29.03.2019)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

P.425077 29 March 2018 (29.03.2018) PL

62/649,752 29 March 2018 (29.03.2018) US

(71) Applicant: ONCOARENDI THERAPEUTICS S.A.

[PL/PL]; Żwirki i Wigury 101, 02-089 Warszawa (PL).

(72) Inventors: BŁASZCZYK, Roman; Pienista 41c/29,

94-109 Łódź (PL). GZIK, Anna; Spółdzielcza 16,

99-220 Wartkowice (PL). BOREK, Bartłomiej; Myśli-

wska 17/20, 93-519 Łódź (PL). DZIĘGIELEWSKI,

Marek; Wyszyńskiego 59/16, 94-047 Łódź (PL). JE-

DRZEJCZAK, Karol; Mielczarskiego 4/23, 91-067 Łódź

(PL). NOWICKA, Julita; Srebrzyńska 3B, 95-070 Wola

Grzymkowska (PL). CHRZANOWSKI, Jacek; Legionów

38/17, 90-702 Łódź (PL). BRZEZIŃSKA, Joanna; Rysia

14/2, 91-503 Łódź (PL). GOŁĘBIOWSKI, Adam; 96

Windsor Court, Madison, Connecticut CT 06 443 (US). OL-

CZAK, Jacek; Gołębia 1/3, 66, 90-340 Łódź (PL). GRZY-

BOWSKI, Marcin Mikołaj; Jesionowa 1/3, 98-100 Łask

(PL). PEČZKOWICZ-SZYSZKA, Jolanta; Batalionów

Chłopskich 87a/75, 01-307 Warszawa (PL).

(74) Agent: KICIAK, Krzysztof; Nowoursynowska 162J,

02-776 Warszawa (PL).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,

CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,

DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,

HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,

KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,

MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,

OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,

SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,

TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH,

GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,

UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,

(54) Title: DIPEPTIDE PIPERIDINE DERIVATIVES

(57) Abstract: The disclosure relates to pharmaceutical compositions, to methods of preparing such compositions, and to methods for using such compositions for treating or preventing a disease or condition associated with arginase activity.



WO 2019/186497 A1

DIPEPTIDE PIPERIDINE DERIVATIVES

BACKGROUND OF THE INVENTION

Cross-Reference to Related Application

- 5 **[0001]** This application claims priority to U.S. Provisional Application No. 62/64,9752, filed March 29, 2018, and to Polish Patent Application No. P.425077, filed March 29, 2018, the disclosures of which are hereby incorporated by reference in their entirety.

Field of the Invention

- 10 **[0002]** The disclosure relates to small molecule therapeutic inhibitors of arginase 1 and arginase 2.

Description of Related Art

- 15 **[0003]** Two arginase isozymes, arginase 1 and arginase 2 (denoted also as ARG1 and ARG2) exist in mammals. Both enzymes catalyze the same biochemical reaction (hydrolysis of L-arginine into L-ornithine and urea), but they differ in cellular expression level, regulation and subcellular localization. ARG1 is a cytosolic protein and ARG2 is mainly localized in mitochondria.

- 20 **[0004]** The arginases are implicated in various pathological states. These include, without limitation: asthma, pulmonary hypertension, hypertension, T cell dysfunction, erectile dysfunction, atherosclerosis, renal disease, ischemia reperfusion injury, neurodegenerative diseases, wound healing, inflammatory diseases, fibrotic diseases and cancer.

- 25 **[0005]** Arginase expression and L-arginine depletion is known as an important immune-suppressive pathway of the mammalian immune system. L-arginine deficiency down-regulates expression of T cell receptor (TCR) ζ chain, a key signaling element of the TCR, thereby impairing T cell function. Depletion of L-arginine from the tumor microenvironment

leads to an arrest in T cell cycle progression, inhibition of IFN- γ production, and blocking of signaling through the T cell receptor.

[0006] Arginases are mainly produced by myeloid-derived suppressor cells (MDSC) that are highly enriched in the tumor-bearing state. Induction of the arginase pathway is an important mechanism involved in the evasion of the anti-tumor immunity. High arginase activity has been observed in patients with various malignancies, both in blood and within tumor mass.

[0007] It was shown that T cell functions are restored and tumor growth is inhibited upon inhibition of arginase produced by tumor-associated MDSCs or tumor-infiltrating CD11b⁺Gr-1⁺ mature myeloid cells in various murine tumor models. Depletion of the myeloid suppressor cells re-establishes T cell activation regulated by TCR and costimulatory signals.

[0008] Arginase was shown to participate in the suppression of tumor-infiltrating lymphocytes in patients with prostate carcinoma, non-small cell lung carcinoma and multiple myeloma. Not only MDSC but also dendritic cells (DCs) have been shown to suppress CD8⁺ T cells and antitumor immune responses through ARG1 production.

[0009] The pathological role of arginase was also revealed in sickle cell disease (SCD), which is an L-arginine deficiency syndrome. Since ARG1 is present in human erythrocytes, in SCD patients it is aberrantly released in active form into plasma resulting in the impaired metabolism of L-arginine. Moreover, arginase together with hemoglobin, both released during the intravascular hemolysis, cause an abnormally high NO consumption leading to the diminished NO bioavailability. Clinically, the hemolysis and altered L-arginine metabolism contribute to the development of various SCD-related complications, i.e.: endothelial dysfunction, vaso-occlusion, pulmonary hypertension, priapism, cutaneous leg ulceration, stroke, renal dysfunction, asthma, and – ultimately – early mortality. Hence, arginase inhibitors represent a group of very promising drug candidates for the treatment of SCD.

[0010] Given the role of arginase in various pathological states and their role in chronic inflammation and suppression of anti-tumor immunity, the present invention provides novel boron-containing compounds as inhibitors of arginase activity, as well as methodologies for using these compounds as therapeutics.


5 **[0011]** Numerous boron-containing arginase inhibitors are well-known from the literature. One of such inhibitors is 2(*S*)-amino-6-boronohecanoic acid, as described in WO 99/19295A1, published on April 22, 1999 (incorporated by reference), and in WO 08/061612A1, published on May 29, 2008 (incorporated by reference). Besides, WO 11/133653, published on October 27, 2011 (incorporated by reference), and WO 13/059437,
10 published on April 25, 2013 (incorporated by reference), describe a number of alpha-amino acid derivatives bearing a terminal B(OH)₂ group and a spacer, usually being a 1,3-cyclobutylene moiety. Mono- or polycyclic boron-containing amino acid compounds suitable as arginase inhibitors are described in WO 12/058065, published on May 3, 2012 (incorporated by reference). Other related patent application publications are WO 10/085797
15 of July 29, 2010 (incorporated by reference), WO 13/158262 of October 24, 2013 (incorporated by reference), and WO 12/091757 of June 5, 2012 (incorporated by reference).

[0012] Significance of the substitution at the alpha center of 2-amino-6-boronohecanoic acid for the inhibitory potency of arginase 1 and arginase 2 inhibitors has been discussed.

[0013] There is a need to investigate the inhibition of arginases, and to discover
20 treatments for conditions associated with elevated expression of arginases, such as asthma and allergic responses. In particular, there is a need to explore new molecular scaffolds that effectively inhibit arginases and, therefore, can act as therapeutic agents for the treatment of these conditions.

SUMMARY OF THE INVENTION

[0014] In one aspect, the invention provides compounds represented by Formula (I):



5 wherein:

R¹ is selected from the group consisting of H, straight-chain or branched (C₁-C₆)alkyl, HC(O)-, and (C₁-C₆)alkyl-C(O)-;

R² and R³ are each independently selected from hydrogen, straight-chain or branched (C₁-C₆)alkyl and (C₁-C₆)alkyl-C(O)-,

10 or R² and R³ taken together with the boron atom and oxygen atoms to which they are bound form a 4-, 5-, 6- or 7- membered ring that is fully saturated, or partially saturated,

or R² and R³ taken together with the boron atom and oxygen atoms to which they are bound form a diester of the boronic acid and polyalcohols selected from (but not limited to): pinanediol, mannitol, glycerol, xylitol, sorbitol, and erythritol,

15 or R² and R³ taken together with the boron atom and oxygen atoms to which they are bound form an anhydride or mixed ester-anhydride of the boronic acid and hydroxy acids or di-carboxylic acids selected from (but not limited to): iminodiacetic acid or *N*-methyliminodiacetic acid or oxalic acid or tartaric acid or citric acid or malic acid or malonic acid or mandelic acid or glycolic acid or lactic acid or 3-hydroxypropionic acid;

20

R⁴ is selected from the group consisting of H and straight-chain or branched (C₁-C₆)alkyl;

R⁵ is selected from the group consisting of H, F, methyl, ethyl, propyl, isopropyl, -CH₂NH₂, -CH₂NHCH₃, -CH₂NHCH₂CH₃, -CH₂NHCH(CH₃)₂, -CH₂N(CH₃)₂, -CH₂N(CH₃)CH₂CH₃, -CH₂N(CH₂CH₃)₂, -CH₂N(CH₃)CH(CH₃)₂, -CH₂-azetidiny, -CH₂-pyrrolidiny, and -CH₂-piperidiny;

5 R⁶ is selected from the amino acid side chains of Gly, Ala, Val, Ser, Phe, Lys, Thr, Met, Tyr, His, Asp, Glu, Asn, Gln, Cys, Sec, Ile, Leu, Arg, Orn, Cit, Trp, 1-Me-Trp and Nva; and

R⁷ and R⁸ are each independently selected from hydrogen and methyl,
or R⁷ is H and R⁶ and R⁸ together with the nitrogen atom carrying R⁸ form a
10 pyrrolidine ring (proline side chain);

or a pharmaceutically acceptable salt thereof.

[0015] In another aspect, the invention provides compounds that are useful as intermediates in the preparation of compounds of formula I.

[0016] Also provided herein are pharmaceutical compositions, comprising (i) a
15 therapeutically effective amount of at least one compound of the invention, or a pharmaceutically acceptable salt thereof; and (ii) a pharmaceutically acceptable carrier, including, but not limited to, bioavailability enhancers, penetration enhancers, biopolymers, PLGA-based nanoparticles, sugar-based nanoparticles, coating to avoid the deleterious effects of the stomach environment, either by protection of the compound of the
20 invention or derivative thereof, or by release of the biologically active material beyond the stomach environment, such as in the intestine.

[0017] In another aspect, the invention provides a method for inhibiting arginase 1, arginase 2, or a combination thereof in a cell, comprising contacting the cell with at least one compound according to the invention, or a pharmaceutically acceptable salt thereof.

25 **[0018]** In another aspect, the invention provides a method for the treatment or prevention of a disease or condition associated with expression or activity of arginase 1, arginase 2, or a

combination thereof in a subject, comprising administering to the subject a therapeutically effective amount of at least one compound according to the invention, or a pharmaceutically acceptable salt thereof.

[0019] In another aspect, the invention provides use of a compound according to the invention, or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment or prevention of a disease or condition associated with expression or activity of arginase 1, arginase 2, or a combination thereof.

[0020] In another aspect, the invention provides a compound according to the invention, or a pharmaceutically acceptable salt thereof for the treatment or prevention of a disease or condition associated with expression or activity of arginase 1, arginase 2, or a combination thereof.

[0021] In another aspect, the invention provides use of a compound according to the invention, or a pharmaceutically acceptable salt thereof, for protecting an organ during transport.

[0022] In a further aspect, a process for manufacturing a compound of Formula I or a pharmaceutically acceptable salt thereof is provided.

BRIEF DESCRIPTION OF THE DRAWINGS

[0023] Figure 1 is a chromatogram indicating certain compounds described herein. See Example 29; Table 3)

[0024] Figure 2 is a chromatogram indicating certain compounds described herein. See Example 29; Table 4)

[0025] Figure 3 is a plot showing the pharmacokinetic results (IV administration) of certain compounds described herein. See Example 34.

[0026] Figure 4 is a plot showing the pharmacokinetic results (PO administration) of certain compounds described herein. See Example 34.

[0027] Figure 5 is a plot showing the pharmacodynamic results (IV administration) of certain compounds described herein. See Example 34.

[0028] Figure 6 is a plot showing the pharmacodynamic results (PO administration) of certain compounds described herein. See Example 34.

5

DETAILED DESCRIPTION

[0029] The present invention is based on a surprising finding that some small molecule arginase inhibitors possess very high activity accompanied by superior pharmacokinetics.

Definitions

[0030] The articles “a” and “an” are used herein to refer to one or to more than one (*i.e.*,
10 to at least one) of the grammatical object of the article. By way of example, “an element” means one element or more than one element.

[0031] The terms used herein may be preceded and/or followed by a single dash “-”, or a double dash “=”, to indicate the bond order of the bond between the named substituent and its parent moiety; a single dash indicates a single bond and a double dash indicates a double
15 bond. In the absence of a single or double dash, it is understood that a single bond is formed between the substituent and its parent moiety; further, substituents are intended to be read “from left to right,” unless a dash indicates otherwise. For example, (C₁-C₆)-alkoxycarbonyloxy and -OC(O)O(C₁-C₆)alkyl indicate the same functionality; similarly arylalkyl and -alkylaryl indicate the same functionality.

20 [0032] The term “heteroatom” is art-recognized and refers to an atom of any element other than carbon or hydrogen. Illustrative heteroatoms include boron, nitrogen, oxygen, phosphorus, sulfur and selenium.

[0033] The term “alkyl” as used herein is a term of art and refers to saturated aliphatic groups, including straight-chain alkyl groups, branched-chain alkyl groups, cycloalkyl
25 (alicyclic) groups, alkyl substituted cycloalkyl groups, and cycloalkyl substituted alkyl groups. In certain embodiments, a straight-chain or branched-chain alkyl has about 30 or fewer

carbon atoms in its backbone (e.g., C₁-C₃₀ for straight chain, C₃-C₃₀ for branched chain), and alternatively, about 20 or fewer, 10 or fewer, or preferably 1-6 carbons. Representative examples of alkyl include, but are not limited to, methyl, ethyl, *n*-propyl, isopropyl, *n*-butyl, *sec*-butyl, isobutyl, *tert*-butyl, *n*-pentyl, isopentyl, neopentyl, and *n*-hexyl.

- 5 **[0034]** The term “cycloalkyl” means mono- or bicyclic or bridged saturated or partially saturated carbocyclic rings, each having from 3 to 12 carbon atoms. Certain cycloalkyls have from 3-8, or from 3-6 carbon atoms in their ring structure. Certain cycloalkyls have from 5-12 carbon atoms in their ring structure, and may have 6-10 carbon atoms in the ring structure. Examples of monocyclic cycloalkyls include cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl, and cyclooctyl. Bicyclic cycloalkyl ring systems include bridged monocyclic rings and fused bicyclic rings. Bridged monocyclic rings contain a monocyclic cycloalkyl ring where two non-adjacent carbon atoms of the monocyclic ring are linked by an alkylene bridge of between one and three additional carbon atoms (*i.e.*, a bridging group of the form -(CH₂)_w, where *w* is 1, 2, or 3). Representative examples of bicyclic ring systems include, but are not limited to, bicyclo[3.1.1]heptane, bicyclo[2.2.1]heptane, bicyclo[2.2.2]octane, bicyclo[3.2.2]nonane, bicyclo[3.3.1]nonane, and bicyclo[4.2.1]nonane. Fused bicyclic cycloalkyl ring systems contain a monocyclic cycloalkyl ring fused to either a phenyl, a monocyclic cycloalkyl, a monocyclic cycloalkenyl, a monocyclic heterocyclyl, or a monocyclic heteroaryl. The bridged or fused bicyclic cycloalkyl is attached to the parent molecular moiety through any carbon atom contained within the monocyclic cycloalkyl ring. Cycloalkyl groups are optionally substituted. In certain embodiments, the fused bicyclic cycloalkyl is a 5 or 6 membered monocyclic cycloalkyl ring fused to either a phenyl ring, a 5 or 6 membered monocyclic cycloalkyl, a 5 or 6 membered monocyclic cycloalkenyl, a 5 or 6 membered monocyclic heterocyclyl, or a 5 or 6 membered monocyclic heteroaryl, wherein the fused bicyclic cycloalkyl is optionally substituted.

[0035] The term “heterocyclyl” as used herein refers to a radical of a non-aromatic ring system, including, but not limited to, monocyclic, bicyclic, and tricyclic rings, which can be

completely saturated or which can contain one or more units of unsaturation, for the avoidance of doubt, the degree of unsaturation does not result in an aromatic ring system, and having 3 to 14, or 3 to 12 atoms including at least one heteroatom, such as nitrogen, oxygen, or sulfur. More preferred heterocycloalkyl groups have from 5-10 ring members where from 1-4 of the ring members are hetero atoms selected from the group consisting of O, N, and S, the remaining ring atoms being C. For purposes of exemplification, which should not be construed as limiting the scope of this invention, the following are examples of heterocyclic rings: aziridinyl, azirinyl, oxiranyl, thiiranyl, thiirenyl, dioxiranyl, diazirinyl, diazepanyl, 1,3-dioxanyl, 1,3-dioxolanyl, 1,3-dithiolanyl, 1,3-dithianyl, imidazoliny, imidazolidinyl, isothiazoliny, isothiazolidinyl, isoxazoliny, isoxazolidinyl, azetyl, oxetanyl, oxetyl, thietanyl, thietyl, diazetidinyl, dioxetanyl, dioxetenyl, dithietanyl, dithietyl, furyl, dioxalanyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, oxadiazolyl, thiadiazolyl, triazolyl, triazinyl, isothiazolyl, isoxazolyl, thiophenyl, pyrazolyl, tetrazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, tetrazinyl, quinolinyl, isoquinolinyl, quinoxalinyl, quinazolinyl, pyridopyrazinyl, benzoxazolyl, benzothiophenyl, benzimidazolyl, benzothiazolyl, benzoxadiazolyl, benzthiadiazolyl, indolyl, benztriazolyl, naphthyridinyl, azepines, azetidiny, morpholinyl, oxadiazoliny, oxadiazolidinyl, oxazoliny, oxazolidinyl, oxopiperidinyl, oxopyrrolidinyl, piperazinyl, piperidinyl, pyranyl, pyrazoliny, pyrazolidinyl, pyrroliny, pyrrolidinyl, quinuclidinyl, thiomorpholinyl, tetrahydropyranyl, tetrahydrofuranyl, tetrahydrothienyl, thiadiazoliny, thiadiazolidinyl, thiazoliny, thiazolidinyl, thiomorpholinyl, 1,1-dioxidothiomorpholinyl (thiomorpholine sulfone), thiopyranyl, and trithianyl. A heterocycl group is optionally substituted by one or more substituents as described below.

[0036] As used herein, the term "heterocyclylene" refers to a bivalent heterocycl (heterocycloalkyl) group, *i.e.*, a cyclic alkylene group, having from 3-10 members and from 1-4 hetero atoms selected from S, O, and N. An example is piperidine-2,3-dicarboxylic acid, *i.e.*, in that compound, the piperidine ring is a heterocycl group.

[0037] The term “heteroatom” is art-recognized, and includes an atom of any element other than carbon or hydrogen. Illustrative heteroatoms include boron, nitrogen, oxygen, phosphorus, sulfur and selenium, and alternatively oxygen, nitrogen or sulfur.

[0038] The term “cycloalkylalkyl” as used herein refers to an alkyl group substituted with one or more cycloalkyl groups.


[0039] The term “heterocycloalkylalkyl” as used herein refers to an alkyl group substituted with one or more heterocycloalkyl (*i.e.*, heterocyclyl) groups.

[0040] The term “alkenyl” as used herein means a straight-chain or branched chain hydrocarbon radical containing from 2 to 10 carbons and containing at least one carbon-carbon double bond formed by the removal of two hydrogens. Representative examples of alkenyl include, but are not limited to, ethenyl, 2-propenyl, 2-methyl-2-propenyl, 3-butenyl, 4-pentenyl, 5-hexenyl, 2-heptenyl, 2-methyl-1-heptenyl, and 3-decenyl. The unsaturated bond(s) of the alkenyl group can be located anywhere in the moiety and can have either the (Z) or the (E) configuration about the double bond(s).

[0041] The term “alkynyl” as used herein means a straight-chain or branched chain hydrocarbon radical containing from 2 to 10 carbon atoms and containing at least one carbon-carbon triple bond. Representative examples of alkynyl include, but are not limited, to acetylenyl, 1-propynyl, 2-propynyl, 3-butylnyl, 2-pentylnyl, and 1-butylnyl.

[0042] The term “alkylene” is art-recognized, and as used herein pertains to a diradical obtained by removing two hydrogen atoms of an alkyl group, as defined above. In one embodiment an alkylene refers to a disubstituted alkane, *i.e.*, an alkane substituted at two positions with substituents such as halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, alkoxyl, amino, nitro, sulfhydryl, imino, amido, phosphonate, phosphinate, carbonyl, carboxyl, silyl, ether, alkylthio, sulfonyl, sulfonamido, ketone, aldehyde, ester, heterocyclyl, aromatic or heteroaromatic moieties, fluoroalkyl (such as trifluoromethyl), cyano, or the like. That is, in one embodiment, a “substituted alkyl” is an “alkylene”.

[0043] The term “amino” is a term of art and as used herein refers to both unsubstituted and substituted amines, *e.g.*, a moiety that may be represented by the general formulas:



wherein R_a , R_b , and R_c each independently represent a hydrogen, an alkyl, an

- 5 alkenyl, $-(\text{CH}_2)_x\text{R}_d$, or R_a and R_b , taken together with the N atom to which they are attached complete a heterocycle having from 4 to 8 atoms in the ring structure; R_d represents an aryl, a cycloalkyl, a cycloalkenyl, a heterocyclyl or a polycyclyl; and x is zero or an integer in the range of 1 to 8. In certain embodiments, only one of R_a or R_b may be a carbonyl, *e.g.*, R_a , R_b , and the nitrogen together do not form an imide. In other embodiments, R_a and R_b (and
- 10 optionally R_c) each independently represent a hydrogen, an alkyl, an alkenyl, or $-(\text{CH}_2)_x\text{R}_d$.

In certain embodiments, the term “amino” refers to $-\text{NH}_2$.

[0044] The term “amido”, as used herein, means $-\text{NHC}(=\text{O})-$, wherein the amido group is bound to the parent molecular moiety through the nitrogen. Examples of amido include alkylamido such as $\text{CH}_3\text{C}(=\text{O})\text{N}(\text{H})-$ and $\text{CH}_3\text{CH}_2\text{C}(=\text{O})\text{N}(\text{H})-$.

- 15 **[0045]** The term “acyl” is a term of art and as used herein refers to any group or radical of the form $\text{RCO}-$ where R is any organic group, *e.g.*, alkyl, aryl, heteroaryl, aralkyl, and heteroaralkyl. Representative acyl groups include acetyl, benzoyl, and malonyl.

- [0046]** The term “aminoalkyl” as used herein refers to an alkyl group substituted with one or more one amino groups. In one embodiment, the term “aminoalkyl” refers to an
- 20 aminomethyl group.

[0047] The term “aminoacyl” is a term of art and as used herein refers to an acyl group substituted with one or more amino groups.

[0048] The term “azide” or “azido”, as used herein, means an $-\text{N}_3$ group.

[0049] The term “carbonyl” as used herein refers to -C(=O)-.

[0050] The term “thiocarbonyl” as used herein refers to -C(=S)-.

[0051] The term “alkylthio” as used herein refers to alkyl-S-.

[0052] The term “carboxy”, as used herein, means a -CO₂H group.

- 5 [0053] The term “aryl” is a term of art and as used herein refers to includes monocyclic, bicyclic and polycyclic aromatic hydrocarbon groups, for example, benzene, naphthalene, anthracene, 1,2,3,4-tetrahydronaphthalene, indene, 2,3-dihydroindene, and pyrene. The aromatic ring may be substituted at one or more ring positions with one or more substituents, such as halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl,
- 10 (cycloalkyl)alkoxyl, hydroxyl, alkoxyl, amino, nitro, sulfhydryl, imino, amido, phosphonate, phosphinate, carbonyl, carboxyl, silyl, ether, alkylthio, sulfonyl, aminosulfonyl, sulfonamido, ketone, aldehyde, ester, heterocyclyl, heterocyclylalkyl, aromatic or heteroaromatic moieties, aminoalkyl, haloalkyl, fluoroalkyl (such as trifluoromethyl), haloalkoxyl, cyano, or the like. The term “aryl” also includes polycyclic ring systems having two or more cyclic rings in which
- 15 two or more carbons are common to two adjoining rings (the rings are “fused rings”) wherein at least one of the rings is an aromatic hydrocarbon, *e.g.*, the other cyclic rings may be cycloalkyls, cycloalkenyls, cycloalkynyls, aryls, heteroaryls, and/or heterocyclyls.
- Representative examples of the polycyclic aryl ring systems include, but are not limited to, azulenyl, naphthyl, dihydroinden-1-yl, dihydroinden-2-yl, dihydroinden-3-yl, dihydroinden-4-yl,
- 20 2,3-dihydroindol-4-yl, 2,3-dihydroindol-5-yl, 2,3-dihydroindol-6-yl, 2,3-dihydroindol-7-yl, inden-1-yl, inden-2-yl, inden-3-yl, inden-4-yl, dihydronaphthalen-2-yl, dihydronaphthalen-3-yl, dihydronaphthalen-4-yl, dihydronaphthalen-1-yl, 5,6,7,8-tetrahydronaphthalen-1-yl, 5,6,7,8-tetrahydronaphthalen-2-yl, 2,3-dihydrobenzofuran-4-yl, 2,3-dihydrobenzofuran-5-yl, 2,3-dihydrobenzofuran-6-yl, 2,3-dihydrobenzofuran-7-yl, benzo[d][1,3]dioxol-4-yl,
- 25 benzo[d][1,3]dioxol-5-yl, 2H-chromen-2-on-5-yl, 2H-chromen-2-on-6-yl, 2H-chromen-2-on-7-yl, 2H-chromen-2-on-8-yl, isoindoline-1,3-dion-4-yl, isoindoline-1,3-dion-5-yl, inden-1-on-4-yl, inden-1-on-5-yl, inden-1-on-6-yl, inden-1-on-6-yl, 2,3-dihydrobenzo[b][1,4]dioxan-5-yl, 2,3-

dihydrobenzo[b][1,4]dioxan-6-yl, 2H-benzo[b][1,4]oxazin3(4H)-on-5-yl, 2H-benzo[b][1,4]oxazin3(4H)-on-6-yl, 2H-benzo[b][1,4]oxazin3(4H)-on-7-yl, 2H-benzo[b][1,4]oxazin3(4H)-on-8-yl, benzo[d]oxazin-2(3H)-on-5-yl, benzo[d]oxazin-2(3H)-on-6-yl, benzo[d]oxazin-2(3H)-on-7-yl, benzo[d]oxazin-2(3H)-on-8-yl, quinazolin-4(3H)-on-5-yl, quinazolin-4(3H)-on-6-yl, quinazolin-4(3H)-on-7-yl, quinazolin-4(3H)-on-8-yl, quinoxalin-2(1H)-on-5-yl, quinoxalin-2(1H)-on-6-yl, quinoxalin-2(1H)-on-7-yl, quinoxalin-2(1H)-on-8-yl, benzo[d]thiazol-2(3H)-on-4-yl, benzo[d]thiazol-2(3H)-on-5-yl, benzo[d]thiazol-2(3H)-on-6-yl, and, benzo[d]thiazol-2(3H)-on-7-yl. In certain embodiments, the bicyclic aryl is (i) naphthyl, or (ii) a phenyl ring fused to either a 5 or 6 membered monocyclic cycloalkyl, a 5 or 6 membered monocyclic cycloalkenyl, or a 5 or 6 membered monocyclic heterocyclyl, wherein the fused cycloalkyl, cycloalkenyl, and heterocyclyl groups are optionally substituted. In certain embodiments, the term "aryl" refers to a phenyl group.

[0054] The term "heteroaryl" is a term of art and as used herein refers to a monocyclic, bicyclic, and polycyclic aromatic group having 3 to 14, 5 to 14, or 3 to 12 total atoms

including one or more heteroatoms such as nitrogen, oxygen, or sulfur in the ring structure.

More preferred heteroaryl groups have from 5-10 ring members where from 1-4 of the ring members are hetero atoms selected from the group consisting of O, N, and S. Exemplary

heteroaryl groups include, for example, azaindolyl, benzo(b)thienyl, benzimidazolyl, benzofuranyl, benzoxazolyl, benzothiazolyl, benzothiadiazolyl, benzotriazolyl,

benzoxadiazolyl, furanyl, imidazolyl, imidazopyridinyl, indolyl, indoliny, indazolyl, isoindoliny, isoxazolyl, isothiazolyl, isoquinoliny, oxadiazolyl, oxazolyl, purinyl, pyranyl, pyrazinyl, pyrazolyl, pyridinyl, pyrimidinyl, pyrrolyl, pyrrolo[2,3-d]pyrimidinyl, pyrazolo[3,4-d]pyrimidinyl, quinoliny, quinazolinyl, triazolyl, thiazolyl, thiophenyl, tetrahydroindolyl, tetrazolyl, thiadiazolyl, thienyl, thiomorpholiny, triazolyl or tropanyl, and the like. The "heteroaryl" may

be substituted at one or more ring positions with one or more substituents such as halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, alkoxyl, amino, nitro, sulfhydryl, imino, amido, phosphonate, phosphinate, carbonyl, carboxyl, silyl, ether, alkylthio, sulfonyl,

sulfonamido, ketone, aldehyde, ester, heterocyclyl, aromatic or heteroaromatic moieties, fluoroalkyl (such as trifluoromethyl), cyano, or the like. The term “heteroaryl” also includes polycyclic ring systems having two or more cyclic rings in which two or more carbons are common to two adjoining rings (the rings are “fused rings”) wherein at least one of the rings is an aromatic group having one or more heteroatoms in the ring structure, e.g., the other cyclic rings may be cycloalkyls, cycloalkenyls, cycloalkynyls, aryls, heteroaryls, and/or heterocyclyls. Representative examples of bicyclic heteroaryl include, but are not limited to, benzimidazolyl, benzofuranyl, benzothienyl, benzoxadiazolyl, benzoxathiadiazolyl, benzothiazolyl, cinnolinyl, 5,6-dihydroquinolin-2-yl, 5,6-dihydroisoquinolin-1-yl, furopyridinyl, indazolyl, indolyl, isoquinolinyl, naphthyridinyl, quinolinyl, purinyl, 5,6,7,8-tetrahydroquinolin-2-yl, 5,6,7,8-tetrahydroquinolin-3-yl, 5,6,7,8-tetrahydroquinolin-4-yl, 5,6,7,8-tetrahydroisoquinolin-1-yl, thienopyridinyl, 4,5,6,7-tetrahydrobenzo[c][1,2,5]oxadiazolyl, and 6,7-dihydrobenzo[c][1,2,5]oxadiazol-4(5H)-onyl. Any heteroaryl or bicyclic heteroaryl can be optionally substituted as detailed below.

[0055] The term “aralkyl”, “arylalkyl”, or “aryl(C₁-C₆)alkyl” is a term of art and as used herein refers to an alkyl group, for example a C₁-C₆ alkyl group, substituted with an aryl group, wherein the moiety is appended to the parent molecule through the alkyl group.

[0056] The term “heteroaralkyl”, “heteroarylalkyl”, or “heteroaryl(C₁-C₆)alkyl” is a term of art and as used herein refers to an alkyl group, for example a C₁-C₆ alkyl group, substituted with a heteroaryl group, appended to the parent molecular moiety through the alkyl group.

[0057] The term “alkoxy” or “alkoxyl” as used herein means an alkyl group, as defined herein, appended to the parent molecular moiety through an oxygen atom. Representative examples of alkoxy include, but are not limited to, methoxy, ethoxy, propoxy, 2-propoxy, butoxy, *tert*-butoxy, pentyloxy, and hexyloxy.

[0058] The term “alkoxycarbonyl” means an alkoxy group, as defined herein, appended to the parent molecular moiety through a carbonyl group, represented by -C(=O)-, as defined

herein. Representative examples of alkoxycarbonyl include, but are not limited to, methoxycarbonyl, ethoxycarbonyl, and *tert*-butoxycarbonyl.

[0059] The term “alkylcarbonyl”, as used herein, means an alkyl group, as defined herein, appended to the parent molecular moiety through a carbonyl group, as defined

herein. Representative examples of alkylcarbonyl include, but are not limited to, acetyl, 1-oxopropyl, 2,2-dimethyl-1-oxopropyl, 1-oxobutyl, and 1-oxopentyl.

[0060] The term “arylcarbonyl”, as used herein, means an aryl group, as defined herein, appended to the parent molecular moiety through a carbonyl group, as defined herein.

Representative examples of arylcarbonyl include, but are not limited to, benzoyl and (2-pyridinyl)carbonyl.

[0061] The term “alkylcarbonyloxy” and “arylcarbonyloxy”, as used herein, means an alkylcarbonyl or arylcarbonyl group, as defined herein, appended to the parent molecular moiety through an oxygen atom. Representative examples of alkylcarbonyloxy include, but are not limited to, acetyloxy, ethylcarbonyloxy, and *tert*-butylcarbonyloxy. Representative examples of arylcarbonyloxy include, but are not limited to phenylcarbonyloxy.

[0062] The term “alkenoxy” or “alkenoxyl” means an alkenyl group, as defined herein, appended to the parent molecular moiety through an oxygen atom. Representative examples of alkenoxyl include, but are not limited to, 2-propen-1-oxyl (*i.e.*, $\text{CH}_2=\text{CH}-\text{CH}_2-\text{O}-$) and vinyloxy (*i.e.*, $\text{CH}_2=\text{CH}-\text{O}-$).

[0063] The term “aryloxy” as used herein means an aryl group, as defined herein, appended to the parent molecular moiety through an oxygen atom.

[0064] The term “heteroaryloxy” as used herein means a heteroaryl group, as defined herein, appended to the parent molecular moiety through an oxygen atom.

[0065] The term “carbocyclyl” as used herein means a monocyclic or multicyclic (*e.g.*, bicyclic, tricyclic, *etc.*) hydrocarbon radical containing from 3 to 12 carbon atoms that is

completely saturated or has one or more unsaturated bonds, and for the avoidance of doubt,

the degree of unsaturation does not result in an aromatic ring system (*e.g.*, phenyl).

Examples of carbocyclyl groups include 1-cyclopropyl, 1-cyclobutyl, 2-cyclopentyl, 1-cyclopentenyl, 3-cyclohexyl, 1-cyclohexenyl and 2-cyclopentenylmethyl.

[0066] The terms “cyano” and “nitrile” are a term of art and as used herein refer to -CN.

5 **[0067]** The term “nitro”, as used herein, means -NO₂.

[0068] The term “halo” is a term of art and as used herein refers to -F, -Cl, -Br, or -I.

[0069] The term “haloalkyl” as used herein refers to an alkyl group, as defined herein, wherein some or all of the hydrogens are replaced with halogen atoms. The term “haloalkoxy” refers to an alkoxy group, as defined herein, wherein some or all of the

10 hydrogens are replaced with halogen atoms. An exemplary haloalkyl group is trifluoromethyl.


[0070] The term “hydroxy” is a term of art and as used herein refers to -OH.

[0071] The term “hydroxyalkyl”, as used herein, means at least one hydroxy group, as defined herein, is appended to the parent molecular moiety through an alkyl group, as defined herein. Representative examples of hydroxyalkyl include, but are not limited to, 15 hydroxymethyl, 2-hydroxyethyl, 3-hydroxypropyl, 2,3-dihydroxypentyl, and 2-ethyl-4-hydroxyheptyl.

[0072] The term “silyl”, as used herein, includes hydrocarbyl derivatives of the silyl (H₃Si-) group (*i.e.*, (hydrocarbyl)₃Si-), wherein hydrocarbyl groups are univalent groups formed by removing a hydrogen atom from a hydrocarbon, *e.g.*, ethyl, phenyl. The 20 hydrocarbyl groups can be combinations of differing groups which can be varied in order to provide a number of silyl groups, such as trimethylsilyl (TMS), *tert*-butyldiphenylsilyl (TBDPS), *tert*-butyldimethylsilyl (TBS/TBDMS), triisopropylsilyl (TIPS), and [2-(trimethylsilyl)ethoxy]methyl (SEM).

[0073] The term “silyloxy”, as used herein, means a silyl group, as defined herein, is 25 appended to the parent molecule through an oxygen atom.

[0074] As used herein, the term “the amino acid side chains of Gly, Ala, Val, Ser, Phe, Lys, Thr, Met, Tyr, His, Asp, Glu, Asn, Gln, Cys, Sec, Ile, Leu, Arg, Orn, Cit, Trp, 1-Me-Trp and Nva” refers to the moiety R_{aa} in the formula shown below



- 5 wherein R_{aa} is hydrogen, methyl, *sec*-butyl, isobutyl, isopropyl, propyl, benzyl, 1*H*-indol-3-ylmethyl, 1-methyl-1*H*-indol-3-ylmethyl, 4-hydroxybenzyl, carboxymethyl, carboxyethyl, 3-guanidinopropyl, 1*H*-imidazol-4-ylmethyl, 4-aminobutyl, hydroxymethyl, 2-hydroxyethyl, thiomethyl, selenylomethyl, methylthioethyl, carbamoylmethyl, carbamoylethyl, 3-aminopropyl, or 3-(carbamoylamino)propyl. The amino acid corresponding to each side
- 10 chain is listed in Table 1, below:

Table 1. Side Chains

R _{aa}	Amino Acid	Abbrev.
hydrogen	Glycine	Gly
methyl	Alanine	Ala
<i>sec</i> -butyl	Isoleucine	Ile
isobutyl	Leucine	Leu
isopropyl	Valine	Val
propyl	Norvaline	Nva
benzyl	Phenylalanine	Phe
1 <i>H</i> -indol-3-ylmethyl	Tryptophan	Trp
1-methyl-1 <i>H</i> -indol-3-ylmethyl	1-Methyltryptophan	1-Me-Trp
4-hydroxybenzyl	Tyrosine	Tyr
carboxymethyl	Aspartic Acid	Asp
carboxyethyl	Glutamic Acid	Glu
3-guanidinopropyl	Arginine	Arg
1 <i>H</i> -imidazol-4-ylmethyl	Histidine	His

4-aminobutyl	Lysine	Lys
hydroxymethyl	Serine	Ser
1-hydroxyethyl	Threonine	Thr
thiomethyl	Cysteine	Cys
selenylomethyl	Selenocysteine	Sec
methylthioethyl	Methionine	Met
carbamoylmethyl	Asparagine	Asn
carbamoylethyl	Glutamine	Gln
3-aminopropyl	Ornithine	Orn
3-(carbamoylamino)propyl	Citrulline	Cit

[0075] Certain compounds contained in compositions of the present invention may exist in particular geometric or stereoisomeric forms. In addition, compounds of the present invention may also be optically active. The present invention contemplates all such compounds, including *cis*- and *trans*-isomers, (*R*)- and (*S*)-enantiomers, diastereoisomers, (D)-isomers, (L)-isomers, the racemic mixtures thereof, and other mixtures thereof, as falling within the scope of the invention. Additional asymmetric carbon atoms may be present in a substituent such as an alkyl group. All such isomers, as well as mixtures thereof, are intended to be included in this invention.

[0076] If, for instance, a particular enantiomer of compound of the present invention is desired, it may be prepared by asymmetric synthesis, or by derivation with a chiral auxiliary, where the resulting diastereomeric mixture is separated and the auxiliary group cleaved to provide the pure desired enantiomers. Alternatively, where the molecule contains a basic functional group, such as amino, or an acidic functional group, such as carboxyl, diastereomeric salts are formed with an appropriate optically-active acid or base, followed by resolution of the diastereomers thus formed by fractional crystallization or chromatographic means well known in the art, and subsequent recovery of the pure enantiomers.

[0077] It will be understood that “substitution” or “substituted with” includes the implicit proviso that such substitution is in accordance with permitted valence of the substituted atom and the substituent, and that the substitution results in a stable compound, *e.g.*, which does not spontaneously undergo transformation such as by rearrangement, fragmentation,
5 decomposition, cyclization, elimination, or other reaction.

[0078] The term “substituted” is also contemplated to include all permissible substituents of organic compounds. In a broad aspect, the permissible substituents include acyclic and cyclic, branched and unbranched, carbocyclic and heterocyclic, aromatic and nonaromatic substituents of organic compounds. Illustrative substituents include, for example, halogen,
10 azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, (cycloalkyl)alkoxyl, hydroxyl, alkoxyl, amino, nitro, sulfhydryl, imino, amido, phosphonate, phosphinate, carbonyl, carboxyl, silyl, ether, alkylthio, sulfonyl, aminosulfonyl, sulfonamido, ketone, aldehyde, ester, heterocyclyl, heterocyclylalkyl, aromatic or heteroaromatic moieties, aminoalkyl, haloalkyl, fluoroalkyl (such as trifluoromethyl), haloalkoxyl, cyano, or other substituents described
15 above. The permissible substituents may be one or more and the same or different for appropriate organic compounds. For purposes of this invention, the heteroatoms such as nitrogen may have hydrogen substituents and/or any permissible substituents of organic compounds described herein which satisfy the valences of the heteroatoms. This invention is not intended to be limited in any manner by the permissible substituents of organic
20 compounds.

[0079] The phrase “protecting group”, as used herein, means temporary substituents which protect a potentially reactive functional group from undesired chemical transformations. Examples of such protecting groups include esters of carboxylic acids, silyl ethers of alcohols, and acetals and ketals of aldehydes and ketones, respectively. The field
25 of protecting group chemistry has been reviewed (Greene, T.W.; Wuts, P.G.M. *Protective Groups in Organic Synthesis*, 2nd ed.; Wiley: New York, 1991). Protected forms of the inventive compounds are included within the scope of this invention.

[0080] A "saturated" or "fully saturated" compound means that the referenced chemical structure does not contain any multiple carbon-carbon bonds. For example, a saturated cycloalkyl group as defined herein includes cyclohexyl, cyclopropyl, and the like.

[0081] An "unsaturated" or "partially saturated" compound means that the referenced chemical structure may contains on or more multiple carbon-carbon bonds, but is not aromatic. For example, an unsaturated cycloalkyl group as defined herein includes cyclohexenyl, cyclopentenyl, cyclohexadienyl, and the like.

[0082] For purposes of the invention, the chemical elements are identified in accordance with the Periodic Table of the Elements, CAS version, Handbook of Chemistry and Physics, 67th Ed., 1986-87, inside cover.

[0083] Other chemistry terms herein are used according to conventional usage in the art, as exemplified by The McGraw-Hill Dictionary of Chemical Terms (ed. Parker, S., 1985), McGraw-Hill, San Francisco, incorporated herein by reference). Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains.

[0084] It will be apparent to one skilled in the art that certain compounds of this disclosure may exist in tautomeric forms, all such tautomeric forms of the compounds being within the scope of the disclosure. Unless otherwise stated, structures depicted herein are also meant to include all stereochemical forms of the structure; *i.e.*, the *R* and *S* configurations for each asymmetric center. Therefore, single stereochemical isomers as well as enantiomeric and diastereomeric mixtures of the present compounds are within the scope of the disclosure. Both the *R* and the *S* stereochemical isomers, as well as all mixtures thereof, are included within the scope of the disclosure.

[0085] The chemical structure of examples that are a mixture of diastereoisomers or a single diastereoisomer but with unknown relative configuration are drawn and named without defined stereochemical configuration.

[0086] In this document, compound structures that are depicted with particular stereochemistry and identified as being "racemic" (or "*rac*-") refer to an equimolar mixture of a pair of enantiomers as described at IUPAC. Compendium of Chemical Terminology, 2nd ed. (the "Gold Book"). Compiled by A. D. McNaught and A. Wilkinson. Blackwell Scientific Publications, Oxford (1997). XML on-line corrected version: <http://goldbook.iupac.org> (2006-) created by M. Nic, J. Jirat, B. Kosata; updates compiled by A. Jenkins. ISBN 0-9678550-9-8. <https://doi.org/10.1351/goldbook>.

[0087] The phrase "pharmaceutically acceptable" is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.

[0088] The term "pharmaceutically acceptable salt" as used herein includes salts derived from inorganic or organic acids including, for example, hydrochloric, hydrobromic, sulfuric, nitric, perchloric, phosphoric, formic, acetic, lactic, maleic, fumaric, pamoic (embonic), succinic, tartaric, glycolic, salicylic, citric, methanesulfonic, benzenesulfonic, benzoic, malonic, trifluoroacetic, trichloroacetic, naphthalene-2-sulfonic, and other acids.

Pharmaceutically acceptable salt forms can include forms wherein the ratio of molecules comprising the salt is not 1:1. For example, the salt may comprise more than one inorganic or organic acid molecule per molecule of base, such as two hydrochloric acid molecules per molecule of compound of Formula (I). As another example, the salt may comprise less than one inorganic or organic acid molecule per molecule of base, such as two molecules of compound of Formula (I) per molecule of tartaric acid.

[0089] As used herein, a protic solvent is a solvent that has a hydrogen atom bound to an oxygen (as in a hydroxyl group) or a nitrogen (as in an amine group). In general terms, any solvent that contains labile H⁺ is called a protic solvent. The molecules of such solvents readily donate protons (H⁺) to reagents. In contrast, an aprotic solvent is a solvent that does

not have a hydrogen atom bound to an oxygen (as in a hydroxyl group) or a nitrogen (as in an amine group), and it cannot donate hydrogen.

[0090] As used herein, a polar protic solvent is a protic solvent that will dissolve many salts. In general, these solvents have high dielectric constants and high polarity. Non-

5 limiting examples of polar protic solvents include acetic acid, ammonia, ethanol, formic acid, isopropanol, methanol, *n*-butanol, nitromethane, *n*-propanol, *t*-butanol, and water.

[0091] As used herein, a polar aprotic solvent is a solvent that will dissolve many salts, but lacks an acidic hydrogen; these solvents generally have intermediate to high dielectric constants and polarity. Non-limiting examples of polar aprotic solvents include acetone,

10 acetonitrile, dichloromethane (DCM), dimethyl sulfoxide (DMSO), ethyl acetate, hexamethylphosphoric triamide (HMPT), *N,N*-dimethylformamide (DMF), and tetrahydrofuran (THF).

[0092] As used herein, a nonpolar aprotic solvent is a solvent that will dissolve many salts, but lacks an acidic hydrogen; these solvents generally have low dielectric constants

15 and polarity. Non-limiting examples of nonpolar aprotic solvents include benzene, chloroform, cyclohexane, diethyl ether, hexane, pentane, and toluene.

[0093] A physician or veterinarian having ordinary skill in the art can readily determine and prescribe the therapeutically effective amount of the pharmaceutical composition required. For example, the physician or veterinarian could start doses of the pharmaceutical
20 composition or compound at levels lower than that required in order to achieve the desired therapeutic effect and gradually increase the dosage until the desired effect is achieved. By “therapeutically effective amount” is meant the concentration of a compound that is sufficient to elicit the desired therapeutic effect. It is generally understood that the effective amount of the compound will vary according to the weight, sex, age, and medical history of the subject.

25 Other factors which influence the effective amount may include, but are not limited to, the severity of the patient's condition, the disorder being treated, the stability of the compound, the mode of administration, the bioavailability of the particular compound, and, if desired,

another type of therapeutic agent being administered with the compound of the invention. A larger total dose can be delivered by multiple administrations of the agent. Methods to determine efficacy and dosage are known to those skilled in the art (Isselbacher *et al.* (1996) Harrison's Principles of Internal Medicine 13 ed., 1814-1882, herein incorporated by reference).

[0094] "Modulating" or "modulate" refers to the treating, prevention, suppression, enhancement or induction of a function, condition or disorder.

[0095] The term "treating" includes prophylactic and/or therapeutic treatments. The term "prophylactic or therapeutic" treatment is art-recognized and includes administration to the host of one or more of the subject compositions. If it is administered prior to clinical manifestation of the unwanted condition (*e.g.*, disease or other unwanted state of the host animal) then the treatment is prophylactic (*i.e.*, it protects the host against developing the unwanted condition), whereas if it is administered after manifestation of the unwanted condition, the treatment is therapeutic, (*i.e.*, it is intended to diminish, ameliorate, or stabilize the existing unwanted condition or side effects thereof).


[0096] As used herein, "subject" refers to a warm-blooded animal such as a mammal, preferably a human, or a human child, which is afflicted with, or has the potential to be afflicted with one or more diseases and disorders described herein.

[0097] "EC₅₀" refers to a dosage, concentration or amount of a particular test compound that elicits a dose-dependent response at 50% of maximal expression of a particular response that is induced, provoked or potentiated by the particular test compound.

[0098] "IC₅₀" refers to an amount, concentration or dosage of a particular test compound that achieves a 50% inhibition of a maximal response in an assay that measures such response.

Compounds of the Invention

[0099] In one aspect, the invention provides compounds represented by Formula (I):



5

wherein:

R¹ is selected from the group consisting of H, straight-chain or branched (C₁-C₆)alkyl, HC(O)-, and (C₁-C₆)alkyl-C(O)-;

10

R² and R³ are each independently selected from hydrogen, straight-chain or branched (C₁-C₆)alkyl and (C₁-C₆)alkyl-C(O)-,

or R² and R³ taken together with the boron atom and oxygen atoms to which they are bound form a 4-, 5-, 6- or 7- membered ring that is fully saturated, or partially saturated,

15

or R² and R³ taken together with the boron atom and oxygen atoms to which they are bound form a diester of the boronic acid and polyalcohols selected from (but not limited to): pinanediol, mannitol, glycerol, xylitol, sorbitol, and erythritol,

20

or R² and R³ taken together with the boron atom and oxygen atoms to which they are bound form an anhydride or mixed ester-anhydride of the boronic acid and hydroxy acids or di-carboxylic acids selected from (but not limited to): iminodiacetic acid or *N*-methyliminodiacetic acid or oxalic acid or tartaric acid or citric acid or malic acid or malonic acid or mandelic acid or glycolic acid or lactic acid or 3-hydroxypropionic acid;

R⁴ is selected from the group consisting of H, straight-chain and branched (C₁-C₆)alkyl;

R⁵ is selected from the group consisting of H, F, methyl, ethyl, propyl, isopropyl, -CH₂NH₂, -CH₂NHCH₃, -CH₂NHCH₂CH₃, -CH₂NHCH(CH₃)₂, -CH₂N(CH₃)₂, -CH₂N(CH₃)CH₂CH₃, -CH₂N(CH₂CH₃)₂, -CH₂N(CH₃)CH(CH₃)₂, -CH₂-azetidiny, -CH₂-pyrrolidiny, and -CH₂-piperidiny;

R⁶ is selected from the amino acid side chain of Gly, Ala, Val, Ser, Phe, Lys, Thr, Met, Tyr, His, Asp, Glu, Asn, Gln, Cys, Sec, Ile, Leu, Arg, Orn, Cit, Trp, 1-Me-Trp and Nva; and

R⁷ and R⁸ are each independently selected from hydrogen and methyl, or R⁷ is H and R⁶ and R⁸ together with the nitrogen atom carrying R⁸ form a pyrrolidine ring (proline side chain);

or a pharmaceutically acceptable salt thereof.

[00100] Additionally, in certain embodiments as otherwise described herein, the invention provides a tautomer, stereoisomer, racemate, or solvate of a compound of Formula I as otherwise described herein. In certain embodiments as otherwise described herein, the invention provides an ester of a compound of Formula I as otherwise described herein.

[00101] The above-defined general Formula (I) covers certain compounds of the invention, which can be described in more detail as follows.

[00102] In certain embodiments, R¹ is H.

[00103] In certain embodiments, R² is H and R³ is H.

[00104] In certain embodiments, R⁴ is H.

[00105] In certain embodiments, R⁵ is H.

[00106] In certain embodiments, R⁵ is CH₃.

[00107] In certain embodiments, R^5 is $-\text{CH}_2\text{NH}_2$ or $-\text{CH}_2\text{N}(\text{CH}_3)_2$ or $-\text{CH}_2\text{NHCH}_3$ or $-\text{CH}_2\text{N}(\text{CH}_3)_2$ or $-\text{CH}_2\text{N}(\text{CH}_3)\text{CH}_2\text{CH}_3$ or $-\text{CH}_2$ -pyrrolidinyl or $-\text{CH}_2$ -azetidinyI or $-\text{CH}_2$ -piperidinyl;

[00108] In certain embodiments, R^6 is selected from the amino acid side chain of Gly, Ala, Val, Ser, Phe, Lys, Thr, Met, Tyr, His, Asp, Glu, Asn, Gln, Cys, Sec, Ile, Leu, Arg, Orn, Cit, Trp, 1-Me-Trp and Nva.


[00109] In certain embodiments, R^6 is selected from the amino acid side chain of Gly, Ala, Val, Ser, Phe, Lys, Thr, Met, Tyr, His, Asp, Glu, Asn, Gln, Cys, Sec, Ile, Leu, Arg, Orn, Cit, Trp, and 1-Me-Trp.

[00110] In certain embodiments, R^7 is H and R^6 and R^8 together with the nitrogen atom carrying R^8 form a pyrrolidine ring (proline side chain).

[00111] In certain embodiments of Formula I, R^5 is hydrogen or methyl and R^6 is C_1 - C_4 alkyl. In other embodiments, R^5 is hydrogen or methyl and R^6 is C_1 - C_2 alkyl. In still other embodiments, R^5 is hydrogen or methyl and R^6 is methyl.

[00112] In certain embodiments of Formula I, R^6 is $-\text{C}_1$ - C_6 -alkyl- $\text{NH}(\text{CO})\text{NH}_2$. In other embodiments, R^6 is $-\text{C}_1$ - C_4 -alkyl- $\text{NH}(\text{NH})\text{NH}_2$. In still other embodiments, R^6 is $-\text{C}_2$ - C_4 -alkyl- $\text{NH}(\text{NH})\text{NH}_2$. In still other embodiments, R^6 is $-\text{C}_3$ -alkyl- $\text{NH}(\text{NH})\text{NH}_2$.

[00113] In certain embodiments, the compounds of Formula (I) according to the invention have the structure of Formula (Ia):



wherein:

R⁵ is selected from the group consisting of

H, -CH₃, -CH₂NH₂, -CH₂NHCH₃, -CH₂N(CH₃)₂, and -CH₂-pyrrolidinyl;

R⁶ is selected from the amino acid side chain of Gly, Ala, Val, Ser, Phe, Lys, Thr, Met,

Tyr, His, Asp, Glu, Asn, Gln, Cys, Sec, Ile, Leu, Arg, Orn, Cit, Trp, 1-Me-Trp and


Nva;

or a pharmaceutically acceptable salt thereof.

[00114] In certain embodiments of Formula Ia, R⁵ is hydrogen or methyl and R⁶ is C₁-C₄ alkyl. In other embodiments, R⁵ is hydrogen or methyl and R⁶ is C₁-C₂ alkyl. In still other embodiments of Formula Ia, R⁵ is hydrogen or methyl and R⁶ is methyl.

[00115] In certain embodiments of Formula Ia, R⁵ is hydrogen or methyl and R⁶ is -C₁-C₆-alkyl-NH(NH)NH₂. In other embodiments of Formula Ia, R⁵ is hydrogen or methyl and R⁶ is -C₁-C₄-alkyl-NH(NH)NH₂. In still other embodiments, R⁵ is hydrogen or methyl and R⁶ is -C₂-C₄-alkyl-NH(NH)NH₂. In still other embodiments, R⁵ is hydrogen or methyl and R⁶ is -C₃-alkyl-NH(NH)NH₂.

[00116] In certain embodiments, the compounds of Formula (I) according to the invention have the structure of Formula (Ib):



wherein:

R⁶ is selected from the amino acid side chains of Gly, Ala, Val, Ser, Phe, Lys, Thr,

Met, Tyr, His, Asp, Glu, Asn, Gln, Cys, Sec, Ile, Leu, Arg, Orn, Cit, Trp, 1-Me-Trp, and Nva

or a pharmaceutically acceptable salt thereof.









[00117] In certain embodiments of Formula Ib, R⁶ is C₁-C₄ alkyl. In other embodiments, R⁶ is C₁-C₂ alkyl. In still other embodiments, R⁶ is methyl.

[00118] In certain embodiments of Formula Ib, R⁶ is -C₁-C₆-alkyl-NH(NH)NH₂. In other embodiments of Formula Ia, R⁶ is -C₁-C₄-alkyl-NH(NH)NH₂. In still other embodiments, R⁶ is -C₂-C₄-alkyl-NH(NH)NH₂. In still other embodiments, R⁶ is -C₃-alkyl-NH(NH)NH₂.

[00119] Representative compounds of Formula (I) according to the invention are provided in Table 2, below:





Table 2. Representative Compounds

Example No.	Compound Structure	Compound Name
1		(3<i>R</i>,5<i>S</i>)-1-(<i>L</i>-alanyl)-3-amino-5-(2-boronoethyl)piperidine-3-carboxylic acid
2		(3<i>S</i>,5<i>R</i>)-1-(<i>L</i>-alanyl)-3-amino-5-(2-boronoethyl)piperidine-3-carboxylic acid
3		(3<i>R</i>,5<i>S</i>)-3-amino-5-(2-boronoethyl)-1-glycylpiperidine-3-carboxylic acid
4		(3<i>R</i>,5<i>S</i>)-1-(<i>L</i>-prolyl)-3-amino-5-(2-boronoethyl)piperidine-3-carboxylic acid
5		(3<i>R</i>,5<i>S</i>)-1-(<i>L</i>-valyl)-3-amino-5-(2-boronoethyl)piperidine-3-carboxylic acid

Example No.	Compound Structure	Compound Name
6		(3 <i>R</i> ,5 <i>S</i>)-1-(<i>L</i> -seryl)-3-amino-5-(2-boronoethyl)piperidine-3-carboxylic acid
7		(3 <i>R</i> ,5 <i>S</i>)-1-(<i>L</i> -lysyl)-3-amino-5-(2-boronoethyl)piperidine-3-carboxylic acid
8		(3 <i>R</i> ,5 <i>S</i>)-1-(<i>L</i> -leucyl)-3-amino-5-(2-boronoethyl)piperidine-3-carboxylic acid
9		(3 <i>R</i> ,5 <i>S</i>)-1-(<i>L</i> -isoleucyl)-3-amino-5-(2-boronoethyl)piperidine-3-carboxylic acid
10		(3 <i>R</i> ,5 <i>S</i>)-1-(<i>L</i> -tyrosyl)-3-amino-5-(2-boronoethyl)piperidine-3-carboxylic acid
11		(3 <i>R</i> ,5 <i>S</i>)-1-(<i>L</i> -phenylalanyl)-3-amino-5-(2-boronoethyl)piperidine-3-carboxylic acid
12		(3 <i>R</i> ,5 <i>S</i>)-1-(<i>L</i> -threonyl)-3-amino-5-(2-boronoethyl)piperidine-3-carboxylic acid
13		(3 <i>R</i> ,5 <i>S</i>)-1-(<i>L</i> -histidyl)-3-amino-5-(2-boronoethyl)piperidine-3-carboxylic acid


Example No.	Compound Structure	Compound Name
14		(3 <i>R</i> ,5 <i>S</i>)-1-(<i>L</i> -aspartyl)-3-amino-5-(2-boronoethyl)piperidine-3-carboxylic acid
15		(3 <i>R</i> ,5 <i>S</i>)-1-(<i>L</i> -glutamyl)-3-amino-5-(2-boronoethyl)piperidine-3-carboxylic acid
16		(3 <i>R</i> ,5 <i>S</i>)-1-(<i>L</i> -glutaminyl)-3-amino-5-(2-boronoethyl)piperidine-3-carboxylic acid
17		(3 <i>R</i> ,5 <i>S</i>)-1-(<i>L</i> -methionyl)-3-amino-5-(2-boronoethyl)piperidine-3-carboxylic acid
18		(3 <i>R</i> ,5 <i>S</i>)-1-(<i>L</i> -tryptophyl)-3-amino-5-(2-boronoethyl)piperidine-3-carboxylic acid
19		(3 <i>R</i> ,5 <i>S</i>)-1-(<i>L</i> -cysteinyl)-3-amino-5-(2-boronoethyl)piperidine-3-carboxylic acid
20		(3 <i>R</i> ,5 <i>S</i>)-1-(<i>L</i> -arginyl)-3-amino-5-(2-boronoethyl)piperidine-3-carboxylic acid
21		(3 <i>R</i> ,5 <i>S</i>)-3-amino-1-((<i>S</i>)-2-amino-5-ureidopentanoyl)-5-(2-boronoethyl)piperidine-3-carboxylic acid

Example No.	Compound Structure	Compound Name
22		(3 <i>R</i> ,5 <i>S</i>)-3-amino-5-(2-boronoethyl)-1-((<i>S</i>)-2,5-diaminopentanoyl)piperidine-3-carboxylic acid
23		(3 <i>R</i> ,5 <i>S</i>)-1-(<i>D</i> -alanyl)-3-amino-5-(2-boronoethyl)piperidine-3-carboxylic acid
24		(3 <i>R</i> ,5 <i>S</i>)-3-amino-5-(2-boronoethyl)-1-(1-methyl- <i>D</i> -tryptophyl)piperidine-3-carboxylic acid
25		(3 <i>R</i> ,5 <i>S</i>)-3-amino-1-((<i>S</i>)-2-aminopentanoyl)-5-(2-boronoethyl)piperidine-3-carboxylic acid
26		(3 <i>R</i> ,5 <i>S</i>)-1-(<i>L</i> -asparaginy)-3-amino-5-(2-boronoethyl)piperidine-3-carboxylic acid
27		(3 <i>R</i> ,5 <i>S</i>)-3-amino-5-(2-boronoethyl)-1-(methylglycyl)piperidine-3-carboxylic acid
28		2-((3 <i>S</i> ,5 <i>R</i>)-1-(<i>L</i> -alanyl)-5-amino-5-(methoxycarbonyl)piperidin-3-yl)ethylboronic acid
29		(3 <i>R</i> ,5 <i>S</i>)-1-(<i>L</i> -arginyl)-3-amino-5-(2-(4-carboxy-4-(carboxymethyl)-6-oxo-1,3,2-dioxaborinan-2-yl)ethyl)piperidine-3-carboxylic acid

Example No.	Compound Structure	Compound Name
30		(2 <i>S</i> ,3 <i>R</i> ,5 <i>S</i>)-1-(<i>L</i> -alanyl)-3-amino-5-(2-boronoethyl)-2-methylpiperidine-3-carboxylic acid
31		(2 <i>S</i> ,3 <i>R</i> ,5 <i>S</i>)-1-(<i>L</i> -Arginyl)-3-amino-5-(2-boronoethyl)-2-methylpiperidine-3-carboxylic acid
32		(3 <i>R</i> ,5 <i>R</i>)-1-(<i>L</i> -alanyl)-3-amino-5-(2-boronoethyl)piperidine-3-carboxylic acid
33		(3 <i>S</i> ,5 <i>S</i>)-1-(<i>L</i> -alanyl)-3-amino-5-(2-boronoethyl)piperidine-3-carboxylic acid


[00120] The above compounds can be obtained and used as a free acid or free base, or as a pharmaceutically acceptable salt thereof, or a stereoisomer, a tautomer, and/or a solvate thereof.

- 5 **[00121]** The invention also provides intermediates useful in preparing compounds of Formula I. Representative compounds of Formula I that may be prepared using the intermediates of this invention include compounds of Formula Ib:



Ib

[00122] Intermediates of this invention include compounds of Formula II:



II

wherein

- 5 R^{21} is hydrogen, C_1 - C_6 alkyl, or R^N , wherein R^N is a nitrogen protecting group; and
- R^{22} is hydrogen, C_1 - C_6 alkyl, or Pg, wherein Pg is a nitrogen protecting group which may be the same as or different than R^N .

[00123] Preferred Pg protecting groups within R^{22} are benzyl, 4-methylbenzyl, 4-methoxybenzyl, 4-bromobenzyl, 4-nitrobenzyl, 3-methylbenzyl, 2-methylbenzyl, 3,4-


10 dimethoxybenzyl, 2,4,6-trimethylbenzyl, benzhydryl, and trityl.

[00124] Preferred R^N protecting groups are acetyl, benzyloxycarbonyl, and t-butoxycarbonyl.

[00125] Particular compounds of Formula II include those where R^{21} is hydrogen. Other particular compounds of Formula II include those where R^{21} is hydrogen and R^{22} is benzyl.

15 [00126] Still other compounds of Formula II are those where R^{22} is benzyl and R^{21} is C_1 - C_6 alkyl. Other compounds of Formula II are those where R^{22} is benzyl and R^{21} is R^N , preferably acetyl or benzyloxycarbonyl.

[00127] Other intermediates of this invention include compounds of Formula III:



III

wherein

R^{23} is hydrogen, C_1 - C_6 alkyl, or R^N , wherein R^N is a nitrogen protecting group; and

R^{24} is hydrogen, C_1 - C_6 alkyl, or Pg, wherein Pg is a nitrogen protecting group which may be the same as or different than R^N .

5 **[00128]** Preferred R^N protecting groups within R^{23} are acetyl, benzyloxycarbonyl, and t-butoxycarbonyl.

[00129] Preferred Pg protecting groups within R^{24} are benzyl, 4-methylbenzyl, 4-methoxybenzyl, 4-bromobenzyl, 4-nitrobenzyl, 3-methylbenzyl, 2-methylbenzyl, 3,4-dimethoxybenzyl, 2,4,6-trimethylbenzyl, benzhydryl, and trityl.

10 **[00130]** Particular compounds of Formula III include those where R^{23} is hydrogen. Other particular compounds of Formula III include those where R^{23} is hydrogen and R^{24} is benzyl.

[00131] Still other compounds of Formula III are those where R^{24} is benzyl and R^{23} is C_1 - C_6 alkyl. Other compounds of Formula III are those where R^{24} is benzyl and R^{23} is R^N , preferably acetyl or benzyloxycarbonyl.

15 *Pharmaceutical Compositions of the Invention*

[00132] Also provided herein are pharmaceutical compositions, comprising (i) a therapeutically effective amount of at least one compound of the invention, or a pharmaceutically acceptable salt thereof; and (ii) a pharmaceutically acceptable carrier, including, but not limited to, bioavailability enhancers, penetration enhancers,

20 biopolymers, PLGA-based nanoparticles, sugar-based nanoparticles, coating to avoid the deleterious effects of the stomach environment, either by protection of the compound of the invention or derivative thereof, or by release of the biologically active material beyond the stomach environment, such as in the intestine.

[00133] The exact nature of the carrier, or, for example, excipient or diluent, will depend
25 upon the desired use for the composition, and may be suitable or acceptable for veterinary

use or suitable or acceptable for human use. The composition may optionally include one or more additional compounds, including one or more additional therapeutic agents.

[00134] Compounds of the invention can be combined with other therapeutic agents. The compound of the invention and other therapeutic agent may be administered simultaneously or sequentially. When the other therapeutic agents are administered simultaneously, they can be administered in the same or separate formulations, but they are administered substantially at the same time. The other therapeutic agents are administered sequentially with one another and with compound of the invention, when the administration of the other therapeutic agents and the compound of the invention is temporally separated. The separation in time between the administration of these compounds may be a matter of minutes or it may be longer.

[00135] Examples of other therapeutic agents that may be administered with the compounds of the invention include steroids, membrane stabilizers, 5LO inhibitors, leukotriene synthesis and receptor inhibitors, inhibitors of IgE isotype switching or IgE synthesis, IgG isotype switching or IgG synthesis, β -agonists, tryptase inhibitors, aspirin, COX inhibitors, methotrexate, anti-TNF drugs, rituximab, p38 inhibitors, PDE4 inhibitors, and antihistamines, immunotherapeutic agents, including checkpoint inhibitors such as PD-1, PD-L1, CTLA-4, LAG-3, TIM-3, TIGIT, VISTA inhibitors, IDO/TDO inhibitors, adenosine A2A receptor antagonists, ectonucleotidase (CD73 and CD39) inhibitors, immunosuppressants, agents affecting interleukins, cytokines and chemokines, kinase inhibitors, chemotherapeutic agents including alkylating antineoplastic agents, antimetabolites, anti-microtubule agents, topoisomerase inhibitors, cytotoxic antibiotics or targeted therapies such as antibodies, antibodies drug conjugates, cell-based immunotherapies, nanoparticles, anti-cancer vaccines and radiotherapy.

[00136] In some embodiments, the one or more additional chemotherapeutic agents includes aminoglutethimide, amsacrine, anastrozole, asparaginase, AZD5363, Bacillus Calmette-Guerin vaccine (BCG), bicalutamide, bleomycin, bortezomib, buserelin, busulfan,

camptothecin, capecitabine, carboplatin, carfilzomib, carmustine, chlorambucil, chloroquine, cisplatin, cladribine, clodronate, cobimetinib, colchicine, cyclophosphamide, cyproterone, cytarabine, dacarbazine, dactinomycin, daunorubicin, demethoxyviridin, dexamethasone, dichloroacetate, dienestrol, diethylstilbestrol, docetaxel, doxorubicin, epirubicin, erlotinib, estradiol, estramustine, etoposide, everolimus, exemestane, filgrastim, fludarabine, fludrocortisone, fluorouracil, fluoxymesterone, flutamide, gemcitabine, genistein, goserelin, hydroxyurea, idarubicin, ifosfamide, imatinib, interferon, irinotecan, lenalidomide, letrozole, leucovorin, leuprolide, levamisole, lomustine, lonidamine, mechlorethamine, medroxyprogesterone, megestrol, melphalan, mercaptopurine, mesna, metformin, methotrexate, miltefosine, mitomycin, mitotane, mitoxantrone, MK-2206, nilutamide, nocodazole, octreotide, olaparib, oxaliplatin, paclitaxel, pamidronate, pazopanib, pentostatin, perifosine, plicamycin, pomalidomide, porfimer, procarbazine, raltitrexed, rituximab, rucaparib, selumetinib, sorafenib, streptozocin, sunitinib, suramin, talazoparib, tamoxifen, temozolomide, temsirolimus, teniposide, testosterone, thalidomide, thioguanine, thiotepa, titanocene dichloride, topotecan, trametinib, trastuzumab, tretinoin, veliparib, vinblastine, vincristine, vindesine, or vinorelbine. In some embodiments, the one or more additional chemotherapeutic agents includes abagovomab, adecatumumab, afutuzumab, anatumomab mafenatox, apolizumab, avelumab, blinatumomab, catumaxomab, durvalumab, epratuzumab, inotuzumab ozogamicin, intelumumab, ipilimumab, isatuximab, lambrolizumab, nivolumab, ocaratuzumab, olatatumab, pembrolizumab, pidilizumab, ticilimumab, samalizumab, tremelimumab, BMS-936559.

[00137] In some embodiments, the one or more additional immunotherapeutic agents includes AB122, AB154, AB680, AB928, BMS202, BMS-813160, BMS-986016, BMS-986205, BMS-986207, CA-170, CA-327, EOS200271, epacadostat, GDC-0919, LY3321367, 1-methyl-D-tryptophan, MGA012, MK-7684, OMP-313M32, PF-06840003, REGN2810, SHR-1210 or TSR-022.

[00138] In some embodiments, the one or more additional chemotherapeutic agents includes atezolizumab, avelumab, durvalumab, ipilimumab, nivolumab, pembrolizumab or pidilizumab.

[00139] In some embodiments, the one or more additional therapeutic agents includes
5 hydroxyurea.

[00140] In other embodiments, the method further comprises administering one or more non-chemical methods of cancer treatment, such as radiation therapy, surgery, thermoablation, focused ultrasound therapy, cryotherapy, or a combination thereof.

[00141] As stated above, an “effective amount” refers to any amount that is sufficient to

10 achieve a desired biological effect. Combined with the teachings provided herein, by choosing among the various active compounds and weighing factors such as potency, relative bioavailability, patient body weight, severity of adverse side-effects and preferred mode of administration, an effective prophylactic or therapeutic treatment regimen can be planned which does not cause substantial unwanted toxicity and yet is effective to treat the
15 particular subject. The effective amount for any particular application can vary depending on such factors as the disease or condition being treated, the particular compound of the invention being administered, the size of the subject, or the severity of the disease or condition. One of ordinary skill in the art can empirically determine the effective amount of a particular compound of the invention and/or other therapeutic agent without necessitating
20 undue experimentation. It is preferred generally that a maximum dose be used, that is, the highest safe dose according to some medical judgment. Multiple doses per day may be contemplated to achieve appropriate systemic levels of compounds. Appropriate systemic levels can be determined by, for example, measurement of the patient’s peak or sustained plasma level of the drug. “Dose” and “dosage” are used interchangeably herein.

25 **[00142]** Generally, daily oral doses of active compounds will be, for human subjects, from about 0.0001 milligrams/kg per day, 0.001 milligrams/kg per day, or 0.01 milligrams/kg per day to about 100 milligrams/kg per day or 1000 milligrams/kg per day. It is expected that oral

doses in the range of 0.5 to 50 milligrams/kg, in one or several administrations per day, will yield the desired results. Dosage may be adjusted appropriately to achieve desired drug levels sufficient to achieve or maintain a desired therapeutic effect, local or systemic, depending upon the mode of administration. For example, it is expected that intravenous administration would be from one order to several orders of magnitude lower dose per day. In the event that the response in a subject is insufficient at such doses, even higher doses (or effective higher doses by a different, more localized delivery route) may be employed to the extent that patient tolerance permits. Multiple doses per day are contemplated to achieve appropriate systemic levels of compounds. The compounds may be administered once per week, several times per week (*e.g.*, every other day), once per day or multiple times per day, depending upon, among other things, the mode of administration, the specific indication being treated and the judgment of the prescribing physician.

[00143] In one embodiment, intravenous administration of a compound of the invention may typically be from 0.1 mg/kg/day to 100 mg/kg/day.

[00144] Determination of an effective dosage of a compound for a particular use and mode of administration is well within the capabilities of those skilled in the art. Effective dosages may be estimated initially from *in vitro* activity and metabolism assays. For example, an initial dosage of compound for use in animals may be formulated to achieve a circulating blood or serum concentration of the metabolite active compound that is at or above an IC_{50} of the particular compound as measured in as *in vitro* assay. Calculating dosages to achieve such circulating blood or serum concentrations taking into account the bioavailability of the particular compound *via* the desired route of administration is well within the capabilities of skilled artisans. Initial dosages of compound can also be estimated from *in vivo* data, such as animal models. For any compound described herein the therapeutically effective amount can be initially determined from animal models. A therapeutically effective dose can also be determined from human data for compounds of the invention which have been tested in humans and for compounds which are known to exhibit similar

pharmacological activities, such as other related active agents. Higher doses may be required for parenteral administration. The applied dose can be adjusted based on the relative bioavailability and potency of the administered compound. Adjusting the dose to achieve maximal efficacy based on the methods described above and other methods as are well-known in the art is well within the capabilities of the ordinarily skilled artisan.

[00145] The formulations of the invention can be administered in pharmaceutically acceptable solutions, which may routinely contain pharmaceutically acceptable concentrations of salt, buffering agents, preservatives, compatible carriers, adjuvants, and optionally other therapeutic ingredients.

[00146] Pharmaceutical compositions comprising the compound of the invention may be manufactured by means of conventional mixing, dissolving, granulating, dragee-making levigating, emulsifying, encapsulating, entrapping or lyophilization processes. The compositions may be formulated in conventional manner using one or more physiologically acceptable carriers, diluents, excipients or auxiliaries which facilitate processing of the compounds into preparations which can be used pharmaceutically.

[00147] For use in therapy, an effective amount of the compound of the invention can be administered to a subject by any mode that delivers the compound of the invention to the desired surface. Administering the pharmaceutical composition of the present invention may be accomplished by any means known to the skilled artisan. Routes of administration include but are not limited to oral, buccal, nasal, rectal, vaginal, ocular, topical, intravenous, intramuscular, intraperitoneal, subcutaneous, transdermal, direct injection (for example, into an abscess), mucosal, inhalation, and insufflation.

[00148] For oral administration, the compounds (*i.e.*, compounds of the invention, and other therapeutic agents) can be formulated readily by combining the active compound(s) with pharmaceutically acceptable carriers well known in the art. Such carriers enable the compounds of the invention to be formulated as tablets, pills, dragées, lozenges, capsules, liquids, gels, syrups, slurries, suspensions and the like, for oral ingestion by a subject to be

treated. Pharmaceutical preparations for oral use can be obtained as solid excipient, optionally grinding a resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries, if desired, to obtain tablets or dragée cores. Suitable excipients are, in particular, binding agents, fillers, lubricants, disintegrants, and wetting agents. Suitable fillers include sugars, including lactose, sucrose, mannitol, or sorbitol; cellulose preparations such as, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methyl cellulose, hydroxypropylmethyl-cellulose, sodium carboxymethylcellulose, and/or polyvinylpyrrolidone (PVP). If desired, disintegrating agents may be added, such as the cross-linked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate. Optionally the oral formulations may also be formulated in saline or buffers, *e.g.*, EDTA, for neutralizing internal acid conditions or may be administered without any carriers.

[00149] Also specifically contemplated are oral dosage forms of the above component or components. The component or components may be chemically modified so that oral delivery of the derivative is efficacious. Generally, the chemical modification contemplated is the attachment of at least one moiety to the component molecule itself, where said moiety permits (a) inhibition of acid hydrolysis; and (b) uptake into the blood stream from the stomach or intestine. Also desired is the increase in overall stability of the component or components and increase in circulation time in the body. Examples of such moieties include: polyethylene glycol, copolymers of ethylene glycol and propylene glycol, carboxymethyl cellulose, dextran, polyvinyl alcohol, polyvinyl pyrrolidone and polyproline. Other polymers that could be used are poly-1,3-dioxolane and poly-1,3,6-tioxocane. Preferred for pharmaceutical usage, as indicated above, are polyethylene glycol moieties.

[00150] For the component (or derivative) the location of release may be the stomach, the small intestine (the duodenum, the jejunum, or the ileum), or the large intestine. One skilled in the art has available formulations which will not dissolve in the stomach, yet will release the material in the duodenum or elsewhere in the intestine. Preferably, the release will avoid the deleterious effects of the stomach environment, either by protection of the compound of

the invention (or derivative) or by release of the biologically active material beyond the stomach environment, such as in the intestine.

[00151] To ensure full gastric resistance a coating impermeable to at least pH 5.0 is essential. Examples of the more common inert ingredients that are used as enteric coatings
5 are cellulose acetate trimellitate (CAT), hydroxypropylmethylcellulose phthalate (HPMCP), HPMCP 50, HPMCP 55, polyvinyl acetate phthalate (PVAP), Eudragit L30D, Aquateric, cellulose acetate phthalate (CAP), Eudragit L, Eudragit S, and shellac. These coatings may be used as mixed films.

[00152] A coating or mixture of coatings can also be used on tablets, which are not
10 intended for protection against the stomach. This can include sugar coatings, or coatings which make the tablet easier to swallow. Capsules may consist of a hard shell (such as gelatin) for delivery of dry therapeutic (*e.g.*, powder); for liquid forms, a soft gelatin shell may be used. The shell material of cachets could be thick starch or other edible paper. For pills, lozenges, molded tablets or tablet triturates, moist massing techniques can be used.

[00153] The therapeutic can be included in the formulation as fine multi-particulates in the
15 form of granules or pellets of particle size about 1 mm. The formulation of the material for capsule administration could also be as a powder, lightly compressed plugs or even as tablets. The therapeutic could be prepared by compression.

[00154] Colorants and flavoring agents may all be included. For example, the compound
20 of the invention (or derivative) may be formulated (such as by liposome or microsphere encapsulation) and then further contained within an edible product, such as a refrigerated beverage containing colorants and flavoring agents.

[00155] One may dilute or increase the volume of the therapeutic with an inert material. These diluents could include carbohydrates, especially mannitol, lactose, anhydrous lactose,
25 cellulose, sucrose, modified dextrans and starch. Certain inorganic salts may be also be used as fillers including calcium triphosphate, magnesium carbonate and sodium chloride.

Some commercially available diluents are Fast-Flo, Emdex, STA-Rx 1500, Emcompress and Avicell.

[00156] Disintegrants may be included in the formulation of the therapeutic into a solid dosage form. Materials used as disintegrates include but are not limited to starch, including the commercial disintegrant based on starch, Explotab. Sodium starch glycolate, Amberlite, sodium carboxymethylcellulose, ultramylopectin, sodium alginate, gelatin, orange peel, acid carboxymethyl cellulose, natural sponge and bentonite may all be used. Another form of the disintegrants are the insoluble cationic exchange resins. Powdered gums may be used as disintegrants and as binders and these can include powdered gums such as agar, Karaya or tragacanth. Alginic acid and its sodium salt are also useful as disintegrants.

[00157] Binders may be used to hold the therapeutic agent together to form a hard tablet and include materials from natural products such as acacia, tragacanth, starch and gelatin. Others include methyl cellulose (MC), ethyl cellulose (EC) and carboxymethyl cellulose (CMC). Polyvinyl pyrrolidone (PVP) and hydroxypropylmethyl cellulose (HPMC) could both be used in alcoholic solutions to granulate the therapeutic.

[00158] An anti-frictional agent may be included in the formulation of the therapeutic to prevent sticking during the formulation process. Lubricants may be used as a layer between the therapeutic and the die wall, and these can include but are not limited to; stearic acid including its magnesium and calcium salts, polytetrafluoroethylene (PTFE), liquid paraffin, vegetable oils and waxes. Soluble lubricants may also be used such as sodium lauryl sulfate, magnesium lauryl sulfate, polyethylene glycol of various molecular weights, Carbowax 4000 and 6000.

[00159] Glidants that might improve the flow properties of the drug during formulation and to aid rearrangement during compression might be added. The glidants may include starch, talc, pyrogenic silica and hydrated silicoaluminate.

[00160] To aid dissolution of the therapeutic into the aqueous environment a surfactant might be added as a wetting agent. Surfactants may include anionic detergents such as sodium lauryl sulfate, dioctyl sodium sulfosuccinate and dioctyl sodium sulfonate. Cationic detergents which can be used and can include benzalkonium chloride and benzethonium chloride. Potential non-ionic detergents that could be included in the formulation as surfactants include laurmacrogol 400, polyoxyl 40 stearate, polyoxyethylene hydrogenated castor oil 10, 50 and 60, glycerol monostearate, polysorbate 40, 60, 65 and 80, sucrose fatty acid ester, methyl cellulose and carboxymethyl cellulose. These surfactants could be present in the formulation of the compound of the invention or derivative either alone or as a mixture in different ratios.

[00161] Pharmaceutical preparations which can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol. The push-fit capsules can contain the active ingredients in admixture with filler such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers. In soft capsules, the active compounds may be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols. In addition, stabilizers may be added. Microspheres formulated for oral administration may also be used. Such microspheres have been well defined in the art. All formulations for oral administration should be in dosages suitable for such administration.

[00162] Liquid preparations for oral administration may take the form of, for example, elixirs, solutions, syrups or suspensions, or they may be presented as a dry product for constitution with water or other suitable vehicle before use. Such liquid preparations may be prepared by conventional means with pharmaceutically acceptable additives such as suspending agents (*e.g.*, sorbitol syrup, cellulose derivatives or hydrogenated edible fats); emulsifying agents (*e.g.*, lecithin or acacia); non-aqueous vehicles (*e.g.*, almond oil, oily esters, ethyl alcohol, or fractionated vegetable oils); and preservatives (*e.g.*, methyl or

propyl-*p*-hydroxybenzoates or sorbic acid). The preparations may also contain buffer salts, preservatives, flavoring, coloring and sweetening agents as appropriate.

[00163] The pharmaceutical compositions may, if desired, be presented in a pack or dispenser device which may contain one or more unit dosage forms containing the

5 compound(s). The pack may, for example, comprise metal or plastic foil, such as a blister pack. The pack or dispenser device may be accompanied by instructions for administration.

[00164] For buccal administration, the compositions may take the form of tablets or lozenges formulated in conventional manner.

[00165] For topical administration, the compound may be formulated as solutions, gels, ointments, creams, suspensions, *etc.* as are well-known in the art. Systemic formulations
10 include those designed for administration by injection, *e.g.*, subcutaneous, intravenous, intramuscular, intrathecal or intraperitoneal injection, as well as those designed for transdermal, transmucosal oral or pulmonary administration.

[00166] For administration by inhalation, the compounds for use according to the present
15 invention may be conveniently delivered in the form of an aerosol spray presentation from pressurized packs or a nebulizer, with the use of a suitable propellant, *e.g.*, dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In the case of a pressurized aerosol the dosage unit may be determined by providing a valve to deliver a metered amount. Capsules and cartridges of *e.g.*, gelatin for
20 use in an inhaler or insufflator may be formulated containing a powder mix of the compound and a suitable powder base such as lactose or starch.

[00167] Also contemplated herein is pulmonary delivery of the compounds of the invention (or derivatives thereof). The compound of the invention (or derivative) is delivered to the lungs of a mammal while inhaling and traverses across the lung epithelial lining to the blood
25 stream.

[00168] Contemplated for use in the practice of this invention are a wide range of mechanical devices designed for pulmonary delivery of therapeutic products, including but not limited to nebulizers, metered dose inhalers, and powder inhalers, all of which are familiar to those skilled in the art.

5 **[00169]** Some specific examples of commercially available devices suitable for the practice of this invention are the Ultravent nebulizer, manufactured by Mallinckrodt, Inc., St. Louis, Mo.; the Acorn II nebulizer, manufactured by Marquest Medical Products, Englewood, Colo.; the Ventolin metered dose inhaler, manufactured by Glaxo Inc., Research Triangle Park, North Carolina; and the Spinhaler powder inhaler, manufactured by Fisons Corp.,
10 Bedford, Mass.

[00170] All such devices require the use of formulations suitable for the dispensing of compound of the invention (or derivative). Typically, each formulation is specific to the type of device employed and may involve the use of an appropriate propellant material, in addition to the usual diluents, adjuvants and/or carriers useful in therapy. Also, the use of liposomes,
15 microcapsules or microspheres, inclusion complexes, or other types of carriers is contemplated. Chemically modified compound of the invention may also be prepared in different formulations depending on the type of chemical modification or the type of device employed.

[00171] Formulations suitable for use with a nebulizer, either jet or ultrasonic, will typically
20 comprise compound of the invention (or derivative) dissolved in water at a concentration of about 0.1 to 25 mg of biologically active compound of the invention per mL of solution. The formulation may also include a buffer and a simple sugar (*e.g.*, for compound of the invention stabilization and regulation of osmotic pressure). The nebulizer formulation may also contain a surfactant, to reduce or prevent surface induced aggregation of the compound of the
25 invention caused by atomization of the solution in forming the aerosol.

[00172] Formulations for use with a metered-dose inhaler device will generally comprise a finely divided powder containing the compound of the invention (or derivative) suspended in

a propellant with the aid of a surfactant. The propellant may be any conventional material employed for this purpose, such as a chlorofluorocarbon, a hydrochlorofluorocarbon, a hydrofluorocarbon, or a hydrocarbon, including trichlorofluoromethane,

dichlorodifluoromethane, dichlorotetrafluoroethanol, and 1,1,1,2-tetrafluoroethane, or

5 combinations thereof. Suitable surfactants include sorbitan trioleate and soya lecithin. Oleic acid may also be useful as a surfactant.

[00173] Formulations for dispensing from a powder inhaler device will comprise a finely divided dry powder containing compound of the invention (or derivative) and may also include a bulking agent, such as lactose, sorbitol, sucrose, or mannitol in amounts which
10 facilitate dispersal of the powder from the device, *e.g.*, 50 to 90% by weight of the formulation. The compound of the invention (or derivative) should advantageously be prepared in particulate form with an average particle size of less than 10 micrometers (μm), most preferably 0.5 to 5 μm , for most effective delivery to the deep lung.

[00174] Nasal delivery of a pharmaceutical composition of the present invention is also
15 contemplated. Nasal delivery allows the passage of a pharmaceutical composition of the present invention to the blood stream directly after administering the therapeutic product to the nose, without the necessity for deposition of the product in the lung. Formulations for nasal delivery include those with dextran or cyclodextran.

[00175] For nasal administration, a useful device is a small, hard bottle to which a
20 metered dose sprayer is attached. In one embodiment, the metered dose is delivered by drawing the pharmaceutical composition of the present invention solution into a chamber of defined volume, which chamber has an aperture dimensioned to aerosolize and aerosol formulation by forming a spray when a liquid in the chamber is compressed. The chamber is compressed to administer the pharmaceutical composition of the present invention. In a
25 specific embodiment, the chamber is a piston arrangement. Such devices are commercially available.

[00176] Alternatively, a plastic squeeze bottle with an aperture or opening dimensioned to aerosolize an aerosol formulation by forming a spray when squeezed is used. The opening is usually found in the top of the bottle, and the top is generally tapered to partially fit in the nasal passages for efficient administration of the aerosol formulation. Preferably, the nasal
5 inhaler will provide a metered amount of the aerosol formulation, for administration of a measured dose of the drug.

[00177] The compounds, when it is desirable to deliver them systemically, may be formulated for parenteral administration by injection, *e.g.*, by bolus injection or continuous infusion. Formulations for injection may be presented in unit dosage form, *e.g.*, in ampoules
10 or in multi-dose containers, with an added preservative. The compositions may take such forms as sterile suspensions, solutions, or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents.

[00178] Pharmaceutical formulations for parenteral administration include aqueous solutions of the active compounds in water-soluble form. Additionally, suspensions of the
15 active compounds may be prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes. Aqueous injection suspensions may contain substances which increase the viscosity of the suspension, such as sodium carboxymethylcellulose, sorbitol, or dextran. Optionally, the suspension may also contain
20 suitable stabilizers or agents which increase the solubility of the compounds to allow for the preparation of highly concentrated solutions.

[00179] Alternatively, the active compounds may be in powder form for constitution with a suitable vehicle, *e.g.*, sterile pyrogen-free water, buffer, dextrose solution, before use. To this end, the active compound may be dried by any art-known technique, such as
25 lyophilization, and reconstituted prior to use.

[00180] The compounds may also be formulated in rectal or vaginal compositions such as suppositories or retention enemas, *e.g.*, containing conventional suppository bases such as cocoa butter or other glycerides.

[00181] For transmucosal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are known in the art.

[00182] For ocular administration, the compound(s) may be formulated as a solution, emulsion, suspension, etc. suitable for administration to the eye. A variety of vehicles suitable for administering compounds to the eye are known in the art.

[00183] In addition to the formulations described above, for prolonged delivery, the compounds may also be formulated as a depot preparation for administration by, for example, implantation or intramuscular injection. Such long acting formulations may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt. Alternatively, transdermal delivery systems manufactured as an adhesive disc or patch which slowly releases the compound for percutaneous absorption may be used. To this end, permeation enhancers may be used to facilitate transdermal penetration of the compound.

[00184] The pharmaceutical compositions also may comprise suitable solid or gel phase carriers or excipients. Examples of such carriers or excipients include but are not limited to calcium carbonate, calcium phosphate, various sugars, starches, cellulose derivatives, gelatin, and polymers such as polyethylene glycols.

[00185] Suitable liquid or solid pharmaceutical preparation forms are, for example, aqueous or saline solutions for inhalation, microencapsulated, encochleated, coated onto microscopic gold particles, contained in liposomes, nebulized, aerosols, pellets for implantation into the skin, or dried onto a sharp object to be scratched into the skin. The pharmaceutical compositions also include granules, powders, tablets, coated tablets,

(micro)capsules, suppositories, syrups, emulsions, suspensions, creams, drops or preparations with protracted release of active compounds, in whose preparation excipients and additives and/or auxiliaries such as disintegrants, binders, coating agents, swelling agents, lubricants, flavorings, sweeteners or solubilizers are customarily used as described
5 above. The pharmaceutical compositions are suitable for use in a variety of drug delivery systems. For a brief review of methods for drug delivery, see Langer R, *Science* 249:1527-33 (1990), which is incorporated herein by reference.

[00186] The compounds of the invention and optionally other therapeutics may be administered *per se* (neat) or in the form of a pharmaceutically acceptable salt. When used
10 in medicine the salts should be pharmaceutically acceptable, but non-pharmaceutically acceptable salts may conveniently be used to prepare pharmaceutically acceptable salts thereof. Such salts include, but are not limited to, those prepared from the following acids: hydrochloric, hydrobromic, sulfuric, nitric, phosphoric, maleic, acetic, salicylic, p-toluenesulfonic, tartaric, citric, methane sulfonic, formic, malonic, succinic, naphthalene-2-
15 sulfonic, and benzenesulfonic. Also, such salts can be prepared as alkaline metal or alkaline earth salts, such as sodium, potassium or calcium salts of the carboxylic acid group. Typically, such salts are more soluble in aqueous solutions than the corresponding free acids and bases, but salts having lower solubility than the corresponding free acids and bases may also be formed.

20 **[00187]** The compounds may alternatively be formulated in the pharmaceutical composition *per se*, or in the form of a hydrate, solvate, or *N*-oxide.

[00188] Suitable buffering agents include: acetic acid and a salt (1-2% w/v); citric acid and a salt (1-3% w/v); boric acid and a salt (0.5-2.5% w/v); and phosphoric acid and a salt (0.8-2% w/v). Suitable preservatives include benzalkonium chloride (0.003-0.03% w/v);
25 chlorobutanol (0.3-0.9% w/v); parabens (0.01-0.25% w/v) and thimerosal (0.004-0.02% w/v).

[00189] Pharmaceutical compositions of the invention contain an effective amount of a compound of the invention and optionally therapeutic agents included in a pharmaceutically

acceptable carrier. The term "pharmaceutically acceptable carrier" means one or more compatible solid or liquid filler, diluents or encapsulating substances which are suitable for administration to a human or other vertebrate animal. The term "carrier" denotes an organic or inorganic ingredient, natural or synthetic, with which the active ingredient is combined to facilitate the application. The components of the pharmaceutical compositions also are capable of being commingled with the compounds of the present invention, and with each other, in a manner such that there is no interaction which would substantially impair the desired pharmaceutical efficiency.

[00190] The therapeutic agent(s), including specifically but not limited to the compound of the invention, may be provided in particles. Particles as used herein means nanoparticles or microparticles (or in some instances larger particles) which can consist in whole or in part of the compound of the invention or the other therapeutic agent(s) as described herein. The particles may contain the therapeutic agent(s) in a core surrounded by a coating, including, but not limited to, an enteric coating. The therapeutic agent(s) also may be dispersed throughout the particles. The therapeutic agent(s) also may be adsorbed into the particles. The particles may be of any order release kinetics, including zero-order release, first-order release, second-order release, delayed release, sustained release, immediate release, and any combination thereof, etc. The particle may include, in addition to the therapeutic agent(s), any of those materials routinely used in the art of pharmacy and medicine, including, but not limited to, erodible, nonerodible, biodegradable, or nonbiodegradable material or combinations thereof. The particles may be microcapsules which contain the compound of the invention in a solution or in a semi-solid state. The particles may be of virtually any shape.

[00191] Both non-biodegradable and biodegradable polymeric materials can be used in the manufacture of particles for delivering the therapeutic agent(s). Such polymers may be natural or synthetic polymers. The polymer is selected based on the period of time over which release is desired. These include polyhyaluronic acids, casein, gelatin, gluten,

polyanhydrides, polyacrylic acid, alginate, chitosan, poly(methyl methacrylates), poly(ethyl methacrylates), poly(butylmethacrylate), poly(isobutyl methacrylate), poly(hexylmethacrylate), poly(isodecyl methacrylate), poly(lauryl methacrylate), poly(phenyl methacrylate), poly(methyl acrylate), poly(isopropyl acrylate), poly(isobutyl acrylate), and
5 poly(octadecyl acrylate).

[00192] The therapeutic agent(s) may be contained in controlled release systems. The term “controlled release” is intended to refer to any drug-containing formulation in which the manner and profile of drug release from the formulation are controlled. This refers to immediate as well as non-immediate release formulations, with non-immediate release
10 formulations including but not limited to sustained release and delayed release formulations. The term “sustained release” (also referred to as “extended release”) is used in its conventional sense to refer to a drug formulation that provides for gradual release of a drug over an extended period of time, and that preferably, although not necessarily, results in substantially constant blood levels of a drug over an extended time period. The term
15 “delayed release” is used in its conventional sense to refer to a drug formulation in which there is a time delay between administration of the formulation and the release of the drug there from. “Delayed release” may or may not involve gradual release of drug over an extended period of time, and thus may or may not be “sustained release.”

[00193] Use of a long-term sustained release implant may be particularly suitable for
20 treatment of chronic conditions. “Long-term” release, as used herein, means that the implant is constructed and arranged to deliver therapeutic levels of the active ingredient for at least 7 days, and preferably 30-60 days. Long-term sustained release implants are well-known to those of ordinary skill in the art and include some of the release systems described above.

[00194] It will be understood by one of ordinary skill in the relevant arts that other suitable
25 modifications and adaptations to the compositions and methods described herein are readily apparent from the description of the invention contained herein in view of information known

to the ordinarily skilled artisan, and may be made without departing from the scope of the invention or any embodiment thereof.

Methods of the Invention

[00195] Another aspect of the invention is a method for treating asthma, comprising

5 administering to a subject in need thereof a therapeutically effective amount of a compound of the invention, for example, a compound of Formula (I).

[00196] In another aspect, the invention provides a method for inhibiting arginase 1, arginase 2, or a combination thereof in a cell, comprising contacting the cell with at least one compound according to the invention, for example, a compound of Formula (I), or a

10 pharmaceutically acceptable salt thereof.

[00197] In another aspect, the invention provides a method for the treatment or prevention of a disease or condition associated with expression or activity of arginase 1, arginase 2, or a combination thereof, comprising administering to a subject in need thereof a therapeutically effective amount of at least one compound according to the invention, for example, a

15 compound of Formula (I), or a pharmaceutically acceptable salt thereof.

[00198] In certain embodiments, the disease or condition is selected from the group consisting of cardiovascular disorders, pulmonary disorders, autoimmune disorders, immune disorders, hemolytic disorders, gastrointestinal disorders, sexual disorders, infections, cancers, and wound healing disorders.

20 **[00199]** In certain embodiments, the disease or condition is cardiovascular disorder selected from the group consisting of systemic hypertension, pulmonary arterial hypertension (PAH), pulmonary arterial hypertension in high altitude, ischemia reperfusion (IR) injury, myocardial infarction and atherosclerosis.

[00200] In certain embodiments, the disease or condition is pulmonary arterial
25 hypertension (PAH).

[00201] In certain embodiments, the disease or condition is myocardial infarction or atherosclerosis.

[00202] In certain embodiments, the disease or condition is a pulmonary disorder selected from the group consisting of chemically-induced lung fibrosis, idiopathic pulmonary fibrosis, cystic fibrosis, chronic obstructive pulmonary disease (COPD), and asthma.

[00203] In certain embodiments, the disease or condition is an autoimmune disorder selected from the group consisting of encephalomyelitis, multiple sclerosis, anti-phospholipid syndrome 1, autoimmune hemolytic anemia, chronic inflammatory demyelinating polyradiculoneuropathy, dermatitis herpetiformis, dermatomyositis, myasthenia gravis, pemphigus, rheumatoid arthritis, stiff-person syndrome, type 1 diabetes, ankylosing spondylitis, paroxysmal nocturnal hemoglobinuria (PNH), paroxysmal cold hemoglobinuria, severe idiopathic autoimmune hemolytic anemia, and Goodpasture's syndrome.

[00204] In certain embodiments, the disease or condition is an immune disorder selected from the group consisting of myeloid-derived suppressor cell (MDSC) mediated T-cell dysfunction, human immunodeficiency virus (HIV) infection, autoimmune encephalomyelitis, and ABO mismatch transfusion reaction.

[00205] In certain embodiments, the disease or condition is T-cell dysfunction mediated by myeloid-derived suppressor cells (MDSC).

[00206] In certain embodiments, the disease or condition is a hemolytic disorder selected from the group consisting of sickle-cell disease, thalassemias, hereditary spherocytosis, stomatocytosis, microangiopathic hemolytic anemias, pyruvate kinase deficiency, infection-induced anemia, cardiopulmonary bypass, mechanical heart valve-induced anemia, and chemical-induced anemia.

[00207] In certain embodiments, the disease or condition is sickle-cell disease.

[00208] In certain embodiments, the disease or condition is a gastrointestinal disorder selected from the group consisting of gastrointestinal motility disorders, gastric cancers, inflammatory bowel disease, Crohn's disease, ulcerative colitis, and gastric ulcers.

[00209] In certain embodiments, the disease or condition is a sexual disorder selected from the group consisting of Peyronie's disease and erectile dysfunction.

[00210] In certain embodiments, the disease or condition is ischemia reperfusion (IR) injury selected from the group consisting of liver IR, kidney IR, and myocardial IR.

[00211] In certain embodiments, the disease or condition is a cancer selected from the group consisting of oesophagic, gastric, colon, ovary, breast, pancreatic, head-and-neck, bladder, and lung cancers (including squamous and non-small cell lung carcinoma), renal cell carcinoma, prostate carcinoma, multiple myeloma, neuroblastoma, glioblastoma, astrocytoma, mesothelioma and melanoma, B cells, T cells and NK cells lymphomas, acute and chronic, myeloid and lymphoid leukemia.

[00212] In certain embodiments, the cancer is selected from the group consisting of gastric (including but not limited to gastric or gastroesophageal junction cancer), colorectal cancer, pancreatic cancer, liver cancer, breast cancer, lung cancers (including but not limited to non-small cell lung carcinoma), renal cell carcinoma, prostate carcinoma, multiple myeloma, acute and chronic leukemias, T cell, B cell and NK cell lymphomas, brain tumors (including but not limited to neuroblastoma, glioblastoma, astrocytoma), squamous-cell carcinomas of the head and neck, and melanoma.

[00213] In certain embodiments, the disease or condition is selected from the group consisting of renal disease inflammation, psoriasis, leishmaniosis, neurodegenerative diseases, wound healing, human immunodeficiency virus (HIV) infection, hepatitis B virus (HBV) infection, *Helicobacter pylori* infection, fibrotic disorders, arthritis, candidiasis, periodontal disease, keloids, adenotonsillar disease, African sleeping sickness and Chagas' disease.

[00214] In certain embodiments, the disease or condition is a wound healing disorder selected from the group consisting of infected and uninfected wound healing.

[00215] In certain embodiments, the subject is a mammal selected from the group consisting of human, dog, cat, horse, cow, pig, sheep, goat, ape and rodent.

5 **[00216]** In certain embodiments, the method of treatment further comprises administering to the patient a therapeutically effective amount of anti-viral agents, a chemotherapeutic agents (including alkylating antineoplastic agents, antimetabolites, anti-microtubule agents), immunosuppressants, radiation, an anti-tumor vaccines, an antiviral vaccines, cytokine therapy, tyrosine kinase inhibitors, immunotherapeutic agents, including checkpoint inhibitors
10 such as PD-1, PD-L1 or CTLA-4 inhibitors and IDO/TDO inhibitors, adenosine A2A receptor antagonists, ectonucleotidase (CD73 and CD39) inhibitors, agent affecting interleukins, cytokines and chemokines, topoisomerase inhibitors, cytotoxic antibiotics or targeted therapies such as antibodies, antibody drug conjugates, cell-based immunotherapy, nanoparticles, radiotherapy prior to, simultaneously with, or after administration of the at least
15 one compound according to the invention, for example, a compound of Formula (I), or a pharmaceutically acceptable salt thereof.

[00217] In certain embodiments, the method of treatment further comprises administering to the subject a therapeutically effective amount of anti-PD-1, anti-PD-L1 or anti-CTLA4 antibodies.

20 **[00218]** In some embodiments, the cancer is chronic lymphocytic leukemia, acute lymphoblastic leukemia, chronic myelogenous leukemia, acute myeloid leukemia, adrenocortical carcinoma, anal cancer, appendix cancer, atypical teratoid/rhabdoid tumor, basal cell carcinoma, bile duct cancer, bladder cancer, bone cancer, brain tumor, brain and spinal cord tumor, brain stem glioma, central nervous system atypical teratoid/rhabdoid
25 tumor, central nervous system embryonal tumors, breast cancer, bronchial tumors, Burkitt lymphoma, carcinoid tumor, carcinoma of unknown primary origin, central nervous system cancer, cervical cancer, childhood cancers, chordoma, chronic myeloproliferative disorders,

colon cancer, craniopharyngioma, cutaneous T-cell lymphoma, ductal carcinoma in situ, embryonal tumors, endometrial cancer, ependymblastoma, ependymoma, esophageal cancer, esthesioneuroblastoma, Ewing sarcoma, extracranial germ cell tumor, extrahepatic bile duct cancer, eye cancer, fibrous histiocytoma of bone, gallbladder cancer, gastric cancer, gastrointestinal carcinoid tumor, gastrointestinal stromal tumors, germ cell tumor, 5 extracranial germ cell tumor, extragonadal germ cell tumor, ovarian germ cell tumor, gestational trophoblastic tumor, glioma, hairy cell leukemia, head and neck cancer, heart cancer, hepatocellular cancer, histiocytosis, Langerhans cell cancer, Hodgkin's lymphoma, hypopharyngeal cancer, intraocular melanoma, islet cell tumors, Kaposi sarcoma, kidney cancer, Langerhans cell histiocytosis, laryngeal cancer, lip and oral cavity cancer, lobular 10 carcinoma in situ, lymphoma, AIDS-related lymphoma, macroglobulinemia, male breast cancer, medulloblastoma, medulloepithelioma, Merkel cell carcinoma, malignant mesothelioma, metastatic squamous neck cancer, midline tract carcinoma involving NUT gene, mouth cancer, multiple endocrine neoplasia syndrome, plasma cell neoplasm, mycosis 15 fungoides, myeloma, chronic myeloproliferative disorder, nasal cavity cancer, paranasal sinus cancer, nasopharyngeal cancer, non-Hodgkin's lymphoma, oral cancer, oral cavity cancer, lip cancer, oropharyngeal cancer, osteosarcoma, ovarian cancer, papillomatosis, paraganglioma, paranasal sinus cancer, nasal cavity cancer, parathyroid cancer, penile cancer, pharyngeal cancer, pheochromocytoma, pineal parenchymal tumors of intermediate 20 differentiation, pineoblastoma, pituitary tumor, plasma cell neoplasm, pleuropulmonary blastoma, primary central nervous system lymphoma, rectal cancer, renal cell cancer, renal pelvis cancer, ureter cancer, transitional cell cancer, retinoblastoma, rhabdomyosarcoma, salivary gland cancer, sarcoma, Sézary syndrome, skin cancer, small cell lung cancer, small intestine cancer, soft tissue sarcoma, squamous cell carcinoma, squamous neck cancer with 25 occult primary, stomach cancer, supratentorial primitive neuroectodermal tumors, testicular cancer, throat cancer, thymoma, thymic carcinoma, thyroid cancer, transitional cell cancer of the renal pelvis and ureter, gestational trophoblastic tumor, unknown primary, unusual

cancer of childhood, urethral cancer, uterine cancer, uterine sarcoma, Waldenströms macroglobulinemia, or Wilms' tumor.

Uses


[00219] In another aspect, the invention provides use of a compound according to the invention, for example, a compound of Formula (I), or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment or prevention of a disease or condition associated with expression or activity of arginase 1, arginase 2, or a combination thereof.

[00220] In another aspect, the invention provides use of a compound according to the invention, for example, a compound of Formula (I), or a pharmaceutically acceptable salt thereof, for protecting an organ during transport.

Process for Manufacturing

[00221] The compounds of Formula I can be prepared by different ways with reactions known to a person skilled in the art.

[00222] The invention further relates to a first process for manufacturing of compounds of Formula Ib comprising steps illustrated below:



[00223] Ketone 1 can be obtained commercially or prepared by several known methods.

Vinylation of Ketone 1 to form racemic piperidone 2 can be accomplished using an

5 appropriate vinyl metal nucleophile, such as a vinyl lithium reagent, a vinyl magnesium reagent, a vinyl zinc reagent, a vinyl copper reagent, or reagents including mixtures of these metals. 1,4-conjugated vinyl addition can be also accomplished using an appropriate vinyl boronic acid, vinyl boronic acid esters, metal salts of vinyl trifluoroborate or vinyl alkoxy silanes. The addition may also be assisted with Lewis acids or transitional metals.

10 Solvents can include any of those suitable for conjugated addition, such as but not limited to diethyl ether, tetrahydrofuran, 2-methyltetrahydrofuran, 1,4-dioxane. For the addition of borane and silane derivatives, methanol, ethanol, isopropanol or their combination can be also used as a solvent, with or without the addition of base like trialkylamines or metal hydroxides. Piperidone 2 can then be transformed to racemic amino acid derivative 3 in a


15 multi-component reaction. Such multi-component reactions can include but are not limited

to, the Ugi reaction, the Bucherer-Bergs reaction, the Strecker reaction, and variations thereof. Solvents can include any of those suitable for such reactions: methanol, ethanol, isopropanol, trifluoroethanol, water, acetonitrile, dichloromethane, tetrahydrofuran, and mixtures thereof, and can include additives such as triethylamine or ammonium hydroxide.

- 5 Single racemic diastereoisomer with the relative configuration as in the structure of compound 3 can be obtained by chromatographic method on silica gel of the diastereoisomeric mixture or by crystallization from appropriate solvents. Such solvents include but are not limited to DCM, chloroform, hexane, pentane, cyclohexane, heptane, ethyl acetate, diisopropyl ether, diethyl ether, methyl *tert*-butyl ether. The racemic amino
- 10 acid derivative 3 can then be resolved into single enantiomers using chromatographic methods with chiral stationary phase. Enantiomerically enriched amino acid derivative can then be deprotected under readily available conditions (e.g., removal of Boc with TFA or HCl) to afford enantiomerically enriched piperidine 4 as an appropriate salt. Piperidine 4 can be then benzylated using known methods readily apparent to those of skill in the art, such as
- 15 with benzaldehyde under reductive amination conditions or by the use of benzyl halide in the presence of base. Hydroboration can be accomplished using known methods readily apparent to those of skill in the art, such as using pinacol borane or bis(pinacolato)diboron in the presence of an appropriate catalyst that include but is not limited to iridium, rhodium, cobalt, iron, nickel, $\text{BH}_3\text{-THF}$ $\text{BH}_3\text{-Me}_2\text{S}$ and can includes additives like NaOH, *t*-BuONa or
- 20 sodium triethylborohydride. Hydrolysis of amide 6 to amino acid 7 can be accomplished using known methods readily apparent to those of skill in the art, such as heating with mineral acids (e.g. hydrochloric or hydrobromic acid). The protection of amino acid 7 can be accomplished using aqueous sodium bicarbonate, sodium carbonate or sodium hydroxide and di-*tert*-butyl dicarbonate (Boc_2O) in the appropriate solvent (e.g. water, acetone,
- 25 acetonitrile, THF, 1,4-dioxane, isopropanol). Boc-amino acid 8 can be next deprotected under hydrogenolytic conditions readily apparent to those of skill in the art (e.g. $\text{H}_2/\text{Pd}(\text{OH})_2/\text{MeOH}$). An amidation of 9 can be accomplished using known methods readily apparent to those of skill in the art. It can include but is not limited to the use of appropriate

protected amino acid with activated carboxyl group (e.g. by using protected hydroxysuccinimide esters or mixed anhydrides). Solvents can include any of those suitable for peptide synthesis, such as but not limited to DMF, acetonitrile, THF, water, acetone, 1,4-dioxane, DCM with or without addition of tertiary amine (e.g. triethylamine). The activation of carboxyl group can be alternatively accomplished *in situ* using coupling reagent that include but is not limited to DCC, EDCI, TBTU, HOBt, HATU. Global deprotection can afford arginase inhibitor represented by formula Ib.

[00224] The invention further relates to an alternative process for manufacturing of compounds of Formula Ib:



Ib


or precursors thereof, wherein:

R⁶ is selected from the amino acid side chain of Gly, Ala, Val, Ser, Phe, Lys, Thr, Met, Tyr, His, Asp, Glu, Asn, Gln, Cys, Sec, Ile, Leu, Arg, Orn, Cit, Trp; 1-Me-Trp and Nva;

or a pharmaceutically acceptable salt thereof;

comprising:

[00225] reducing an ester of the formula




in which


P_g is methyl substituted with 1, 2, or 3 phenyl groups, where each phenyl group is optionally substituted with 1, 2 or 3 groups independently selected from halogen, nitro, C_1 - C_6 alkoxy, or C_1 - C_6 alkyl;

R^E is C_1 - C_6 alkyl, C_3 - C_6 cycloalkyl, C_3 - C_6 cycloalkyl(C_1 - C_6)alkyl, or methyl substituted with 1, 2, or 3 phenyl groups, where each phenyl group is optionally substituted with 1, 2 or 3 groups independently selected from halogen, nitro, C_1 - C_6 alkoxy, or C_1 - C_6 alkyl


to yield a protected hydroxymethylpyrrolidine of the formula:




10 **[00226]** subjecting the protected hydroxymethylpyrrolidine to ring expansion conditions to produce a protected piperidine of the formula:




[00227] oxidizing the protected piperidine to form an enantiomerically enriched product comprising a ketone of the formula:



[00228] reacting the ketone with cyanide and an amine source to yield an α -cyanoamine of the formula:




[00229] acylating the amino group of the α -cyanoamine to produce an acylated α -cyanoamine of the formula:




wherein R^N is C_2 - C_6 alkanoyl.

- 5 [00230] In certain such embodiments, the process further comprises subjecting the acylated α -cyanoamine to hydroboration conditions, and then deprotecting the resulting cyclic boronate ester to produce a boronic acid of the formula:




- [00231] In certain such embodiments, the process further comprises hydrolyzing the acyl group to yield an α -amino acid with an unprotected amino group, and then protecting the amino group of the α -amino acid to generate a boronic acid of formula B-1:
- 10



wherein R^N is a nitrogen protecting group.

- [00232] In certain such embodiments, the process further comprises reacting the compound of formula B-1 with a compound of the formula:
- 15



in which

L is a leaving group, such as *N*-hydroxysuccinimidyl or carboxylate or carbonate;

Pg¹ is a nitrogen protecting group;

R⁶ represents a side chain of an amino acid selected from the group consisting of


5 Gly, Ala, Val, Ser, Phe, Lys, Thr, Met, Tyr, His, Asp, Glu, Asn, Gln, Cys, Sec, Ile, Leu, Arg, Orn, Cit, Trp; 1-Me-Trp and Nva; and

R⁷ is hydrogen or methyl.

[00233] In certain embodiments of the process, desired stereoisomers can be obtained at any point using appropriate methods, for example, by fractional crystallization or


10 chromatographic means well known in the art.

[00234] For example, in certain embodiments, the process for preparing a compound of formula Ib comprises the following steps:



[00235] Methyl (2*R*,4*R*)-1-benzyl-4-hydroxypyrrolidine-2-carboxylate 11 can be obtained commercially or prepared from *cis*-hydroxy-*D*-proline using literature methods. Reduction of ester 11 to alcohol 12 can be accomplished using known methods, for example, by using LiAlH₄, LiBH₄ or NaBH₄ in an appropriate solvent such as THF, diethyl ether or a mixture of THF and methanol. Pyrrolidine 12 can be then reacted to form to piperidine 13 via a ring expansion reaction according to the methods as otherwise described herein.

[00236] The ring expansion of enantiomerically and diastereoisomerically enriched protected (3*R*,5*R*)-5-(hydroxymethyl)pyrrolidin-3-ol A into enantiomerically and diastereoisomerically enriched protected (3*R*,5*R*)-5-vinylpiperidin-3-ol C is illustrated in the scheme below:



[00237] In this example, Pg is a protecting group including benzyl and its derivatives. The protecting group of A includes but is not limited to benzyl, 4-methylbenzyl, 4-methoxybenzyl, 4-bromobenzyl, 4-nitrobenzyl, 3-methylbenzyl, 2-methylbenzyl, 3,4-dimethoxybenzyl, 2,4,6-trimethylbenzyl, benzhydryl, trityl. Preferentially, the protecting group is benzyl. The formation of C take place via azabicyclo[3.1.0]hexan-1-ium salt B. A is treated with acid anhydride in the presence of the base in an appropriate solvent. The acid anhydride can include but is not limited to trifluoromethanesulfonic (triflic) anhydride, methanesulfonic anhydride, p-toluenesulfonic anhydride, trifluoroacetic anhydride. Preferentially, the acid anhydride is trifluoromethanesulfonic anhydride. The base can include but is not limited to *N,N*-diisopropylethylamine (DIPEA), trimethylamine (TEA), DBU, DBN, DABCO, proton-sponge, Cs₂CO₃; preferentially the base is DIPEA. In some embodiment the formation of B can be accomplished without use of any external base. The solvent can include but is not limited to dichloromethane (DCM), tetrahydrofuran (THF), diethyl ether (Et₂O); preferentially

the solvent is DCM. The reaction can be performed at a temperature within the range of -78 °C to room temperature; preferentially at -40 °C. The same conditions can be used to synthesize protected (3*S*,5*S*)-5-vinylpiperidin-3-ol, starting from protected (3*S*,5*S*)-5-(hydroxymethyl)pyrrolidin-3-ol.

- 5 **[00238]** The formation of protected (3*R*,5*R*)-5-vinylpiperidin-3-ol C can be accomplished by aziridinium ring opening of azabicyclo[3.1.0]hexan-1-ium salt B, using a vinyl metal nucleophile such as a vinyl lithium reagent, a vinyl magnesium reagent, a vinyl zinc reagent, a vinyl copper reagent, or reagents including mixtures of these metals. Preferentially, the vinyl metal nucleophile is vinylmagnesium chloride (solution in THF). The ring opening
- 10 reaction may also be assisted with copper salts [Cu] that include but are not limited to copper(I) chloride, copper(I) bromide, copper(I) iodide, copper(I) cyanide, copper(I) bromide dimethyl sulfide complex, and lithium tetrachlorocuprate; preferentially copper(I) chloride. The solvent can include but is not limited to THF, 2-Me-THF, and Et₂O. The reaction can be performed at a temperature within the range of -78 °C to room temperature; preferentially at -
- 15 40 °C.

[00239] The enantio- and diastereomerically enriched alcohol 13 can then be oxidized to enantiomerically enriched ketone 14 using known methods for secondary alcohols, such as but not limited to, Corey-Kim oxidation, Parikh-Doering oxidation, Swern oxidation, oxidation using hypervalent iodine, and the like.

- 20 **[00240]** Ketone 14 can then be transformed to diastereomerically enriched amino acid derivative 15 in a multi-component reaction. Such multi-component reactions can include but are not limited to, the Strecker reaction, the Ugi reaction, the Bucherer-Bergs reaction, and variations thereof. Solvents can include any of those suitable for such reactions: methanol, ethanol, isopropanol, trifluoroethanol, water, acetonitrile, dichloromethane, tetrahydrofuran,
- 25 and mixtures thereof, and can include additives such as triethylamine or ammonium hydroxide. In the case of the Strecker reaction the cyanide source can be but is not limited to acetone cyanohydrine, sodium cyanide, and potassium cyanide. The ammonia source

can be but is not limited to aqueous ammonia solution (NH₄OH), methanolic solution of ammonia, ammonium chloride, and ammonium acetate. Solvents can include any of those suitable for such reactions: methanol, ethanol, isopropanol, trifluoroethanol, water, acetonitrile, tetrahydrofuran, and mixtures thereof. The reaction can be performed at a temperature within the range of room temperature to 100 °C; preferentially at 60 °C. In the case of the Strecker reaction the appropriate cyanoamine 15 can be formed as a mixture of epimers, (3*R*,5*R*)-3-amino-1-benzyl-5-vinylpiperidine-3-carbonitrile and (3*S*,5*R*)-3-amino-1-benzyl-5-vinylpiperidine-3-carbonitrile, present in the range from 1:1 to 10:1. The pure single epimer (3*R*,5*R*)-3-amino-1-benzyl-5-vinylpiperidine-3-carbonitrile can be obtained through chromatographic methods or by crystallization of the appropriate salt (e.g. oxalate) from a suitable solvent (e.g. ethanol). Preferentially the mixture of epimers can be used in subsequent steps without separation. The mixture of epimers 15 can then be protected under readily available conditions (e.g., acetylation with Ac₂O or AcCl in the presence of TEA) to afford a mixture of protected cyanoamines that can be then separated into the single enantiomerically and diastereomerically enriched protected cyanoamine 16 through chromatography (e.g. SiO₂ column chromatography) or crystallization of the appropriate salt (e.g. oxalate). Further steps can include hydroboration of cyanoamine 16 followed by pinacole removal by transesterification using phenylboronic acid to afford boronic acid 17, and can be accomplished using known methods. Subsequent hydrolysis and protection can be accomplished under readily available conditions (e.g., hydrolysis with aqueous hydrochloric acid, then Boc –protection using Boc₂O in alkaline aqueous media) to afford intermediate 8. Intermediate 8 can be subjected to steps as otherwise described herein to afford arginase inhibitors of formula Ib.

EXAMPLES

[00241] The present invention is further illustrated by the following examples, which in no way should be construed as limiting the scope of the claimed invention.

Methods of Preparation and Characterization

[00242] The compounds of the present disclosure may be prepared by use of known chemical reactions and procedures. Representative methods for synthesizing compounds of the disclosure are presented below. It is understood that the nature of the substituents required for the desired target compound often determines the method of synthesis. All variable groups of these methods are as described in the generic description if they are not specifically defined below.

[00243] Those having skill in the art will recognize that the starting materials and reaction conditions may be varied, the sequence of the reactions altered, and additional steps employed to produce compounds encompassed by the present disclosure, as demonstrated by the following examples. Many general references providing commonly known chemical synthetic schemes and conditions useful for synthesizing the disclosed compounds are available (see, *e.g.*, Smith and March, *March's Advanced Organic Chemistry: Reactions, Mechanisms, and Structure*, Fifth Edition, Wiley-Interscience, 2001; or Vogel, *A Textbook of Practical Organic Chemistry, Including Qualitative Organic Analysis*, Fourth Edition, New York: Longman, 1978).

[00244] For the more specific guidance concerning the synthetic approach to boron bearing alpha-amino acids, the reader is referred to the international patent application publications WO 11/133653 (incorporated by reference), WO 13/059437 (incorporated by reference), WO 17/075363, WO 16/108707 and WO 17/191130.

[00245] The reactions are performed in a solvent appropriate to the reagents and materials employed and suitable for the transformations being effected. It will be understood by those skilled in the art of organic synthesis that the functionality present on the molecule should be consistent with the transformations proposed. This will sometimes require a judgment to modify the order of the synthetic steps or to select one particular process scheme over another in order to obtain a desired compound of the disclosure.

[00246] In some cases, protection of certain reactive functionalities may be necessary to achieve some of the above transformations. In general, the need for such protecting groups as well as the conditions necessary to attach and remove such groups will be apparent to those skilled in the art of organic synthesis. An authoritative account describing the many alternatives to the trained practitioner are in J. F. W. McOmie, "*Protective Groups in Organic Chemistry*," Plenum Press, London and New York 1973, in T. W. Greene and P. G. M. Wuts, "*Protective Groups in Organic Synthesis*," Third edition, Wiley, New York 1999, in "*The Peptides*," Volume 3 (editors: E. Gross and J. Meienhofer), Academic Press, London and New York 1981, in "*Methoden der organischen Chemie*," Houben-Weyl, 4th edition, Vol. 15/1, Georg Thieme Verlag, Stuttgart 1974, in H.-D. Jakubke and H. Jescheit, "*Aminosäuren, Peptide, Proteine*," Verlag Chemie, Weinheim, Deerfield Beach, and Basel 1982, and/or in Jochen Lehmann, "*Chemie der Kohlenhydrate: Monosaccharide und Derivate*," Georg Thieme Verlag, Stuttgart 1974. The protecting groups may be removed at a convenient subsequent stage using methods known from the art. The disclosures of all articles and references mentioned in this application, including patents, are incorporated herein by reference in their entirety.

[00247] Starting materials can be obtained from commercial sources or prepared by literature methods.

[00248] All solvents, substrates and reagents that were commercially available were used without further purification. TLC analysis was performed using pre-coated glass plates (TLC silica gel 60 F₂₅₄) from Merck. Column chromatography was performed using high-purity grade silica gel (pore size 60 Å, 230-400 mesh particle size, 40-63 µm particle size) from Merck.

[00249] Preparative HPLC were performed on LC-20AP Shimadzu with ELSD-LTII detector equipped with Hypersil GOLD 21.2/250 mm, 5 µm C18 column.

[00250] ¹H and ¹³C NMR spectra were recorded on Bruker AVANCE II PLUS (Ultra Shield) NMR spectrometer at 700 MHz.

[00251] All spectra were recorded in appropriate deuterated solvents (CDCl₃, DMSO-d₆, D₂O, CD₃OD, *etc.*) that were commercially available.

[00252] Resonances are given in parts per million relative to tetramethylsilane. Data are reported as follows: chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, m =


5 multiplet, bs = broad singlet), coupling constants (Hz) and integration.

[00253] ESI-MS spectra were obtained on a Shimadzu LC-20AD LPG separation module with a SPD-M20A UV detector and LCMS-2020 mass detector equipped with Kinetex 2.1/50 mm, 2.6 µm C18 column eluted with 0.5 mL/min flow of 10-90% gradient (over 5 min) of acetonitrile in water.


10 **[00254]** Abbreviations used are those conventional in the art or the following:

[00255] Ac = acetyl, aq = aqueous, Bn = benzyl, Boc = *tert*-butoxycarbonyl, *t*-Bu = *tert*-butyl, °C = degree Celsius, Cit = citrulline or citrullinyl, cod = 1,5-cyclooctadiene, DCE = 1,2-dichloroethane, DCM = dichloromethane, DMF = *N,N*-dimethylformamide, DMSO = dimethyl sulfoxide, dppe = 1,2-bis(diphenylphosphino)ethane, ELSD = evaporative light scattering
15 detector, EtOAc or AcOEt = ethyl acetate, EtOH = ethanol, ESI+MS = electrospray ionisation mass spectrometry (in the positive ion mode), ESI-MS = electrospray ionisation mass spectrometry (in the negative ion mode), g = gram, h = hour(s), HMPA = hexamethylphosphoramide, HPLC = high pressure liquid chromatography, K = kelvin, L = liter, LCMS = liquid chromatography and mass spectrometry, MeCN = acetonitrile, MeOH =
20 methanol, min = minutes, mL = milliliter(s), M = molar, m/z = mass to charge ratio, NCS = *N*-chlorosuccinimide, nM = nanomolar, NMR = nuclear magnetic resonance, N = normal, Nva = norvaline or norvalinyl, Orn = ornithine or ornithinyl, OSu = *N*-oxysuccinimidyl, RT or rt = room temperature, TEA = triethyl amine, TFA = trifluoroacetic acid, THF = tetrahydrofuran, TMSCl = chlorotrimethylsilane.


[00256] Exemplary general synthetic methodologies for making compounds of Formula (I) are provided below.



5 **Example 1. (3R,5S)-1-(L-Alanyl)-3-amino-5-(2-boronoethyl)piperidine-3-carboxylic acid dihydrochloride.**



Step A. *tert*-Butyl 3-oxo-3,6-dihydropyridine-1(2*H*)-carboxylate.




5

[00257] To a solution of *tert*-butyl 3-hydroxy-3,6-dihydropyridine-1(2*H*)-carboxylate (CAS: 224779-27-5, 10 g, 50.19 mmol) in DCM (200 mL) was added Dess-Martin periodinane (25.55 g, 60.2 mmol). After stirring for 1.5 h additional amount of Dess-Martin periodinane (2.50 g, 12.54 mmol) was added together with DCM (50 mL). The reaction mixture was stirred for additional 1.5 h; then 750 mL of hexane was added and stirring was continued for 10 min. The solid that precipitated was filtered off. The filtrate was concentrated and treated with a fresh portion of hexane (500 mL), filtered and concentrated in vacuo to give 10.01 g (100%) of *tert*-butyl 3-oxo-3,6-dihydropyridine-1(2*H*)-carboxylate as a pale orange solid. ESI+MS: $m/z = 142.20$ ($M - 56 + 1$)⁺. ¹H NMR (700 MHz, 300 K, DMSO-*d*₆) δ 7.22 (bs, 1H), 6.10 (dt, $J = 10.3, 2.3$ Hz, 1H), 4.18 (bs, 1H), 4.01 (bs, 1H), 1.42 (s, 9H).

15

Step B. *tert*-Butyl 3-oxo-5-vinylpiperidine-1-carboxylate.




20

[00258] To a flask charged with CuBr x Me₂S complex (0.78 g, 3.8 mmol) and dry THF (125 mL) were added HMPA (17.60 mL, 101.40 mmol) and vinylmagnesium bromide 1M solution in THF (88.72 mL, 88.72 mmol) at -78°C under Ar. The reaction mixture was stirred

for 15 min followed by a solution of *tert*-butyl 3-oxo-3,6-dihydropyridine-1(2*H*)-carboxylate (5 g, 25.35 mmol) and chlorotrimethylsilane (16.08 mL, 126.75 mmol) in THF (75 mL) was added dropwise for over 30 min. The reaction mixture was stirred for 2 h at -78°C and subsequently overnight at RT. After the reaction was completed, 60 mL of saturated aqueous NH₄Cl solution was added, and then the layers were separated. The organic layer was washed with NH₄Cl (3 x 30 mL). The aqueous layer was diluted with H₂O (100 mL) and washed with AcOEt (2 x 40 mL). The combined organic layers were washed with brine (20 mL), dried over MgSO₄ and concentrated *in vacuo*. The crude product was purified by silica gel column chromatography using hexane/EtOAc (1:0 to 1:4) as an eluent. The desired product was obtained as a colorless oil. Yield: 4.23 g (74 %). ESI+MS: *m/z* = 170.15 (M -56 +1)⁺. ¹H NMR (700 MHz, 300 K, chloroform-*d*) δ 5.77 (ddd, *J* = 17.0, 10.5, 6.3 Hz, 1H), 5.15 – 5.10 (m, 2H), 4.09 (d, *J* = 18.0 Hz, 1H), 4.05 – 3.72 (m, 2H), 3.21 (bs, 1H), 2.78 – 2.71 (m, 1H), 2.61 (dd, *J* = 16.3, 4.7 Hz, 1H), 2.37 (dd, *J* = 16.2, 10.0 Hz, 1H), 1.46 (s, 9H).


Step C. *tert*-Butyl (3*R*,5*R*)-3-acetamido-3-(*tert*-butylcarbamoyl)-5-vinylpiperidine-1-carboxylate (racemate).



[00259] To the stirred solution of *tert*-butyl 3-oxo-5-vinylpiperidine-1-carboxylate (4.23 g, 21.45 mmol), and ammonium acetate (5.80 g, 77.25 mmol) in 2,2,2-trifluoroethanol (60 mL), *tert*-butyl isocyanide (3.10 mL, 27.41 mmol) was added dropwise and the resulting mixture was stirred at room temperature overnight. After the reaction was completed, the solvent was evaporated under reduced pressure and the residue was diluted with DCM (60 mL) and water (25 mL). The separated aqueous layer was washed with DCM (3 x 10 mL). The

combined organic layers were washed with brine (20 mL), dried over MgSO_4 , filtered and concentrated under reduced pressure to volume of 10-15 mL. The residue was treated with hexane (50 mL) and left for 24 h for crystallization. The precipitated solid was filtered and dried under vacuum to give 3.85 g (49% yield) of the desired product as a white crystalline solid (single racemic diastereoisomer). ESI+MS: $m/z = 368.25 (M+1)^+$. ^1H NMR (700 MHz, 300K, chloroform- d) δ 7.00 (bs, 1H), 5.96 (bs, 1H), 5.73 (ddd, $J = 17.1, 10.6, 6.1$ Hz, 1H), 5.14 (dt, $J = 17.1, 1.2$ Hz, 1H), 5.08 (dt, $J = 10.6, 1.2$ Hz, 1H), 4.38 (d, $J = 14.2$ Hz, 1H), 3.78 (dd, $J = 13.5, 2.4$ Hz, 1H), 3.47 (d, $J = 13.9$ Hz, 1H), 3.02 (dd, $J = 12.8, 8.8$ Hz, 1H), 2.36 (bs, 1H), 2.27 (d, $J = 11.8$ Hz, 1H), 1.96 – 1.89 (m, 4H), 1.48 (s, 9H), 1.33 (s, 9H).


Step D. *tert*-Butyl (3*S*,5*S*)-3-acetamido-3-(*tert*-butylcarbamoyl)-5-vinylpiperidine-1-carboxylate and *tert*-butyl (3*R*,5*R*)-3-acetamido-3-(*tert*-butylcarbamoyl)-5-vinylpiperidine-1-carboxylate.



[00260] The racemic mixture of *tert*-butyl (3*R*,5*R*)-3-acetamido-3-(*tert*-butylcarbamoyl)-5-vinylpiperidine-1-carboxylate (1.9 g, 5.17 mmol) was separated for its enantiomers using a chiral preparative HPLC method (LumiSep Chiralcel AD column) with propan-2-ol and *n*-hexane (gradient: 5 - 30%) as an eluent and ELSD detection. Retention time of *tert*-butyl (3*S*,5*S*)-3-acetamido-3-(*tert*-butylcarbamoyl)-5-vinylpiperidine-1-carboxylate in preparative HPLC was in the range from 4.3 to 8.2 min. Retention time of *tert*-butyl (3*R*,5*R*)-3-acetamido-3-(*tert*-butylcarbamoyl)-5-vinylpiperidine-1-carboxylate in preparative HPLC was in the range from 9.7 to 14.7 min. The enantiomeric excess for both enantiomers was determined with the use of chiral analytical HPLC method with ELSD detection with RegisPack (5 μm , 4.6 x 250 mm) column using 10% propan-2-ol in *n*-hexane as eluent for 10


min. The first enantiomer *tert*-butyl (3*S*,5*S*)-3-acetamido-3-(*tert*-butylcarbamoyl)-5-vinylpiperidine-1-carboxylate (0.85 g, 45%, white solid) with the retention time of 5.21 min and the second desired enantiomer *tert*-butyl (3*R*,5*R*)-3-acetamido-3-(*tert*-butylcarbamoyl)-5-vinylpiperidine-1-carboxylate (0.82 g, 43%, white solid) at 7.57 min, each with enantiomeric excess of approximately 98% ee or higher.

Step E. (3*R*,5*R*)-3-Acetamido-*N*-(*tert*-butyl)-5-vinylpiperidine-3-carboxamide hydrochloride.




[00261] *tert*-Butyl (3*R*,5*R*)-3-acetamido-3-(*tert*-butylcarbamoyl)-5-vinylpiperidine-1-carboxylate (732 mg, 1.99 mmol) was treated with 4M HCl in EtOAc (15 mL). The reaction mixture was stirred for 1 h. The solvent was evaporated under reduced pressure to give 603 mg (100%) of the desired product as a white solid. ESI+MS: $m/z = 268.25$ ($M+1$)⁺. ¹H NMR (700 MHz, 300K, chloroform-*d*) δ 10.44 (d, $J = 6.8$ Hz, 1H), 8.52 (s, 1H), 8.17 (d, $J = 8.2$ Hz, 1H), 7.35 (s, 1H), 5.66 (ddd, $J = 17.1, 10.4, 6.5$ Hz, 1H), 5.17 (d, $J = 17.1$, 1H), 5.15 (d, $J = 10.4$ Hz, 1H), 4.17 (d, $J = 12.4$ Hz, 1H), 3.37 (d, $J = 11.4$ Hz, 1H), 2.93 (t, $J = 10.8$ Hz, 1H), 2.86 (q, $J = 12.2$ Hz, 1H), 2.59 – 2.49 (m, 2H), 2.10 (s, 3H), 1.95 (t, $J = 12.8$ Hz, 1H), 1.33 (s, 9H).

Step F. (3*R*,5*R*)-3-Acetamido-1-benzyl-*N*-(*tert*-butyl)-5-vinylpiperidine-3-carboxamide.




- 5 **[00262]** To the solution of (3*R*,5*R*)-3-acetamido-*N*-(*tert*-butyl)-5-vinylpiperidine-3-carboxamide hydrochloride (684 mg, 2.25 mmol) and benzaldehyde (274 μ L, 2.70 mmol) in 1,2-dichloroethane (20 mL) was added $\text{NaBH}(\text{OAc})_3$ (2384 mg, 11.25 mmol). The reaction mixture was stirred overnight at RT. In the next step the mixture was washed with 5% aqueous solution of NaHCO_3 (3 x 15 mL), and subsequent with 1M aqueous KHSO_4 (2 x 20
- 10 mL). The combined aqueous acidic layers were alkalized to pH 12 with 2M NaOH and washed with DCM (5 x 15 mL). The combined organic layers were washed with brine (20 mL), dried over MgSO_4 , concentrated *in vacuo* to give 696 mg (87 %) of the desired product as a white solid. ESI+MS: $m/z = 358.25$ ($M+1$)⁺. ^1H NMR (700 MHz, 300K, acetonitrile- d_3 500 μ L + deuterium oxide 100 μ L) δ 7.36 - 7.31 (m, 2H), 7.31 - 7.27 (m, 3H), 5.64 (ddd, $J =$
- 15 17.3, 10.4, 6.6 Hz, 1H), 4.99 (dt, $J = 17.3, 1.3$ Hz, 1H), 4.96 (dt, $J = 10.4, 1.1$ Hz, 1H), 3.67 (d, $J = 11.7$ Hz, 1H), 3.56 (d, $J = 12.3$ Hz, 1H), 3.43 (d, $J = 12.9$ Hz, 1H), 2.90 - 2.85 (m, 1H), 4.41 - 2.33 (m, 1H), 2.00 (d, $J = 11.3$ Hz, 1H), 1.86 - 1.83 (m, 1H), 1.81 (s, 3H), 1.72 (t, $J =$
- 20 11.4 Hz, 1H), 1.31 - 1.23 (m, 10H).

- 20 Step G. (3*R*,5*S*)-3-Acetamido-1-benzyl-*N*-(*tert*-butyl)-5-(2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)ethyl)piperidine-3-carboxamide.



[00263] A round-bottom flask charged with bis(1,5-cyclooctadiene)diiridium (I) dichloride (40 mg, 0.06 mmol), 1,2-bis(diphenylphosphino)ethane (48 mg, 0.12 mmol) and dry DCM (10 mL) was flushed with argon (bubbling). Subsequently, the separately prepared solution of 4,4,5,5-tetramethyl-1,3,2-dioxaborolane (702 μ L, 4.84 mmol) and (3*R*,5*R*)-3-acetamido-1-benzyl-*N*-(*tert*-butyl)-5-vinylpiperidine-3-carboxamide (692 mg, 1.94 mmol) in DCM (19 mL) was added dropwise. The resulting mixture was then stirred at room temperature for 24 h. The solvent was removed under reduced pressure and the residue was subjected to flash chromatography on silica gel (using EtOAc-hexane, 1:10 to 1:0 as the eluent) to afford 639 mg (68%) of the desired product as a light yellow oil. ESI+MS: m/z = 486.10 ($M+1$)⁺. ¹H NMR (700 MHz, 300K, chloroform-*d*) δ 9.11 (s, 1H), 7.37 – 7.33 (m, 2H), 7.32 – 7.26 (m, 3H), 6.71 (s, 1H), 3.54 (s, 2H), 3.13 (d, J = 11.2 Hz, 1H), 2.99 – 2.93 (m, 2H), 2.00 – 1.97 (m, 1H), 1.96 (s, 3H), 1.81 – 1.76 (m, 2H), 1.76 – 1.71 (m, 1H), 1.39 – 1.26 (m, 11H), 1.24 (12H), 0.76 (ddd, J = 16.1, 10.5, 6.3 Hz, 1H), 0.68 (ddd, J = 16.1, 10.4, 6.2 Hz, 1H).

Step H. (3*R*,5*S*)-3-Amino-1-benzyl-5-(2-boronoethyl)piperidine-3-carboxylic acid dihydrochloride.




[00264] A mixture of (3*R*,5*S*)-3-acetamido-1-benzyl-*N*-(*tert*-butyl)-5-(2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)ethyl)piperidine-3-carboxamide (0.63 g, 1.30 mmol) and 12M HCl_(aq) (15 mL) was heated at 130°C overnight. The reaction mixture was concentrated under reduced pressure to give 0.49 g (99%) of the corresponding product as a beige solid.

ESI+MS: $m/z = 307.10$ ($M+1$)⁺. ¹H NMR (700 MHz, 300 K, deuterium oxide) δ 7.61 – 7.56 (m, 5H), 4.66 (d, $J = 13.3$ Hz, 1H), 4.34 (d, $J = 13.3$ Hz, 1H), 3.76 – 3.69 (m, 1H), 3.66 (dt, $J = 12.0, 1.9$ Hz, 1H), 3.08 (d, $J = 12.0$ Hz, 1H), 2.87 (t, $J = 12.3$ Hz, 1H), 2.37 (ddt, $J = 13.1, 3.6, 1.7$ Hz, 1H), 2.17 – 2.09 (m, 1H), 1.58 – 1.40 (m, 3H), 0.91 – 0.76 (m, 2H).

5

Step I. (3*R*,5*S*)-1-Benzyl-5-(2-boronoethyl)-3-((*tert*-butoxycarbonyl)amino)piperidine-3-carboxylic acid.




10

[00265] To a suspension of (3*R*,5*S*)-3-amino-1-benzyl-5-(2-boronoethyl)piperidine-3-carboxylic acid dihydrochloride (0.50 g, 1.32 mmol) in acetone (12 mL) was added 1M NaOH (8 mL, to pH ~ 9) and di-*tert*-butyl dicarbonate (0.63 g, 2.90 mmol). The resulting mixture was stirred at room temperature overnight. An inorganic contaminations were precipitated

15 using acetone (10 mL) and were filtered off. A filtrate was neutralized to pH ~ 7 with 1M HCl (2 drops) and concentrated under reduced pressure. The residue was triturated with small amount of methanol to remove the rest of the inorganic salts. The crude product was obtained after filtration of methanolic solution and concentration to give 0.53 g of a pale yellow foam that was used to the next step without any further purification. ESI+MS: $m/z = 407.10$

20 ($M+1$)⁺; ESI-MS: $m/z = 405.15$ ($M-1$)⁻. ¹H NMR (700 MHz, 300 K, deuterium oxide) δ 7.63 – 7.52 (m, 5H), 4.70 – 4.58 (m, 1H), 4.06 (d, $J = 13.1$ Hz, 1H), 3.85 – 3.73 (m, 1H), 3.69 (d, $J = 11.9$ Hz, 1H), 2.87 – 2.60 (m, 2H), 2.12 – 2.07 (m, 1H), 1.99 – 1.88 (m, 1H), 1.54 – 1.29 (m, 3H), 1.11 (s, 9H), 0.90 – 0.73 (m, 2H).

Step J. (3*R*,5*S*)-5-(2-Boronoethyl)-3-((*tert*-butoxycarbonyl)amino)piperidine-3-carboxylic acid.




5

[00266] To a solution of (3*R*,5*S*)-1-benzyl-5-(2-boronoethyl)-3-((*tert*-butoxycarbonyl)amino)piperidine-3-carboxylic acid (0.27 g, 0.66 mmol), in MeOH (5 mL) under argon, 20% Pd(OH)₂/C (50 mg) was added. The mixture was degassed, charged with H₂, and stirred for 2 days at room temperature under hydrogen atmosphere (7 bar). The reaction mixture was filtered through a Celite pad, washed with MeOH (2 x 5 mL) and filtered. The filtrate was concentrated *in vacuo*. The residue was purified by preparative HPLC (5 - 60% of acetonitrile in water) to give the corresponding product (0.09 g, 43%, white solid). ESI+MS: *m/z* = 317.00 (M+1)⁺; ESI-MS: *m/z* = 315.05 (M-1)⁻. ¹H NMR (700 MHz, 300 K, deuterium oxide) δ 4.01 (dt, *J* = 12.1, 1.6 Hz, 1H), 3.45 (dd, *J* = 12.3, 4.1 Hz, 1H), 2.79 (d, *J* = 12.1 Hz, 1H), 2.64 (t, *J* = 12.4 Hz, 1H), 2.12 (bs, 1H), 1.83 (bs, 1H), 1.49 – 1.34 (m, 12H), 0.88 – 0.76 (m, 2H).

20

Step K. (3*R*,5*S*)-5-(2-Boronoethyl)-1-((*tert*-butoxycarbonyl)-*L*-alanyl)-3-((*tert*-butoxycarbonyl)amino)piperidine-3-carboxylic acid.




[00267] To a stirred solution of (3*R*,5*S*)-5-(2-boronoethyl)-3-((*tert*-butoxycarbonyl)amino)piperidine-3-carboxylic acid (0.08 g, 0.25 mmol) in DMF (2 mL), Boc-*L*-Ala-OSu (0.13 g, 0.46 mmol) was added and the resulting mixture was stirred at room temperature overnight. DMF was evaporated under reduced pressure and the residue was purified by column chromatography on silica gel using DCM/MeOH (80:1 to 0:1) to afford 0.11 g (89 %) of the corresponding product as a colorless film (5 : 2 mixture of rotamers in CD₃OD solution at room temperature based on NMR). ESI+MS: *m/z* = 488.20 (*M*+1)⁺; ESI-MS: *m/z* = 486.25 (*M*-1)⁻. ¹H NMR (700 MHz, 300 K, methanol-*d*₄) δ 5.17 – 5.07 (m, 0.3H), 4.80 – 4.73 (m, 0.7H), 4.59 – 4.42 (m, 1H), 4.19 (bs, 0.7H), 4.03 (bs, 0.3H), 2.62 – 2.75 (m, 3H), 2.38 (d, *J* = 12.8 Hz, 0.3H), 2.30 (d, *J* = 12.9 Hz, 0.7H), 1.64 (s, 1H), 1.47 (dd, *J* = 7.5, 4.9 Hz, 18H), 1.38 – 1.24 (m, 5H), 0.94 – 0.76 (m, 2H).

Step L. (3*R*,5*S*)-1-(*L*-Alanyl)-3-amino-5-(2-boronoethyl)piperidine-3-carboxylic acid dihydrochloride.

[00268] (3*R*,5*S*)-5-(2-Boronoethyl)-1-((*tert*-butoxycarbonyl)-*L*-alanyl)-3-((*tert*-butoxycarbonyl)amino)piperidine-3-carboxylic acid (0.10 g, 0.21 mmol) was treated with 4M HCl in EtOAc (4 mL) and the resulting mixture was stirred at room temperature for 1.5 h. Then the reaction mixture was concentrated under reduced pressure and the residue was purified by preparative HPLC (0.1 - 1% of acetonitrile in water) to give (after acidification with 2M HCl and subsequent lyophilization) 52 mg (67%) of the corresponding product as a white solid (4 : 1 mixture of rotamers in D₂O solution at room temperature based on NMR). ESI+MS: *m/z* = 288.10 (*M*+1)⁺; 270.00 (*M*-18+1)⁺; ESI-MS: *m/z* = 268.05 (*M*-18-1)⁻. ¹H NMR (700 MHz, 300 K, deuterium oxide) δ 4.95 – 4.92 (m, 1H), 4.56 (q, *J* = 7.1 Hz, 1H), 3.88 (dd, *J* = 13.1, 4.2 Hz, 1H), 3.01 – 2.91 (m, 2H), 2.54 – 2.47 (m, 1H), 2.15 – 2.06 (m, 0.8H), 2.01 – 1.95 (m, 0.2H), 1.62 – 1.48 (m, 5H), 1.48 – 1.35 (m, 1H), 0.92 – 0.81 (m, 2H).


(3*R*,5*S*)-1-(*L*-alanyl)-3-amino-5-(2-boronoethyl)piperidine-3-carboxylic acid.




- 5 **[00269]** (3*R*,5*S*)-1-(*L*-Alanyl)-3-amino-5-(2-boronoethyl)piperidine-3-carboxylic acid dihydrochloride can be converted to zwitterionic form using DOWEX® ion exchange resin. Thus (3*R*,5*S*)-1-(*L*-alanyl)-3-amino-5-(2-boronoethyl)piperidine-3-carboxylic acid dihydrochloride (680 mg) was subjected to flash chromatography on DOWEX® ion exchange resin 50WX8 hydrogen form; 50 – 100 mesh (eluent 0.1N ammonia in water) to give (after
- 10 lyophilization) the corresponding (3*R*,5*S*)-1-(*L*-Alanyl)-3-amino-5-(2-boronoethyl)piperidine-3-carboxylic acid (405 mg) as a white solid (5 : 2 mixture of rotamers in D₂O solution at 333 K based on NMR). ESI+MS: *m/z* = 288.10 (*M*+1)⁺; 270.05 (*M*-18+1)⁺; ESI-MS: *m/z* = 268.05 (*M*-18-1)⁻. ¹H NMR (700 MHz, 333 K, deuterium oxide) δ 5.02 (d, *J* = 12.9 Hz, 0.7H), 4.65 (d, *J* = 7.3 Hz, 1H), 4.51 (d, *J* = 13.1 Hz, 0.3H), 4.40 (d, *J* = 13.3 Hz, 0.3H), 4.07 (d, *J* = 13.7 Hz, 0.7H), 3.45 (d, *J* = 13.4 Hz, 0.3H), 3.10 (t, *J* = 12.7 Hz, 0.7H), 3.00 (d, *J* = 12.9 Hz, 0.7H),
- 15 2.86 (t, *J* = 12.4 Hz, 0.3H), 2.61 (d, *J* = 12.8 Hz, 1H), 2.23 (bs, 0.7H), 2.08 (bs, 0.3H), 1.78 – 1.61 (m, 5H), 1.59– 1.48 (m, 1H), 1.1– 1.06 (m, 2H).

Example 2. (3*S*,5*R*)-1-(*L*-Alanyl)-3-amino-5-(2-boronoethyl)piperidine-3-carboxylic acid

20 **dihydrochloride.**



Step A. (3*S*,5*S*)-3-Acetamido-*N*-(*tert*-butyl)-5-vinylpiperidine-3-carboxamide hydrochloride.




5

[00270] The title compound was obtained according to step (E) of Example 1, using *tert*-butyl (3*S*,5*S*)-3-acetamido-3-(*tert*-butylcarbamoyl)-5-vinylpiperidine-1-carboxylate (0.99 g, 2.68 mmol) and 4M HCl in EtOAc (30 mL). The reaction mixture was concentrated under reduced pressure to give a corresponding product (0.66g, 80%, pale yellow foam). ESI+MS:

10 $m/z = 268.25$ ($M+1$)⁺. ¹H NMR (700 MHz, 300 K, chloroform-*d*) δ 10.33 (bs, 1H), 8.52 (s, 1H), 8.17 (bs, 1H), 7.27 (s, 1H), 5.66 (ddd, $J = 17.1, 10.5, 6.5$ Hz, 1H), 5.21 – 5.00 (m, 2H), 4.20 (d, $J = 12.1$ Hz, 1H), 3.38 (d, $J = 12.5$ Hz, 1H), 2.94 – 2.81 (m, 2H), 2.57 – 2.48 (m, 2H), 2.10 (s, 3H), 2.00 – 1.90 (m, 1H), 1.33 (s, 9H).

15 Step B. (3*S*,5*S*)-3-Acetamido-1-benzyl-*N*-(*tert*-butyl)-5-vinylpiperidine-3-carboxamide.




[00271] The title compound was obtained according to step (F) of Example 1, using (3*S*,5*S*)-3-acetamido-*N*-(*tert*-butyl)-5-vinylpiperidine-3-carboxamide hydrochloride (0.64 g, 2.11 mmol), benzaldehyde (0.26 mL, 2.53 mmol), sodium triacetoxyborohydride (2.23 g, 10.53 mmol) and DCE (21.5 mL). The desired product was obtained as a white solid (0.75 g, 99%). ESI+MS: $m/z = 358.25$ ($M+1$)⁺; 380.25 ($M+23$)⁺; ESI-MS: $m/z = 356.15$ ($M-1$)⁻. ¹H

20

NMR (700 MHz, 300 K, chloroform-*d*) δ 9.04 (s, 1H), 7.42 – 7.29 (m, 5H), 6.70 (s, 1H), 5.63 (ddd, J = 17.2, 10.4, 6.6 Hz, 1H), 5.30 (s, 2H), 5.05 – 4.96 (m, 2H), 3.59 – 3.49 (m, 2H), 3.16 (d, J = 11.5 Hz, 1H), 3.00 – 2.89 (m, 2H), 2.55 – 2.41 (m, 1H), 2.23 (t, J = 12.9 Hz, 1H), 1.95 (s, 3H), 1.35 (s, 9H).

5

Step C. (3*S*,5*R*)-3-Acetamido-1-benzyl-*N*-(*tert*-butyl)-5-(2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)ethyl)piperidine-3-carboxamide.




10

[00272] The title compound was obtained according to step (G) of Example 1, using (3*S*,5*S*)-3-acetamido-1-benzyl-*N*-(*tert*-butyl)-5-vinylpiperidine-3-carboxamide (0.73 g, 2.04 mmol), dppe (49 mg, 0.12 mmol), bis(1,5-cyclooctadiene)diiridium(I) dichloride (41 mg, 0.06 mmol), 4,4,5,5-tetramethyl-1,3,2-dioxaborolane (0.74 mL, 5.10 mmol) and DCM (40 mL).

15 The crude product was purified by column chromatography on silica gel (hexane: EtOAc, 5:1 to 1:3) to give 0.57 g (58%) of the corresponding product as a white solid. ESI+MS: m/z = 486.35 ($M+1$)⁺; 508.40 ($M+23$)⁺. ¹H NMR (700 MHz, 300 K, chloroform-*d*) δ 9.08 (s, 1H), 7.32 – 7.26 (m, 5H), 6.69 (s, 1H), 3.51 (s, 2H), 3.10 (d, J = 11.4 Hz, 1H), 2.97 – 2.87 (m, 2H), 1.93 (s, 3H), 1.80 – 1.68 (m, 3H), 1.36 – 1.34 (m, 1H), 1.33 (s, 9H), 1.27 (s, 2H), 1.21 (s, 12H), 0.76 – 0.63 (m, 2H).

20

Step D. (3*S*,5*R*)-3-Amino-1-benzyl-5-(2-boronoethyl)piperidine-3-carboxylic acid dihydrochloride.




5

[00273] The title compound was obtained according to step (H) of Example 1, using (3*S*,5*R*)-3-acetamido-1-benzyl-*N*-(*tert*-butyl)-5-(2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)ethyl)piperidine-3-carboxamide (0.56 g, 1.14 mmol) and 12M HCl_(aq) (25 mL). The reaction mixture was concentrated under reduced pressure to afford the corresponding product (0.43 g, 99%, beige solid). ESI+MS: $m/z = 307.25$ ($M+1$)⁺. ¹H NMR (700 MHz, 300 K, deuterium oxide) δ 7.61 – 7.56 (m, 5H), 4.66 (d, $J = 13.3$ Hz, 1H), 4.34 (d, $J = 13.3$ Hz, 1H), 3.76 – 3.69 (m, 1H), 3.66 (dt, $J = 12.0, 1.9$ Hz, 1H), 3.08 (d, $J = 12.0$ Hz, 1H), 2.87 (t, $J = 12.3$ Hz, 1H), 2.37 (ddt, $J = 13.1, 3.6, 1.7$ Hz, 1H), 2.17 – 2.09 (m, 1H), 1.58 – 1.40 (m, 3H), 0.91 – 0.76 (m, 2H).

15

Step E. (3*S*,5*R*)-1-Benzyl-5-(2-boronoethyl)-3-((*tert*-butoxycarbonyl)amino)piperidine-3-carboxylic acid.




20

[00274] The title compound was obtained according to step (I) of Example 1, using (3*S*,5*R*)-3-amino-1-benzyl-5-(2-boronoethyl)piperidine-3-carboxylic acid dihydrochloride (0.43 g, 1.13 mmol), di-*tert*-butyl dicarbonate (0.62 g, 2.84 mmol), 1M NaOH_(aq) (4 mL) and

acetone (10 mL). The desired product was obtained as a white solid (0.45 g, 99%).


ESI+MS: $m/z = 407.25$ ($M+1$)⁺; ESI-MS: $m/z = 405.10$ ($M-1$)⁻. ¹H NMR (700 MHz, 300 K, deuterium oxide) δ 7.57 (s, 5H), 4.66 (d, $J = 13.1$ Hz, 1H), 4.06 (d, $J = 13.1$ Hz, 1H), 3.78 (d, $J = 11.8$ Hz, 1H), 3.69 (d, $J = 11.9$ Hz, 1H), 2.85 – 2.61 (m, 2H), 2.11 (d, $J = 13.0$ Hz, 1H),
 5 1.99 – 1.88 (m, 1H), 1.52 – 1.41 (m, 3H), 1.11 (s, 9H), 0.88 – 0.75 (m, (s, 2H).

Step F. (3*S*,5*R*)-5-(2-Boronoethyl)-3-((*tert*-butoxycarbonyl)amino)piperidine-3-carboxylic acid.



[00275] The title compound was obtained according to step (J) of Example 1, using (3*S*,5*R*)-1-benzyl-5-(2-boronoethyl)-3-((*tert*-butoxycarbonyl)amino)piperidine-3-carboxylic acid (0.24 g, 0.59 mmol), 20% Pd(OH)₂/C (50 mg) and MeOH (5 mL). The desired product
 15 was obtained as a grey solid (0.18 g, 99%). ESI+MS: $m/z = 317.20$ ($M+1$)⁺; ESI-MS: $m/z = 315.10$ ($M-1$)⁻. ¹H NMR (700 MHz, 300 K, methanol-*d*₄) δ 4.56 (s, 1H), 3.89 (d, $J = 11.7$ Hz, 1H), 3.38 – 3.36 (m, 1H), 2.94 – 2.85 (m, 1H), 2.50 (t, $J = 12.3$ Hz, 1H), 2.08 – 2.00 (m, 1H), 1.97 – 1.88 (m, 1H), 1.43 (s, 9H), 1.40 – 1.28 (m, 2H), 0.85 – 0.73 (m, 2H).

Step G. (3*S*,5*R*)-5-(2-Boronoethyl)-1-((*tert*-butoxycarbonyl)-*L*-alanyl)-3-((*tert*-butoxycarbonyl)amino)piperidine-3-carboxylic acid.



5

[00276] The title compound was obtained according to step (K) of Example 1, using (3*S*,5*R*)-5-(2-boronoethyl)-3-((*tert*-butoxycarbonyl)amino)piperidine-3-carboxylic acid (0.17 g, 0.54 mmol), Boc-*L*-Ala-OSu (0.20 g, 0.70 mmol), and DMF (4.5 mL). The reaction mixture was stirred overnight at room temperature. DMF was evaporated and the residue was purified by column chromatography on silica gel using DCM/MeOH (20:1 to 0:1) to give 0.20 g (76%) of the desired product as a white solid (3: 2 mixture of rotamers in CD₃OD at room temperature based on NMR). ESI+MS: *m/z* = 488.20 (*M*+1)⁺; ESI-MS: *m/z* = 486.20 (*M*-1)⁻. ¹H NMR (700 MHz, 300 K, methanol-*d*₄) δ 5.14 – 5.05 (m, 0.6H), 5.04 – 4.97 (m, 0.4H), 4.67 – 4.55 (m, 1.4H), 4.53 – 4.46 (m, 0.6H), 3.06 – 2.94 (m, 0.4H), 2.76 – 2.60 (m, 2.6H), 2.42 – 2.14 (m, 2H), 1.54 – 1.43 (m, 18H), 1.42 – 1.23 (m, 5H), 0.91 – 0.81 (m, 2H).


Step H. (3*S*,5*R*)-1-(*L*-Alanyl)-3-amino-5-(2-boronoethyl)piperidine-3-carboxylic acid dihydrochloride.

[00277] The title compound was obtained according to step (L) of Example 1, using (3*S*,5*R*)-5-(2-boronoethyl)-1-((*tert*-butoxycarbonyl)-*L*-alanyl)-3-((*tert*-butoxycarbonyl)amino)piperidine-3-carboxylic acid (0.20 g, 0.41 mmol) and 4M HCl in EtOAc (6 mL). The crude product was purified by preparative HPLC (0.1 - 1% of acetonitrile in water) to give (after acidification with 2M HCl and subsequent lyophilization) 47 mg (32%) of the corresponding product as a white solid (5 : 2 mixture of rotamers in D₂O solution at room

temperature, based on NMR). ESI+MS: $m/z = 288.00$ ($M+1$)⁺. ¹H NMR (700 MHz, 300 K, deuterium oxide) δ 4.93 (dt, $J = 13.3, 1.9$ Hz, 0.7H), 4.63 (dt, $J = 14.1, 7.1$ Hz, 1H), 4.54 – 4.49 (m, 0.3H), 4.27 (dt, $J = 13.7, 1.9$ Hz, 0.3H), 3.96 – 3.91 (m, 0.7H), 3.43 (d, $J = 13.7$ Hz, 0.3H), 2.98 (d, $J = 13.4$ Hz, 0.7H), 2.91 (dd, $J = 14.1, 12.1$ Hz, 0.7H), 2.53 – 2.44 (m, 1H), 2.42 (dd, $J = 13.3, 12.0$ Hz, 0.3H), 2.12 (ddt, $J = 14.6, 11.7, 4.9$ Hz, 0.7H), 1.77 (ddt, $J = 11.9, 8.8, 3.9$ Hz, 0.3H), 1.62 – 1.34 (m, 6H), 0.91 – 0.84 (m, 2H).


Example 3. (3*R*,5*S*)-3-Amino-5-(2-boronoethyl)-1-glycylpiperidine-3-carboxylic acid dihydrochloride.

10



Step A. (3*R*,5*S*)-5-(2-Boronoethyl)-3-((*tert*-butoxycarbonyl)amino)-1-((*tert*-butoxycarbonyl)glycyl)piperidine-3-carboxylic acid.

15




[00278] The title compound was obtained according to step (K) of Example 1, using (3*R*,5*S*)-5-(2-boronoethyl)-3-((*tert*-butoxycarbonyl)amino)piperidine-3-carboxylic acid (0.10 g, 0.33 mmol), Boc-Gly-OSu (0.12 g, 0.42 mmol) and DMF (2.5 mL). The crude product was purified by column chromatography on silica gel using DCM/MeOH (80:1 to 0:1) to give 130

mg (84%) of the corresponding product as a white solid (4 : 1 mixture of rotamers in CD₃OD solution at room temperature, based on NMR). ESI+MS: m/z = 474.15 (M+1)⁺; ESI-MS: m/z = 472.15 (M-1)⁻. ¹H NMR (700 MHz, 300 K, methanol-*d*₄) δ 4.70 – 4.62 (m, 0.7H), 4.58 – 4.51 (m, 1.3H), 3.93 – 3.80 (m, 1H), 3.70 – 3.60 (m, 1H), 2.96 – 2.87 (m, 0.7H), 2.64 – 2.54 (m, 0.3H), 2.41 – 2.33 (m, 0.3H), 2.32 – 2.25 (m, 0.7H), 2.24 – 2.11 (m, 0.7H), 1.58 – 1.43 (m, 18H), 1.42 – 1.18 (m, 4H), 0.88 – 0.80 (m, 2H).

Step B. (3*R*,5*S*)-3-Amino-5-(2-boronoethyl)-1-glycylpiperidine-3-carboxylic acid dihydrochloride.


[00279] The title compound was obtained according to step (L) of Example 1, using (3*R*,5*S*)-5-(2-boronoethyl)-3-((*tert*-butoxycarbonyl)amino)-1-((*tert*-butoxycarbonyl)glycyl)piperidine-3-carboxylic acid (0.12 g, 0.26 mmol) and 4M HCl in EtOAc (5 mL). The crude product was purified by preparative HPLC (0.1 -1% of acetonitrile in water) to give (after acidification with 2M HCl and subsequent lyophilization) 36 mg (34%) of the corresponding product as a white foam (5 : 2 mixture of rotamers in D₂O solution at room temperature, based on NMR). ESI+MS: m/z = 274.00 (M+1)⁺; ESI-MS: m/z = 272.05 (M-1)⁻. ¹H NMR (700 MHz, 300 K, deuterium oxide) δ 4.92 – 4.84 (m, 0.7H), 4.55 – 4.49 (m, 0.3H), 4.22 – 4.17 (m, 0.3H), 4.16 – 4.01 (m, 2H), 3.82 – 3.75 (m, 0.7H), 3.39 (d, *J* = 14.0 Hz, 0.3H), 3.06 (d, *J* = 13.5 Hz, 0.7H), 2.87 (t, *J* = 12.6 Hz, 0.7H), 2.50 (dd, *J* = 13.4, 4.6 Hz, 1H), 2.43 (t, *J* = 12.6 Hz, 0.3H), 2.10 – 2.02 (m, 0.7H), 1.77 – 1.69 (m, 0.3H), 1.61 – 1.53 (m, 1H), 1.50 – 1.44 (m, 1H), 1.43 – 1.37 (m, 1H), 0.87 – 0.80 (m, 2H).

Example 4. (3*R*,5*S*)-1-(*L*-Prolyl)-3-amino-5-(2-boronoethyl)piperidine-3-carboxylic acid dihydrochloride.



5

Step A. (3*R*,5*S*)-5-(2-Boronoethyl)-1-((*tert*-butoxycarbonyl)-*L*-prolyl)-3-((*tert*-butoxycarbonyl)amino)piperidine-3-carboxylic acid.



10

[00280] The title compound was obtained according to step (K) of Example 1, using (3*R*,5*S*)-5-(2-boronoethyl)-3-((*tert*-butoxycarbonyl)amino)piperidine-3-carboxylic acid (0.10 g, 0.33 mmol), Boc-*L*-Pro-OSu (0.18 g, 0.59 mmol) and DMF (2.5 mL). The reaction mixture was stirred for 2 days at 50°C. DMF was evaporated under reduced pressure and the residue was purified by column chromatography on silica gel using DCM/MeOH (80:1 to 0:1) to afford 86 mg (51%) of the desired product as a white solid (4 : 1 mixture of rotamers in CD₃OD solution at room temperature, based on NMR). ESI+MS: *m/z* = 514.00 (*M*+1)⁺; 414.15 (*M*-Boc+1)⁺. ¹H NMR (700 MHz, 300 K, methanol-*d*₄) δ 4.78 – 4.66 (m, 1.2H), 4.65 – 4.46 (m, 0.8H), 4.40 – 4.30 (m, 0.8H), 3.97 – 3.89 (m, 0.2), 3.69 – 3.61 (m, 0.2), 3.60 – 3.41 (m, 2.8H), 2.79 – 2.62 (m, 1H), 2.58 – 2.49 (m, 0.4H), 2.44 – 2.23 (m, 2.6H), 2.19 – 2.09 (m,

20


1H), 2.09 – 1.83 (m, 2.2H), 1.76 – 1.65 (m, 0.8H), 1.59 – 1.42 (m, 18H), 1.42 – 1.19 (m, 2H), 0.92 – 0.76 (m, 2H).

Step B. (3*R*,5*S*)-1-(*L*-Prolyl)-3-amino-5-(2-boronoethyl)piperidine-3-carboxylic acid


5 dihydrochloride.

[00281] The title compound was obtained according to step (L) of Example 1, using (3*R*,5*S*)-5-(2-boronoethyl)-1-((*tert*-butoxycarbonyl)-*L*-prolyl)-3-((*tert*-butoxycarbonyl)amino)piperidine-3-carboxylic acid (0.08 g, 0.16 mmol) and 4M HCl in EtOAc (5 mL). The crude product was purified by preparative HPLC (0.1 - 1% of acetonitrile in water) to give (after acidification with 2M HCl and subsequent lyophilization) 33 mg (54%) of the corresponding product as a white foam (4 : 1 mixture of rotamers in D₂O solution at 333 K, based on NMR). ESI+MS: *m/z* = 314.00 (*M*+1)⁺; ESI-MS: *m/z* = 294.05 (*M*-18-1)⁻. ¹H NMR (700 MHz, 333 K, deuterium oxide) δ 5.24 (d, *J* = 13.3 Hz, 0.8H), 5.09 (t, *J* = 7.9 Hz, 0.8H), 5.01 (t, *J* = 8.3 Hz, 0.2H), 4.59 (d, *J* = 13.9 Hz, 0.2H), 4.24 – 4.15 (m, 0.8H), 3.90 – 3.83 (m, 1H), 3.82 – 3.75 (m, 1.2H), 3.37 (d, *J* = 13.3 Hz, 1H), 3.28 (t, *J* = 12.8 Hz, 0.8H), 3.00 – 2.86 (m, 1H), 2.88 – 2.81 (m, 1.2H), 2.54 – 2.31 (m, 4H), 1.95 – 1.80 (m, 2H), 1.80 – 1.71 (m, 1H), 1.25 – 1.12 (m, 2H).

20 **Example 5. (3*R*,5*S*)-1-(*L*-Valyl)-3-amino-5-(2-boronoethyl)piperidine-3-carboxylic acid dihydrochloride.**



Step A. (3*R*,5*S*)-5-(2-Boronoethyl)-1-((*tert*-butoxycarbonyl)-*L*-valyl)-3-((*tert*-butoxycarbonyl)amino)piperidine-3-carboxylic acid.



5

[00282] The title compound was obtained according to step (K) of Example 1, using (3*R*,5*S*)-5-(2-boronoethyl)-3-((*tert*-butoxycarbonyl)amino)piperidine-3-carboxylic acid (97 mg, 0.31 mmol), Boc-*L*-Val-OSu (0.13 g, 0.40 mmol) and DMF (2 mL). The crude product was purified by column chromatography on silica gel using DCM/MeOH (80:1 to 0:1) to give 38 mg (24%) of the corresponding product as a white solid (3 : 2 mixture of rotamers in CD₃OD solution at room temperature, based on NMR). ESI+MS: *m/z* = 516.20 (*M*+1)⁺; ESI-MS: *m/z* = 514.20 (*M*-1)⁻. ¹H NMR (700 MHz, 300 K, methanol-*d*₄) δ 5.05 – 5.02 (m, 0.4H), 4.46 – 4.41 (m, 0.4H), 4.24 – 4.18 (m, 0.6H), 4.05 – 3.89 (m, 0.6H), 3.60 – 3.55 (m, 1H), 2.84 – 2.73 (m, 2H), 2.45 – 2.36 (m, 0.6H), 2.35 – 2.31 (m, 0.4H), 2.22 – 2.17 (m, 0.6H), 2.15 – 2.04 (m, 0.4H), 1.89 – 1.82 (m, 0.4H), 1.81 – 1.72 (m, 0.6H), 1.63 – 1.55 (m, 1H), 1.53 – 1.45 (m, 18H), 1.41 – 1.29 (m, 2H), 1.04 – 0.91 (m, 6H), 0.92 – 0.71 (m, 2H).


Step B. (3*R*,5*S*)-1-(*L*-Valyl)-3-amino-5-(2-boronoethyl)piperidine-3-carboxylic acid dihydrochloride.

[00283] The title compound was obtained according to step (L) of Example 1, using (3*R*,5*S*)-5-(2-boronoethyl)-1-((*tert*-butoxycarbonyl)-*L*-valyl)-3-((*tert*-butoxycarbonyl)amino)piperidine-3-carboxylic acid (17 mg, 0.03 mmol) and 4M HCl in EtOAc


(2 mL). The crude product was purified by preparative HPLC (0.1 -1% of acetonitrile in water) to give (after acidification with 2M HCl and subsequent lyophilization) 7.5 mg (59%) of the corresponding product as a white foam (9 : 1 mixture of rotamers in D₂O solution at room temperature). ESI+MS: $m/z = 316.10$ ($M+1$)⁺; ESI-MS: $m/z = 296.05$ ($M-18-1$)⁻. ¹H NMR

(700 MHz, 300 K, deuterium oxide) δ 4.98 – 4.93 (m, 0.9H), 4.45 (d, $J = 4.9$ Hz, 0.9H), 4.38 (d, $J = 4.0$ Hz, 0.1H), 4.34 (dd, $J = 13.1, 4.2$ Hz, 0.1H), 4.29 – 4.22 (m, 0.1H), 3.94 (dd, $J = 13.7, 4.3$ Hz, 0.9H), 3.49 (d, $J = 13.8$ Hz, 0.1H), 3.03 – 2.86 (m, 1.8H), 2.67 – 2.63 (m, 0.1H), 2.47 (d, $J = 12.6$ Hz, 1H), 2.43 – 2.38 (m, 0.1H), 2.37 – 2.28 (m, 0.9H), 2.18 – 2.10 (m, 0.9H), 2.09 – 2.01 (d, $J = 12.8$ Hz, 0.1H), 1.55 – 1.45 (m, 2H), 1.43 – 1.37 (m, 1H), 1.12 (d, $J = 7.0$ Hz, 3H), 1.01 (d, $J = 6.9$ Hz, 2.7H), 0.97 (d, $J = 6.9$ Hz, 0.3H), 0.93 – 0.80 (m, 2H).

Example 6. (3*R*,5*S*)-1-(*L*-Seryl)-3-amino-5-(2-boronoethyl)piperidine-3-carboxylic acid dihydrochloride.




Step A. (3*R*,5*S*)-1-(*O*-Benzyl-*N*-(*tert*-butoxycarbonyl)-*L*-seryl)-5-(2-boronoethyl)-3-((*tert*-butoxycarbonyl)amino)piperidine-3-carboxylic acid.



[00284] The title compound was obtained according to step (K) of Example 1, using (3*R*,5*S*)-5-(2-boronoethyl)-3-((*tert*-butoxycarbonyl)amino)piperidine-3-carboxylic acid (96 mg, 0.30 mmol), Boc-*L*-Ser(Bzl)-OSu (0.16 g, 0.40 mmol) and DMF (2 mL). The crude product was purified by column chromatography on silica gel using DCM/MeOH (80:1 to 0:1) to give 75 mg (42%) of the corresponding product as a white solid (3 : 2 mixture of rotamers in CD₃OD solution at room temperature, based on NMR). ESI+MS: *m/z* = 594.25 (*M*+1)⁺; ESI-MS: *m/z* = 592.15 (*M*-1)⁻. ¹H NMR (700 MHz, 300 K, methanol-*d*₄) δ 7.41 – 7.23 (m, 5H), 5.13 – 5.00 (m, 1H), 4.65 – 4.59 (m, 1H), 4.59 – 4.51 (m, 1H), 4.03 – 3.87 (m, 1H), 3.81 – 3.76 (m, 1H), 3.77 – 3.70 (m, 1H), 3.69 – 3.63 (m, 1H), 2.67 – 2.60 (m, 1H), 2.44 – 2.36 (m, 0.6H), 2.29 – 2.24 (m, 0.4H), 1.70 – 1.60 (m, 2H), 1.47 (d, *J* = 2.5 Hz, 18H), 1.43 – 1.24 (m, 3H), 0.93 – 0.70 (m, 2H).

Step B. (3*R*,5*S*)-3-Amino-1-(*O*-benzyl-*L*-seryl)-5-(2-boronoethyl)piperidine-3-carboxylic acid dihydrochloride.



[00285] The title compound was obtained according to step (L) of Example 1, using (3*R*,5*S*)-1-(*O*-benzyl-*N*-(*tert*-butoxycarbonyl)-*L*-seryl)-5-(2-boronoethyl)-3-((*tert*-butoxycarbonyl)amino)piperidine-3-carboxylic acid (39 mg, 0.07 mmol) and 4M HCl in EtOAc (2 mL). The crude product was obtained as a white foam (30 mg, 99%; 4 : 1 mixture of rotamers in CD₃OD solution at 333 K, based on NMR). ESI+MS: *m/z* = 394.05 (*M*+1)⁺; ESI-MS: *m/z* = 374.00 (*M*-18-1)⁻. ¹H NMR (700 MHz, 300 K, methanol-*d*₄) δ 7.47 – 7.31 (m, 5H), 5.02 (d, *J* = 13.1 Hz, 0.8H), 4.73 – 4.62 (m, 2.2H), 3.90 – 3.85 (m, 1H), 3.79 – 3.67 (m, 2H),


2.87 (d, $J = 12.9$ Hz, 1H), 2.69 – 2.55 (m, 1H), 2.51 – 2.38 (m, 2H), 2.21 – 2.17 (m, 1H), 1.56 – 1.27 (m, 3H), 0.94 – 0.80 (m, 2H).

Step C. (3*R*,5*S*)-1-(*L*-Seryl)-3-amino-5-(2-boronoethyl)piperidine-3-carboxylic acid


5 dihydrochloride.

[00286] (3*R*,5*S*)-3-Amino-1-(*O*-benzyl-*L*-seryl)-5-(2-boronoethyl)piperidine-3-carboxylic acid dihydrochloride (30 mg, 0.06 mmol) was dissolved in 2 mL of MeOH and flushed with argon. Next, 5 mg of Pd/C (wet, 10%) was added and the resulting mixture was stirred under
 10 hydrogen atmosphere (balloon) overnight. In the next step, the reaction mixture was filtered through the pad of Celite and concentrated. The crude product was purified by preparative HPLC (0.1 -1% of acetonitrile in water) to give (after acidification with 2M HCl and subsequent lyophilization) 12.4 mg (51%) of the corresponding product as a yellow foam (4 : 1 mixture of rotamers in D₂O solution at room temperature, based on NMR). ESI+MS: $m/z =$
 15 304.00 ($M+1$)⁺; ESI-MS: $m/z = 283.95$ ($M-18-1$)⁻. ¹H NMR (700 MHz, 300 K, deuterium oxide) δ 4.99 – 4.92 (m, 0.8H), 4.68 (dd, $J = 5.7, 3.9$ Hz, 0.8H), 4.58 (dd, $J = 6.7, 3.8$ Hz, 0.2H), 4.47 – 4.41 (m, 0.2H), 4.03 (dd, $J = 12.6, 3.8$ Hz, 1H), 3.94 (dd, $J = 12.7, 5.6$ Hz, 1.8H), 3.88 (dd, $J = 12.6, 6.9$ Hz, 0.2H), 3.48 (d, $J = 13.7$ Hz, 0.1H), 2.99 – 2.94 (m, 1.8H), 2.78 – 2.74 (m, 0.1H), 2.58 – 2.47 (m, 1H), 2.21 – 2.06 (m, 0.8H), 1.99 – 1.90 (m, 0.2H), 1.59
 20 – 1.46 (m, 2H), 1.46 – 1.36 (m, 1H), 0.92 – 0.80 (m, 2H).

Example 7. (3*R*,5*S*)-1-(*L*-Lysyl)-3-amino-5-(2-boronoethyl)piperidine-3-carboxylic acid trihydrochloride.



Step A. (3*R*,5*S*)-1-(*N*^ε,*N*^δ-bis(*tert*-Butoxycarbonyl)-*L*-lysyl)-5-(2-boronoethyl)-3-((*tert*-butoxycarbonyl)amino)piperidine-3-carboxylic acid.



5

[00287] The title compound was obtained according to step (K) of Example 1, using (3*R*,5*S*)-5-(2-boronoethyl)-3-((*tert*-butoxycarbonyl)amino)piperidine-3-carboxylic acid (97 mg, 0.31 mmol), Boc-*L*-Lys(Boc)-OSu (0.18 g, 0.40 mmol) and DMF (2 mL). The crude product was purified by column chromatography on silica gel using DCM/MeOH (80:1 to 3:1) to give 79.6 mg (40%) of the corresponding product as a white solid (3 : 2 mixture of rotamers in CD₃OD solution at room temperature, based on NMR). ESI+MS: *m/z* = 645.30 (*M*+1)⁺; ESI-MS: *m/z* = 643.25 (*M*-1)⁻. ¹H NMR (700 MHz, 300 K, methanol-*d*₄) δ 5.23 – 5.11 (m, 0.6H), 4.70 – 4.60 (m, 0.4H), 4.43 – 4.30 (m, 0.6H), 4.05 – 3.94 (m, 1H), 3.71 – 3.57 (m, 0.4H), 3.11 – 3.04 (m, 3H), 2.87 – 2.76 (m, 0.4H), 2.63 – 2.53 (m, 0.6H), 2.43 – 2.37 (m, 0.6H), 2.33 – 2.25 (m, 0.4H), 1.94 – 1.86 (m, 0.4H), 1.85 – 1.78 (m, 0.6H), 1.71 – 1.62 (m, 1H), 1.50 – 1.44 (m, 29H), 1.43 – 1.26 (m, 6H), 0.95 – 0.76 (m, 2H).

15

Step B. (3*R*,5*S*)-1-(*L*-Lysyl)-3-amino-5-(2-boronoethyl)piperidine-3-carboxylic acid trihydrochloride.


20

[00288] The title compound was obtained according to step (L) of Example 1, using (3*R*,5*S*)-1-(*N*^ε,*N*^δ-bis(*tert*-butoxycarbonyl)-*L*-lysyl)-5-(2-boronoethyl)-3-((*tert*-butoxycarbonyl)amino)piperidine-3-carboxylic acid (40 mg, 0.06 mmol) and 4M HCl in EtOAc

(5 mL). The crude product was purified by preparative HPLC (0.1 -1% of acetonitrile in water) to give (after acidification with 2M HCl and subsequent lyophilization) 16.2 mg, (58%) of the corresponding product as a white foam (9 : 1 mixture of rotamers in D₂O at room temperature, based on NMR). ESI+MS: $m/z = 345.10$ ($M+1$)⁺; ESI-MS: $m/z = 325.05$ ($M-18$ -
 5 1)⁻. ¹H NMR (700 MHz, 300 K, deuterium oxide) δ 4.89 (d, $J = 13.3$, 0.9H), 4.53 (dd, $J = 7.2$, 4.9 Hz, 0.9H), 4.46 (dd, $J = 7.3$, 4.1 Hz, 0.1H), 4.38 (dd, $J = 13.3$, 4.3 Hz, 0.1H), 4.24 (d, $J = 13.7$ Hz, 0.1H), 3.81 (dd, $J = 13.8$, 4.4 Hz, 0.9H), 3.40 (d, $J = 13.7$ Hz, 0.1H), 3.00 – 2.84 (m, 3.8H), 2.47 – 2.40 (m, 1.1H), 2.08 – 1.98 (m, 0.9H), 1.89 – 1.80 (m, 2.1H), 1.69 – 1.62 (m, 2H), 1.51 – 1.38 (m, 4H), 1.37 – 1.29 (m, 1H), 0.85 – 0.71 (m, 2H).


10

Example 8. (3*R*,5*S*)-1-(*L*-Leucyl)-3-amino-5-(2-boronoethyl)piperidine-3-carboxylic acid dihydrochloride.



15

Step A. (3*R*,5*S*)-5-(2-Boronoethyl)-1-((*tert*-butoxycarbonyl)-*L*-leucyl)-3-((*tert*-butoxycarbonyl)amino)piperidine-3-carboxylic acid.




[00289] The title compound was obtained according to step (K) of Example 1, using (3*R*,5*S*)-5-(2-boronoethyl)-3-((*tert*-butoxycarbonyl)amino)piperidine-3-carboxylic acid (97 mg, 0.31 mmol), Boc-*L*-Leu-OSu (111 mg, 0.34 mmol) and DMF (1 mL). The crude reaction mixture was purified by preparative HPLC to give a desired product as a white solid. Yield: 23 mg (14%). ESI+MS: $m/z = 530.25$ ($M+1$)⁺.

Step B. (3*R*,5*S*)-1-(*L*-Leucyl)-3-amino-5-(2-boronoethyl)piperidine-3-carboxylic acid dihydrochloride.


[00290] (3*R*,5*S*)-5-(2-Boronoethyl)-1-((*tert*-butoxycarbonyl)-*L*-leucyl)-3-((*tert*-butoxycarbonyl)amino)piperidine-3-carboxylic acid (23 mg, 43.44 μ mol) was treated with a solution of 50% 2,2,2-trifluoroacetic acid in dichloromethane (5 mL) and stirred for 30 min. Next, the solvent was evaporated and a crude product was purified by preparative HPLC. The concentrated fractions contained a corresponding product were evaporated from 0.5 M HCl_(aq) two times and freeze dried from water to give a desired product as a colorless solid (as 9 : 1 mixture of rotamers in D₂O at room temperature, based on NMR). Yield: 10.6 mg (61%). ESI+MS: $m/z = 330.05$ ($M+1$)⁺. ¹H NMR (700 MHz, 300K, deuterium oxide) δ 4.88 (d, $J = 13.3$ Hz, 0.9H), 4.5 (dd, $J = 9.4, 3.6$ Hz, 0.9H), 4.44 – 4.33 (m, 0.2H), 4.18 (d, $J = 13.6$ Hz, 0.1H), 3.83 – 3.67 (m, 1H), 3.41 (d, $J = 13.8$ Hz, 0.1H), 2.90 (d, $J = 13.3, 0.9$ Hz, 0.9H), 2.90 (t, $J = 5.3$ Hz, 1H), 2.50 - 2.37 (m, 1H), 2.17 – 1.90 (m, 1H), 1.84 – 1.58 (m, 3H), 1.55 – 1.29 (m, 3H), 1.06 – 0.89 (m, 6H), 0.86 – 0.72 (m, 2H).

Example 9. (3*R*,5*S*)-1-(*L*-Isoleucyl)-3-amino-5-(2-boronoethyl)piperidine-3-carboxylic acid dihydrochloride.



5

Step A. (3*R*,5*S*)-5-(2-Boronoethyl)-1-((*tert*-butoxycarbonyl)-*L*-isoleucyl)-3-((*tert*-butoxycarbonyl)amino)piperidine-3-carboxylic acid.



10

[00291] The title compound was obtained according to step (K) of Example 1, using (3*R*,5*S*)-5-(2-boronoethyl)-3-((*tert*-butoxycarbonyl)amino)piperidine-3-carboxylic acid (97 mg, 0.31 mmol), Boc-*L*-Ile-OSu (111 mg, 0.34 mmol) and DMF (1 mL). The crude reaction mixture was purified by preparative HPLC to give a desired product as a white solid. Yield: 22 mg (13%). ESI+MS: $m/z = 530.25$ ($M+1$)⁺.

15


Step B. (3*R*,5*S*)-1-(*L*-Isoleucyl)-3-amino-5-(2-boronoethyl)piperidine-3-carboxylic acid dihydrochloride.

[00292] (3*R*,5*S*)-5-(2-Boronoethyl)-1-((*tert*-butoxycarbonyl)-*L*-isoleucyl)-3-((*tert*-butoxycarbonyl)amino)piperidine-3-carboxylic acid (22 mg, 41.55 μ mol) was treated with a solution of 50% 2,2,2-trifluoroacetic acid in dichloromethane (5 mL) and stirred for 30 min.

- 5 Next, solvent was evaporated and the crude product was purified by preparative HPLC. The concentrated fractions contained a corresponding product were evaporated from 0.5 M HCl_(aq) two times and freeze dried from water to give 9 mg (62%) of a desired product as a colorless solid (as a 9 : 1 mixture of rotamers in D₂O solution at 300K, based on NMR).
ESI+MS: $m/z = 330.05$ ($M+1$)⁺. ¹H NMR (700 MHz, 300K, deuterium oxide) δ 4.92 (d, $J =$
10 13.1 Hz, 1H), 4.44 (d, $J = 4.2$ Hz, 0.9H), 4.34 (d, $J = 3.9$ Hz, 0.1H), 4.23 (d, $J = 13.3$ Hz, 0.9H), 3.95 – 3.80 (m, 0.9H), 3.46 (d, $J = 14.7$ Hz, 0.1H), 3.05 (d, $J = 12.3$ Hz, 0.1H), 2.93 (d, $J = 13.1$ Hz, 0.9H), 2.92 (t, $J = 12.9$ Hz, 0.9H), 2.58 (t, $J = 12.8$ Hz, 0.1H), 2.50 – 2.37 (m, 1H), 2.19 - 1.88 (m, 2H), 1.56 – 1.27 (m, 4H), 1.26 – 1.08 (m, 1H), 1.04 (d, $J = 6.5$ Hz, 3H), 0.94 – 0.69 (m, 5H).


15

Example 10. (3*R*,5*S*)-1-(*L*-Tyrosyl)-3-amino-5-(2-boronoethyl)piperidine-3-carboxylic acid dihydrochloride.



20

Step A. (3*R*,5*S*)-5-(2-Boronoethyl)-1-((*tert*-butoxycarbonyl)-*L*-tyrosyl)-3-((*tert*-butoxycarbonyl)amino)piperidine-3-carboxylic acid.



[00293] The title compound was obtained according to step (K) of Example 1, using

5 (3*R*,5*S*)-5-(2-boronoethyl)-3-((*tert*-butoxycarbonyl)amino)piperidine-3-carboxylic acid (97 mg, 0.31 mmol), Boc-*L*-Tyr-OSu (127 mg, 0.34 mmol) and DMF (1 mL). The crude reaction mixture was purified by preparative HPLC to give a desired product as a colorless solid. Yield: 26 mg (15%). ESI+MS: $m/z = 580.25$ ($M+1$)⁺.

10 Step B. (3*R*,5*S*)-1-(*L*-Tyrosyl)-3-amino-5-(2-boronoethyl)piperidine-3-carboxylic acid dihydrochloride.


[00294] (3*R*,5*S*)-5-(2-Boronoethyl)-1-((*tert*-butoxycarbonyl)-*L*-tyrosyl)-3-((*tert*-butoxycarbonyl)amino)piperidine-3-carboxylic acid (26 mg, 44.87 μ mol) was treated with a

15 solution of 50% 2,2,2-trifluoroacetic acid in dichloromethane (5 mL) and stirred for 30 min. Next, solvent was evaporated and the product was purified by preparative HPLC. The concentrated fractions contained a corresponding product were evaporated from 0.5 M HCl_(aq) two times and freeze dried from water to give a desired product as a colorless solid. Yield: 19.9 mg (73%). ESI+MS: $m/z = 380.05$ ($M+1$)⁺. ¹H NMR (700 MHz, 300K, deuterium oxide) δ 7.19 – 7.07 (m, 2H), 6.92 – 6.83 (m, 2H), 4.93 – 4.76 (m, 2H), 4.71 (dd, $J = 8.4, 6.2$ Hz, 1H), 3.52 (d, $J = 9.7$ Hz, 0.9H), 3.44 (d, $J = 9.7$ Hz, 0.1H), 3.17 (dd, $J = 13.9, 6.4$ Hz, 1H), 3.02 (dd, $J = 13.8, 8.4$ Hz, 1H), 2.72 (d, $J = 13.2$ Hz, 0.9H), 2.63 (d, $J = 11.6$ Hz, 0.1H), 2.45


20

(d, $J = 12.7$ Hz, 0.1H), 2.35 (d, $J = 13.4$ Hz, 0.9H), 2.06 – 1.82 (m, 2H), 1.47 – 1.15 (m, 3H), 0.88 – 0.75 (m, 0.2H), 0.75 – 0.61 (m, 1.8).

Example 11. (3*R*,5*S*)-1-(*L*-Phenylalanyl)-3-amino-5-(2-boronoethyl)piperidine-3-carboxylic acid dihydrochloride.



Step A. (3*R*,5*S*)-5-(2-Boronoethyl)-1-((*tert*-butoxycarbonyl)-*L*-phenylalanyl)-3-((*tert*-butoxycarbonyl)amino)piperidine-3-carboxylic acid.




[00295] The title compound was obtained according to step (K) of Example 1, using (3*R*,5*S*)-5-(2-boronoethyl)-3-((*tert*-butoxycarbonyl)amino)piperidine-3-carboxylic acid (0.12 g, 0.37 mmol), Boc-*L*-Phe-OSu (0.17 g, 0.48 mmol) and DMF (2 mL). The crude product was purified by column chromatography on silica gel using DCM/MeOH (80:1 to 0:1) to give 103 mg (49%) of the corresponding product as a white solid (5 : 2 mixture of rotamers in CD₃OD solution at room temperature, based on NMR). ESI+MS: $m/z = 564.25$ ($M+1$)⁺; ESI-MS: $m/z = 562.15$ ($M-1$)⁻. ¹H NMR (250 MHz, 300 K, Methanol-*d*₄) δ 7.33 – 7.11 (m, 5H), 5.16 – 5.00 (m, 0.7H), 4.64 – 6.52 (m, 1H), 4.48 – 4.4 (m, 0.3H), 3.90 – 3.73 (m, 1H), 3.06 – 2.77 (m, 2H), 2.55 – 2.17 (m, 2H), 1.69 – 1.54 (m, 1H), 1.51 – 1.10 (m, 22H), 0.92 – 0.65 (m, 2H).

Step B. (3*R*,5*S*)-1-(*L*-Phenylalanyl)-3-amino-5-(2-boronoethyl)piperidine-3-carboxylic acid dihydrochloride.

- 5 **[00296]** The title compound was obtained according to step (L) of Example 1, using (3*R*,5*S*)-5-(2-boronoethyl)-1-((*tert*-butoxycarbonyl)-*L*-phenylalanyl)-3-((*tert*-butoxycarbonyl)amino) piperidine-3-carboxylic acid (55 mg, 0.01 mmol) and 4M HCl in EtOAc (4 mL). The crude product was purified by preparative HPLC (0.1 -1% of acetonitrile) to give (after acidification with 2M HCl and subsequent lyophilization) 15 mg (35%) of the
- 10 corresponding product as a white solid. ESI-MS: $m/z = 364.05$ ($M+1$)⁺; ESI-MS: $m/z = 344.05$ ($M-18-1$)⁻. ¹H NMR (250 MHz, 333 K, Deuterium Oxide) δ 7.85 – 7.66 (m, 3H), 7.66 – 7.53 (m, 2H), 5.18 (d, $J = 13.2$ Hz, 1H), 5.13 – 4.99 (m, 1H), 3.86 – 3.78 (m, 1H), 3.63 – 3.40 (m, 2H), 3.07 (d, $J = 13.2$ Hz, 1H), 2.74 – 2.62 (m, 1H), 2.34 – 2.13 (m, 2H), 1.78 – 1.47 (m, 3H), 1.11 – 0.96 (m, 2H).


15

Example 12. (3*R*,5*S*)-1-(*L*-Threonyl)-3-amino-5-(2-boronoethyl)piperidine-3-carboxylic acid dihydrochloride.



20

Step A. (3*R*,5*S*)-5-(2-Boronoethyl)-1-((*tert*-butoxycarbonyl)-*L*-threonyl)-3-((*tert*-butoxycarbonyl)amino)piperidine-3-carboxylic acid.



5


[00297] The title compound was obtained according to step (K) of Example 1, using (3*R*,5*S*)-5-(2-boronoethyl)-3-((*tert*-butoxycarbonyl)amino)piperidine-3-carboxylic acid (87 mg, 0.28 mmol), Boc-*L*-Thr-OSu (113 mg, 0.36 mmol) and DMF (2 mL). The crude product was purified by column chromatography on silica gel using DCM/MeOH (20:1 to 0:1) to give 117 mg (71%) of the corresponding product as a white solid (7 : 3 mixture of rotamers in CD₃OD solution at room temperature, based on NMR). ESI+MS: *m/z* = 518.15 (*M*+1)⁺; ESI-MS: *m/z* = 515.95 (*M*-1)⁻. ¹H NMR (700 MHz, 300K, Methanol-*d*₄) δ 5.30 – 5.18 (m, 0.7H), 4.76 – 4.63 (m, 0.3H), 4.63 – 4.55 (m, 0.3H), 4.46 – 4.39 (m, 0.3H), 4.36 – 4.16 (m, 2.4H), 4.06 – 3.93 (m, 4H), 2.58 – 2.49 (m, 1H), 2.47 – 2.36 (m, 0.7H), 2.30 (d, *J* = 13.7 Hz, 0.3H), 1.43 – 1.25 (m, 3H), 1.22 (s, 9H), 1.21 (s, 9H), 1.02 – 0.68 (m, 3H).

Step B. (3*R*,5*S*)-1-(*L*-Threonyl)-3-amino-5-(2-boronoethyl)piperidine-3-carboxylic acid dihydrochloride.


[00298] The title compound was obtained according to step (L) of Example 1, using (3*R*,5*S*)-5-(2-boronoethyl)-1-((*tert*-butoxycarbonyl)-*L*-threonyl)-3-((*tert*-butoxycarbonyl)amino)piperidine-3-carboxylic acid (115 mg, 0.22 mmol) and 4M HCl in EtOAc (8 mL). The crude product was purified by preparative HPLC (0.1 -1% of acetonitrile in water) to give (after acidification with 2M HCl and subsequent lyophilization) 15.4 mg, (17%) of the corresponding

product as a white solid (9 : 1 mixture of rotamers in D₂O at room temperature, based on NMR). ESI+MS: $m/z = 317.80$ ($M+1$)⁺; ESI-MS: $m/z = 315.90$ ($M-1$)⁻. ¹H NMR (700 MHz, 300K, Deuterium Oxide) δ 4.94 (dt, $J = 13.0, 1.9$ Hz, 0.9H), 4.55 (d, $J = 4.7$ Hz, 0.9H), 4.45 (d, $J = 3.5$ Hz, 0.1H), 4.41 (dd, $J = 6.6, 3.5$ Hz, 0.1H), 4.34 (dd, $J = 6.6, 4.7$ Hz, 0.1H), 4.27 (qd, $J = 6.5, 4.6$ Hz, 0.9H), 3.99 (dd, $J = 13.7, 4.4$ Hz, 0.9H), 3.79 – 3.70 (m, 0.1H), 3.50 (d, $J = 13.7$ Hz, 0.1H), 3.04 – 2.89 (m, 1.9H), 2.72 – 2.63 (m, 0.1H), 2.52 – 2.40 (m, 0.9H), 2.30 – 2.08 (m, 0.9H), 2.06 – 1.98 (m, 0.1H), 1.55 – 1.30 (m, 6H), 0.98 – 0.78 (m, 2H).

Example 13. (3*R*,5*S*)-1-(*L*-Histidyl)-3-amino-5-(2-boronoethyl)piperidine-3-carboxylic acid trihydrochloride.



Step A. (3*R*,5*S*)-1-(*N*¹,*N*⁵-bis(*tert*-Butoxycarbonyl)-*L*-histidyl)-5-(2-boronoethyl)-3-((*tert*-butoxycarbonyl)amino)piperidine-3-carboxylic acid.




[00299] The title compound was obtained according to step (K) of Example 1, using (3*R*,5*S*)-5-(2-boronoethyl)-3-((*tert*-butoxycarbonyl)amino)piperidine-3-carboxylic acid (0.12 g, 0.34 mmol), Boc-*L*-His-(1-Boc)-OSu (0.22 g, 0.49 mmol) and DMF (2 mL). The crude product was purified by column chromatography on silica gel using DCM/MeOH (80:1 to 0:1)

to give 38 mg (16%) of the corresponding product as a white solid. ESI+MS: $m/z = 654.25$ ($M+1$)⁺; ESI-MS: $m/z = 652.25$ ($M-1$)⁻. ¹H NMR (250 MHz, 300 K, Methanol-*d*₄) δ 8.19 – 8.01 (m, 1H), 7.32 – 7.24 (m, 1H), 5.25 – 5.01 (m, 1H), 4.65 – 4.50 (m, 1H), 3.98 – 3.81 (m, 1H), 3.74 – 3.53 (m, 1H), 3.15 – 2.71 (m, 3H), 2.55 – 2.40 (m, 2H), 1.61 (s, 9H), 1.50 – 1.21 (m, 20H), 1.18 – 1.12 (m, 1H), 0.91 – 0.65 (m, 2H).

Step B. (3*R*,5*S*)-1-(*L*-Histidyl)-3-amino-5-(2-boronoethyl)piperidine-3-carboxylic acid trihydrochloride.


- 10 **[00300]** The title compound was obtained according to step (L) of Example 1, using (3*R*,5*S*)-1-(*N*^α,*N*^β-bis(*tert*-butoxycarbonyl)-*L*-histidyl)-5-(2-boronoethyl)-3-((*tert*-butoxycarbonyl)amino)piperidine-3-carboxylic acid (35 mg, 0.05 mmol) and 4M HCl in EtOAc (5 mL). The crude product was purified by preparative HPLC (0.1 -1% of acetonitrile) to give (after acidification with 2M HCl and subsequent lyophilization) 15 mg, (61%) of the
- 15 corresponding product as a white solid (4 : 1 mixture of rotamers in D₂O solution at room temperature, based on NMR). ESI+MS: $m/z = 354.05$ ($M+1$)⁺; ESI-MS: $m/z = 352.05$ ($M-1$)⁻. ¹H NMR (250 MHz, 300 K, Deuterium Oxide) δ 8.64 (d, $J = 1.4$ Hz, 0.8H), 8.61 (d, $J = 1.4$ Hz, 0.2H), 7.38 (d, $J = 1.4$ Hz, 0.8H), 7.35 (d, $J = 1.4$ Hz, 0.2H), 4.86 – 4.73 (m, 2H), 4.33 – 4.21 (m, 0.2H), 3.82 – 3.66 (m, 0.8H), 3.40 – 3.22 (m, 2.2H), 2.83 (d, $J = 13.2$ Hz, 0.8H), 2.72 –
- 20 2.52 (m, 0.8H), 2.42 – 2.32 (m, $J = 12.7$ Hz, 1.2H), 2.10 – 1.90 (m, 0.8H), 1.75 – 1.88 (m, 0.2H), 1.46 – 1.16 (m, 3H), 0.80 – 0.60 (m, 3H).

Example 14. (3*R*,5*S*)-1-(*L*-Aspartyl)-3-amino-5-(2-boronoethyl)piperidine-3-carboxylic acid dihydrochloride.



5

Step A. (3*R*,5*S*)-1-((*S*)-4-(Benzyloxy)-2-((*tert*-butoxycarbonyl)amino)-4-oxobutanoyl)-5-(2-boronoethyl)-3-((*tert*-butoxycarbonyl)amino)piperidine-3-carboxylic acid.




10

[00301] The title compound was obtained according to step (K) of Example 1, using (3*R*,5*S*)-5-(2-boronoethyl)-3-((*tert*-butoxycarbonyl)amino)piperidine-3-carboxylic acid (0.103 g, 0.326 mmol), Boc-*L*-Asp(OBzl)-OSu (0.178 g, 0.423 mmol) and DMF (5 mL). The crude product was purified by column chromatography on silica gel using CHCl₃/MeOH (100:1 to 10:1) to give 0.1206 mg (59.6 %) of the corresponding product as a white solid. ESI+MS: $m/z = 622.15$ ($M+1$)⁺. ¹H NMR (700 MHz, 300 K, DMSO-*d*₆) δ 7.56 – 7.24 (m, 4H), 7.12 – 6.20 (m, 3H), 5.08 (d, $J = 8.3$ Hz, 2H), 4.83 (m, 1H), 4.45 – 4.17 (m, 1H), 4.07 (s, 1H), 3.65 (s, 0.3H), 3.01 – 2.76 (m, 1H), 2.66 – 2.54 (m, 1H), 2.29 – 2.05 (m, 1H), 2.04 – 1.60 (m, 2H), 1.37 (d, $J = 18.9$ Hz, 18H), 1.27 – 1.17 (m, 2H), 0.69 – 0.41 (m, 2H).

20

Step B. (3*R*,5*S*)-3-amino-1-((*S*)-2-amino-4-(benzyloxy)-4-oxobutanoyl)-5-(2-boronoethyl)piperidine-3-carboxylic acid dihydrochloride.



5

[00302] The title compound was obtained in the same manner like in Example 1, step L, using (3*R*,5*S*)-1-((*S*)-4-(benzyloxy)-2-((*tert*-butoxycarbonyl)amino)-4-oxobutanoyl)-5-(2-boronoethyl)-3-((*tert*-butoxycarbonyl)amino)piperidine-3-carboxylic acid (0.101 g, 0.163 mmol) and 4M HCl in EtOAc (3 mL). The crude product (80 mg, 100%) was used in the next step without any further purification ESI+MS: $m/z = 421.95$ ($M+1$)⁺; ESI-MS: $m/z = 401.85$ ($M-18$)⁻.

10

Step C. (3*R*,5*S*)-1-(*L*-Aspartyl)-3-amino-5-(2-boronoethyl)piperidine-3-carboxylic acid dihydrochloride.

15


[00303] (3*R*,5*S*)-3-amino-1-((*S*)-2-amino-4-(benzyloxy)-4-oxobutanoyl)-5-(2-boronoethyl)piperidine-3-carboxylic acid dihydrochloride (0.080 g, 0.163 mmol) was dissolved in MeOH (5 mL). The reaction mixture was degassed and refilled with argon. Pd/C (10 mg) was added and the mixture was degassed and refilled with H₂. The reaction mixture was stirred overnight at room temperature, under hydrogen atmosphere (balloon), filtered through a pad of Celite, washed with MeOH (2 x 5 mL) and concentrated. The crude product was purified by preparative HPLC (0.1 -1% of acetonitrile in water) to give (after acidification with 2M HCl and subsequent lyophilization) 21.3 mg (31.3%) of the corresponding product as a white solid (3 : 1 mixture of rotamers in D₂O solution at room temperature, based on NMR). ESI+MS: $m/z = 331.85$ ($M+1$)⁺; ESI-MS: $m/z = 329.85$ ($M-1$)⁻.

20


25

¹H NMR (700 MHz, Deuterium Oxide) δ 5.00 – 4.84 (m, 2H), 4.59 – 4.40 (m, 0.3H), 4.32 (t, J = 5.5 Hz, 0.6H), 3.89 (d, J = 18.1 Hz, 1H), 3.80 (d, J = 13.1 Hz, 0.6H), 3.56 (dd, J = 12.6, 4.0 Hz, 0.6H), 3.45 (d, J = 13.4 Hz, 0.2H), 3.33 – 3.16 (m, 1H), 3.18 – 3.11 (m, 1H), 3.08 (dd, J = 17.9, 3.7 Hz, 1H), 3.01 – 2.86 (m, 3H), 2.79 – 2.59 (m, 1H), 2.57 – 2.26 (m, 0.6H), 2.21 – 2.01 (m, 1H), 1.89-1.80 (m, 0.2H), 1.65 – 1.24 (m, 5H), 0.86 (ddtt, J = 30.0, 19.8, 9.4, 5.1 Hz, 3H).

Example 15. (3*R*,5*S*)-1-(*L*-Glutamyl)-3-amino-5-(2-boronoethyl)piperidine-3-carboxylic acid dihydrochloride.



Step A. (3*R*,5*S*)-5-(2-Boronoethyl)-1-((*tert*-butoxycarbonyl)-*L*-glutamyl)-3-((*tert*-butoxycarbonyl)amino)piperidine-3-carboxylic acid.



[00304] The title compound was obtained according to step (K) of Example 1, using (3*R*,5*S*)-5-(2-boronoethyl)-3-((*tert*-butoxycarbonyl)amino)piperidine-3-carboxylic acid (0.1 g,

0.32 mmol), Boc-*L*-Glu(*O**t*-Bu)-OSu (0.16 g, 0.41 mmol) and DMF (2 mL). The crude product was purified by column chromatography on silica gel using DCM/MeOH (80:1 to 6:1) to give 143 mg (75%) of the corresponding product as a pale yellow solid (5 : 2 mixture of rotamers in CD₃OD solution at room temperature, based on NMR). ESI+MS: *m/z* = 602.10 (*M*+1)⁺;

5 ESI-MS: *m/z* = 600.15 (*M*-1)⁻. ¹H NMR (700 MHz, Methanol-*d*₄) δ 4.74 – 4.68 (m, 0.7H), 4.62 – 4.47 (m, 1.3H), 4.08 – 3.97 (m, 1H), 2.84 – 2.58 (m, 2H), 2.42 – 2.21 (m, 3H), 2.06 – 2.00 (m, 0.7H), 1.91 – 1.78 (m, 1.3H), 1.72 – 1.51 (m, 2H), 1.51 – 1.40 (m, 27H), 1.39 – 1.26 (m, 2H), 0.87 – 0.77 (m, 2H).


10 Step B. (3*R*,5*S*)-1-(*L*-Glutamyl)-3-amino-5-(2-boronoethyl)piperidine-3-carboxylic acid dihydrochloride.

[00305] The title compound was obtained according to step (L) of Example 1, using (3*R*,5*S*)-5-(2-boronoethyl)-1-((*tert*-butoxycarbonyl)-*L*-glutamyl)-3-((*tert*-

15 butoxycarbonyl)amino) piperidine-3-carboxylic acid (75 mg, 0.12 mmol) and 4M HCl in EtOAc (5 mL). The crude product was purified by preparative HPLC (0.1 -1% of acetonitrile) to give (after acidification with 2M HCl and subsequent lyophilization) 36 mg (68%) of the corresponding product as a white solid (9 : 1 mixture of rotamers in D₂O solution at room temperature, based on NMR). ESI+MS: *m/z* = 345.90 (*M*+1)⁺; ESI-MS: *m/z* = 343.85 (*M*-1)⁻.


20 ¹H NMR (700 MHz, Deuterium Oxide) δ 4.84 (dt, *J* = 13.3, 2.0 Hz, 0.9H), 4.59 (dd, *J* = 7.7, 4.3 Hz, 0.9H), 4.53 (dd, *J* = 7.7, 4.3 Hz, 0.1H), 4.36 (dd, *J* = 13.3, 4.3 Hz, 0.1H), 4.30 (dt, *J* = 13.3, 2.0 Hz, 0.1H), 3.92 (dd, *J* = 13.5, 4.3 Hz, 0.9H), 3.41 (d, *J* = 13.7 Hz, 0.1H), 2.94 – 2.81 (m, 1.8H), 2.57 – 2.53 (t, *J* = 7.0 Hz, 2H), 2.52 – 2.43 (m, 0.1H), 2.44 – 2.37 (m, 1H), 2.31 – 2.21 (m, 0.1H), 2.23 – 2.13 (m, 0.9H), 2.10 (dq, *J* = 14.6, 6.9 Hz, 1H), 2.06 – 1.97 (m, 1H),
25 1.93 – 1.82 (m, 0.1H), 1.51 – 1.40 (m, 2H), 1.38 – 1.31 (m, 1H), 0.84 – 0.74 (m, 2H).

Example 16. (3*R*,5*S*)-1-(*L*-Glutaminyl)-3-amino-5-(2-boronoethyl)piperidine-3-carboxylic acid dihydrochloride.



5

Step A. (3*R*,5*S*)-5-(2-Boronoethyl)-1-((*tert*-butoxycarbonyl)-*L*-glutaminyl)-3-((*tert*-butoxycarbonyl)amino)piperidine-3-carboxylic acid.



10

[00306] The title compound was obtained according to step (K) of Example 1, using (3*R*,5*S*)-5-(2-boronoethyl)-3-((*tert*-butoxycarbonyl)amino)piperidine-3-carboxylic acid (0.10 g, 0.32 mmol), Boc-*L*-Gln-OSu (0.28 g, 0.92 mmol) and DMF (2 mL). The reaction mixture was heated to 50 °C and stirred for 2 days (10% of product, the progress of reaction was controlled on LCMS). After this time to reaction mixture was added *N,N*-diisopropylethylamine (0.17 mL, 0.99 mmol) and reaction continued for 1 day at 50 °C. Then to reaction mixture was added *O*-(benzotriazol-1-yl)-*N,N,N',N'*-tetramethyluronium tetrafluoroborate (0.10 g, 0.32 mmol) and stirring was continued for 3 days at 50 °C. The crude product was purified by column chromatography on silica gel using DCM/MeOH (80:1 to 0:1) to give 33 mg (19%) of the corresponding product as a colorless film. ESI+MS: *m/z* = 545.05 (*M*+1)⁺; ESI-MS: *m/z* = 543.05 (*M*-1)⁻. ¹H NMR (250 MHz, 300 K, Methanol-*d*₄) δ 4.58


20

– 4.55 (m, 1H), 4.06 – 4.00 (m, 2H), 2.40 – 2.23 (m, 4H), 2.13 – 2.05 (m, 2H), 1.96 – 1.92 (m, 2H), 1.48 – 1.44 (m, 18H), 1.40 – 1.38 (m, 1H), 1.37 – 1.33 (m, 2H), 0.85 – 0.80 (m, 2H).


Step B. (3*R*,5*S*)-1-(*L*-Glutaminy)-3-amino-5-(2-boronoethyl)piperidine-3-carboxylic acid dihydrochloride.

[00307] The title compound was obtained according to step (L) of Example 1, (3*R*,5*S*)-5-(2-boronoethyl)-1-((*tert*-butoxycarbonyl)-*L*-glutaminy)-3-((*tert*-butoxycarbonyl)amino) piperidine-3-carboxylic acid (33 mg, 0.06 mmol) and 3M HCl in EtOAc (2.5 mL). The crude product was purified by preparative HPLC (0.1 -1% of acetonitrile in water) to give (after acidification with 2M HCl and subsequent lyophilization) 3.7 mg (15%) of the corresponding product as a colorless film (9 : 1 mixture of rotamers in D₂O solution at room temperature, based on NMR). ESI+MS: $m/z = 344.09$ ($M+1$)⁺; ESI-MS: $m/z = 342.85$ ($M-1$)⁻. ¹H NMR (700 MHz, Deuterium Oxide) δ 4.84 (d, $J = 13.2$ Hz, 0.9H), 4.59 – 4.53 (m, 0.9H), 4.55 – 4.46 (m, 0.1H), 4.27 (d, $J = 13.2$ Hz, 0.1H), 3.88 (dd, $J = 13.7, 4.2$ Hz, 0.9H), 3.40 (dd, $J = 13.6, 4.2$ Hz, 0.1H), 2.97 – 2.78 (m, 1.8H), 2.63 – 2.52 (m, 0.2H), 2.51 – 2.33 (m, 3H), 2.25 – 2.07 (m, 2H), 2.07 – 1.99 (m, 0.9) 1.93 – 1.86 (m, 0.1H), 1.49 – 1.30 (m, 3H), 0.84 – 0.73 (m, 2H).

Example 17. (3*R*,5*S*)-1-(*L*-Methionyl)-3-amino-5-(2-boronoethyl)piperidine-3-carboxylic acid dihydrochloride.



Step A. (3*R*,5*S*)-5-(2-Boronoethyl)-1-((*tert*-butoxycarbonyl)-*L*-methionyl)-3-((*tert*-butoxycarbonyl)amino)piperidine-3-carboxylic acid.



5

[00308] The title compound was obtained according to step (K) of Example 1, using (3*R*,5*S*)-5-(2-boronoethyl)-3-((*tert*-butoxycarbonyl)amino)piperidine-3-carboxylic acid (0.1 g, 0.32 mmol), Boc-*L*-Met-OSu (0.14 g, 0.41 mmol) and DMF (2 mL). The crude product was purified by column chromatography on silica gel using DCM/MeOH (80:1 to 0:1) to give 93 mg (54%) of the corresponding product as a white solid (5 : 2 mixture of rotamers in CD₃OD solution at room temperature, based on NMR). ESI+MS: *m/z* = 548.10 (*M*+1)⁺; ESI-MS: *m/z* = 546.10 (*M*-1)⁻. ¹H NMR (700 MHz, 300 K, Methanol-*d*₄) δ 5.12 – 5.03 (m, 0.7H), 4.62 – 4.52 (m, 0.7H), 4.33 – 4.25 (m, 0.3H), 4.09 – 4.03 (m, 0.3H), 4.01 – 3.97 (m, 1H), 2.82 – 2.73 (m, 1H), 2.59 – 2.48 (m, 2H), 2.44 – 2.33 (m, 0.7H), 2.27 – 2.19 (m, 0.3H), 2.15 – 2.07 (m, 3H), 1.94 – 1.83 (m, 0.7H), 1.72 – 1.63 (m, 0.3H), 1.52 – 1.41 (m, 20H), 1.39 – 1.27 (m, 4H), 0.88 – 0.75 (m, 2H).


Step B. (3*R*,5*S*)-1-(*L*-Methionyl)-3-amino-5-(2-boronoethyl)piperidine-3-carboxylic acid dihydrochloride.

20


[00309] The title compound was obtained according to step (L) of Example 1, using (3*R*,5*S*)-5-(2-boronoethyl)-1-((*tert*-butoxycarbonyl)-*L*-methionyl)-3-((*tert*-butoxycarbonyl)amino) piperidine-3-carboxylic acid (89 mg, 0.16 mmol) and 4M HCl in EtOAc (8 mL). The crude product was purified by preparative HPLC (0.1 -1% of acetonitrile

in water) to give (after acidification with 2M HCl and subsequent lyophilization) 16 mg (23%) of the corresponding product as a white solid (9 : 1 mixture of rotamers in D₂O solution at room temperature, based on NMR). ESI+MS: $m/z = 347.75$ ($M+1$)⁺; ESI-MS: $m/z = 327.95$ ($M-18-1$)⁻. ¹H NMR (700 MHz, 300 K, Deuterium Oxide) δ 4.88 (dt, $J = 13.3, 2.0$ Hz, 0.9H), 4.65 (dd, $J = 8.1, 4.0$ Hz, 0.9H), 4.55 (dd, $J = 8.1, 4.0$ Hz, 0.1H), 4.37 (dd, $J = 13.1, 4.3$ Hz, 0.1H), 4.26 (dt, $J = 13.3, 2.0$ Hz, 0.1H), 4.16 (dd, $J = 6.9, 5.9$ Hz, 0.1H), 3.91 (dd, $J = 13.4, 4.3$ Hz, 0.9H), 3.44 (d, $J = 13.8$ Hz, 0.1H), 2.95 – 2.84 (m, 1.8H), 2.68 – 2.55 (m, 2.2H), 2.50 – 2.42 (m, 1.2H), 2.30 – 2.21 (m, 0.1H), 2.21 – 2.01 (m, 5.4H), 1.89 – 1.83 (m, 0.1H), 1.52 – 1.32 (m, 3H), 0.86 – 0.73 (m, 2H).

Example 18. (3*R*,5*S*)-1-(*L*-Tryptophyl)-3-amino-5-(2-boronoethyl)piperidine-3-carboxylic acid dihydrochloride.



Step A. (3*R*,5*S*)-5-(2-Boronoethyl)-1-((*tert*-butoxycarbonyl)-*L*-tryptophyl)-3-((*tert*-butoxycarbonyl)amino)piperidine-3-carboxylic acid.




[00310] The title compound was obtained according to step (K) of Example 1, using (3*R*,5*S*)-5-(2-boronoethyl)-3-((*tert*-butoxycarbonyl)amino)piperidine-3-carboxylic acid (0.116

g, 0.37 mmol), Boc-*L*-Trp-OSu (0.192 g, 0.48 mmol) and DMF (2 mL). The crude product was purified by column chromatography on silica gel using CHCl₃/MeOH (50:1 to 5:1) to give 0.140 mg (63 %) of the corresponding product as a white solid. ESI+MS: *m/z* = 603.20 (*M*+1)⁺. ¹H NMR (700 MHz, 300 K, Methanol-*d*₄) δ 7.60 (dd, *J* = 15.1, 7.9 Hz, 1H), 7.30 (dd, *J* = 29.2, 8.1 Hz, 1H), 7.26 – 6.57 (m, 3H), 5.24 – 4.91 (m, 1H), 3.77 – 3.64 (m, 1H), 3.57 – 3.39 (m, 1H), 3.26 – 2.99 (m, 2H), 2.62–2.44 (m, 1H), 2.31 – 1.96 (m, 2H), 1.73 – 1.51 (m, 1H), 1.49 – 1.30 (m, 20H), 1.33 – 1.26 (m, 1H), 0.85 – 0.48 (m, 2H).

Step B. (3*R*,5*S*)-1-(*L*-Tryptophyl)-3-amino-5-(2-boronoethyl)piperidine-3-carboxylic acid dihydrochloride.


[00311] The title compound was obtained according to step (L) of Example 1, using ((3*R*,5*S*)-5-(2-boronoethyl)-1-((tert-butoxycarbonyl)-*L*-tryptophyl)-3-((tert-butoxycarbonyl)amino)piperidine-3-carboxylic acid (0.101 g, 0.167 mmol) and 4M HCl in EtOAc (4 mL). The crude product was purified by preparative HPLC (0.1 -1% of acetonitrile) to give (after acidification with 2M HCl and subsequent lyophilization) 37 mg (47%) of the corresponding product as a white solid (9 : 1 mixture of rotamers in D₂O solution at room temperature, based on NMR). ESI+MS: *m/z* = 403.00 (*M*+1)⁺; ¹H NMR (700 MHz, 300 K, Deuterium Oxide) δ 7.64 (d, *J* = 8.0 Hz, 0.1H), 7.58 (d, *J* = 8.9 Hz, 2H), 7.35 (s, 1H), 7.34 – 7.28 (m, 1H), 7.26 – 7.19 (m, 1H), 4.72–4.75 (m, 1H), 3.79 (dd, *J* = 13.3, 3.7 Hz, 0.1H), 3.56 – 3.40 (m, 1H), 3.41 – 3.14 (m, 2H), 2.90 – 2.73 (m, 0.1H), 2.46 (d, *J* = 13.0 Hz, 1H), 2.38 (dd, *J* = 13.7, 3.0 Hz, 0.1H), 2.26 – 2.12 (m, 1H), 1.87 (dq, *J* = 12.0, 6.8 Hz, 1H), 1.80 – 1.70 (m, 0.1H), 1.62 – 1.45 (m, 1H), 1.44 – 1.31 (m, 0.1H), 1.24 – 1.07 (m, 2H), 1.06 – 0.94 (m, 1H), 0.88 – 0.77 (m, 0.1H), 0.56 (ddd, *J* = 16.3, 11.0, 5.7 Hz, 1H), 0.41 (ddd, *J* = 15.8, 11.2, 5.7 Hz, 1H).

Example 19. (3*R*,5*S*)-1-(*L*-Cysteinyl)-3-amino-5-(2-boronoethyl)piperidine-3-carboxylic acid dihydrochloride.



5

Step A. (3*R*,5*S*)-5-(2-Boronoethyl)-1-(*N*-(*tert*-butoxycarbonyl)-*S*-trityl-*L*-cysteinyl)-3-((*tert*-butoxycarbonyl)amino)piperidine-3-carboxylic acid.




10

[00312] The title compound was obtained according to step (K) of Example 1, using (3*R*,5*S*)-5-(2-boronoethyl)-3-((*tert*-butoxycarbonyl)amino)piperidine-3-carboxylic acid (0.11 g, 0.35 mmol), Boc-*L*-Cys(Trt)-OSu (195 mg, 0.35 mmol), TEA (53 μ L, 0.38 mmol) and acetonitrile (1.5 mL; instead of DMF). Next day, acetonitrile was evaporated. The residue was diluted with EtOAc (50 mL) and washed with 1M KHSO₄ (10 mL), H₂O (20 mL), brine (20 mL), dried over Na₂SO₄ and concentrated to give a crude product. A crude product was trituated with hexane (2 mL) to give 211 mg (79%) of the corresponding product as an off-white solid. ESI+MS: m/z = 762.4 ($M+1$)⁺; ESI-MS: m/z = 760.15 ($M-1$)⁻.


Step B. (3*R*,5*S*)-1-(*L*-Cysteinyl)-3-amino-5-(2-boronoethyl)piperidine-3-carboxylic acid dihydrochloride.

[00313] The title compound was obtained according to step (L) of Example 1, using (3*R*,5*S*)-5-(2-boronoethyl)-1-(*N*-(*tert*-butoxycarbonyl)-*S*-trityl-*L*-cysteiny)-3-((*tert*-butoxycarbonyl)amino)piperidine-3-carboxylic acid (0.143 g, 0.188 mmol) and 4M HCl in dioxane (4 mL). Stirred for 5 days. The crude product was purified by preparative HPLC (0.1 -1% of acetonitrile in water) to give (after acidification with 2M HCl and subsequent lyophilization) 20 mg (27 %) of the corresponding product as a white solid (5 : 1 mixture of rotamers in D₂O solution at room temperature, based on NMR). ESI+MS: *m/z* = 319.85 (*M*+1)⁺; ¹H NMR (700 MHz, 300 K, Deuterium Oxide) δ 4.88 (ddt, *J* = 13.2, 9.1, 2.0 Hz, 0.83H), 4.74 (dd, *J* = 6.3, 4.7 Hz, 0.83H), 4.69 – 4.66 (m, 0.83H), 4.47 – 4.38 (m, 0.17H), 4.33 – 4.24 (m, 0.17H), 3.87 (ddd, *J* = 45.8, 14.0, 4.2 Hz, 0.83H), 3.42 (dd, *J* = 13.9, 12.2 Hz, 0.17H), 3.10 – 2.82 (m, 3.2H), 2.48 – 2.42 (m, 1H), 2.42 – 2.36 (m, 0.17H), 2.07 – 1.96 (m, 0.83H), 1.58 – 1.28 (m, 3H), 0.85 – 0.70 (m, 2H).

Example 20. (3*R*,5*S*)-1-(*L*-Arginyl)-3-amino-5-(2-boronoethyl)piperidine-3-carboxylic acid trihydrochloride.



Step A. (3*R*,5*S*)-1-(*N*^w,*N*^{w'}-bis((Benzyloxy)carbonyl)-*N*^p-(*tert*-butoxycarbonyl)-*L*-arginyl)-5-(2-boronoethyl)-3-((*tert*-butoxycarbonyl)amino)piperidine-3-carboxylic acid.



[00314] The title compound was obtained according to step (K) of Example 1, using (3*R*,5*S*)-5-(2-boronoethyl)-3-((*tert*-butoxycarbonyl)amino)piperidine-3-carboxylic acid (0.35 g, 1.11 mmol), Boc-*L*-Arg(Cbz)₂-OSu (0.17 g, 0.48 mmol) and DMF (7 mL). The crude product was purified by column chromatography on silica gel using DCM/MeOH (80:1 to 0:1) to give 505 mg (54%) of the corresponding product as a white foam (3 : 2 mixture of rotamers in CD₃OD solution at room temperature, based on NMR). ESI+MS: *m/z* = 841.05 (M+1)⁺; ESI-MS: *m/z* = 839.25 (M-1)⁻. ¹H NMR (700 MHz, 300 K, Methanol-*d*₄) δ 7.49 – 7.25 (m, 10H), 5.31 – 5.24 (m, 2H), 5.16 – 5.09 (m, 2H), 5.05 – 4.95 (m, 0.4H), 4.67 – 4.56 (m, 0.4H), 4.49 – 4.37 (m, 0.6H), 4.10 – 3.82 (m, 2.6H), 2.58 – 2.45 (m, 1H), 2.36 – 2.20 (m, 1H), 1.78 – 1.55 (m, 5H), 1.48 – 1.29 (m, 22H), 1.27 – 1.21 (m, 1H), 0.88 – 0.66 (m, 2H).

Step B. (3*R*,5*S*)-1-(*L*-Arginyl)-3-amino-5-(2-boronoethyl)piperidine-3-carboxylic acid trihydrochloride.

[00315] To a solution of (3*R*,5*S*)-1-(*N*^ω,*N*^{ω'}-bis((benzyloxy)carbonyl)-*N*^ε-(*tert*-butoxycarbonyl)-*L*-arginyl)-5-(2-boronoethyl)-3-((*tert*-butoxycarbonyl)amino)piperidine-3-carboxylic acid (0.78 g, 0.57 mmol) in MeOH (7 mL) under argon 10% Pd/C (50 mg) was added. The mixture was degassed, charged with H₂, and stirred overnight at room temperature under hydrogen atmosphere. The reaction mixture was filtered through a pad of Celite, washed with MeOH (3 x 2 mL) and then the filtrate was concentrated *in vacuo* to give 300 mg (92%) of the corresponding product as a white solid. ESI+MS: *m/z* = 573.30 (M+1)⁺; ESI-MS: *m/z* = 571.30 (M-1)⁻. The crude product was used to the next step without further


butoxycarbonyl)amino)piperidine-3-carboxylic acid (300 mg, 0.52 mmol) and 4M HCl in EtOAc (10 mL). The crude product was purified by preparative HPLC (0.1 -1% of acetonitrile

of the corresponding product as a white foam (9 : 1 mixture of rotamers in D₂O solution at room temperature, based on NMR). ESI+MS: m/z = 372.90 (M+1)⁺; ESI-MS: m/z = 370.9


4.22 (dt, $J = 13.2, 2.0$ Hz, 0.1H), 3.81 (dd, $J = 13.4, 4.3$ Hz, 0.9H), 3.38 (d, $J = 13.7$ Hz,

0.9H), 1.94 – 1.84 (m, 2.1H), 1.71 – 1.53 (m, 2H), 1.51 – 1.29 (m, 3H), 0.85 – 0.70 (m, 2H).

piperidine-3-carboxylic acid dihydrochloride.



Step A. (3*R*,5*S*)-5-(2-Boronoethyl)-3-((*tert*-butoxycarbonyl)amino)-1-((*S*)-2-((*tert*-butoxycarbonyl)amino)-5-ureidopentanoyl)piperidine-3-carboxylic acid.



5

[00316] To a solution of Boc-*L*-Cit-OH (87 mg, 0.32 mmol) in DCM/DMF (2 mL/0.3 mL) were added DIPEA (110 μ L, 0.632 mmol) and CDI (53 mg, 0.33 mmol). The mixture was stirred for 30 min. and then (3*R*,5*S*)-5-(2-boronoethyl)-3-((*tert*-butoxycarbonyl)amino)piperidine-3-carboxylic acid (100 mg, 0.32) was added. The resulting mixture was stirred at room temperature for 48 h. The solvents were evaporated and the crude product was purified by column chromatography on silica gel using DCM/MeOH (80:1 to 0:1) to give 105 mg (56%) of the corresponding product as a white solid (3 : 2 mixture of rotamers in CD₃OD solution at room temperature, based on NMR). ESI+MS: m/z = 574.15 ($M+1$)⁺; ESI-MS: m/z = 572.10 ($M-1$)⁻. ¹H NMR (700 MHz, 300K, Methanol-*d*₄) δ 5.16 (d, J = 14.3 Hz, 0.4H), 4.76 – 4.69 (m, 0.6H), 4.57 – 4.48 (m, 0.6H), 4.43 – 4.34 (m, 0.4H), 4.32 – 4.24 (m, 0.4H), 4.02 – 3.91 (m, 0.6H), 3.20 – 2.99 (m, 3H), 2.68 (t, J = 12.1 Hz, 0.4H), 2.53 – 2.40 (m, 0.4H), 2.33 (dd, J = 42.0, 13.1 Hz, 1.2H), 1.84 – 1.73 (m, 1H), 1.63 (dt, J = 14.7, 7.6 Hz, 2H), 1.57 – 1.47 (m, 3H), 1.44 (s, 9H), 1.43 (s, 9H), 1.36 – 1.23 (m, 2H), 0.90 – 0.71 (m, 2H).

20


Step B. (3*R*,5*S*)-3-Amino-1-((*S*)-2-amino-5-ureidopentanoyl)-5-(2-boronoethyl)piperidine-3-carboxylic acid dihydrochloride.

[00317] The title compound was obtained according to step (L) of Example 1, using


25 (3*R*,5*S*)-5-(2-boronoethyl)-3-((*tert*-butoxycarbonyl)amino)-1-((*S*)-2-((*tert*-

butoxycarbonyl)amino)-5-ureidopentanoyl)piperidine-3-carboxylic acid (100 mg, 0.17 mmol) and 4M HCl in EtOAc (8 mL). The crude product was purified by preparative HPLC (0.1 -1% of acetonitrile in water) to give (after acidification with 2M HCl and subsequent lyophilization) 28.9 mg, (37%) of the corresponding product as a white solid (4 : 1 mixture of rotamers in D₂O at room temperature, based on NMR). ESI+MS: $m/z = 373.90$ ($M+1$)⁺; ESI-MS: $m/z = 371.90$ ($M-1$)⁻. ¹H NMR (700 MHz, 300K, Deuterium Oxide) δ 4.93 – 4.85 (m, 0.8H), 4.57 (dd, $J = 7.4, 4.9$ Hz, 0.8H), 4.51 (dd, $J = 8.1, 3.7$ Hz, 0.2H), 4.37 (d, $J = 13.5$ Hz, 0.2H), 4.21 (d, $J = 13.5$ Hz, 0.2H), 3.87 (dd, $J = 13.6, 4.4$ Hz, 0.8H), 3.43 (d, $J = 13.5$ Hz, 0.2H), 3.18 (q, $J = 7.0$ Hz, 2H), 2.93 (t, $J = 13.0$ Hz, 1.8H), 2.67 – 2.54 (m, 0.2H), 2.47 – 2.39 (m, 1H), 2.19 – 2.13 (m, 0.8H), 2.09 – 1.98 (m, 0.2H), 1.92 (tt, $J = 16.8, 7.0$ Hz, 1.8H), 1.67 – 1.59 (m, 2H), 1.57 – 1.37 (m, 3H), 0.96 – 0.75 (m, 2H).

Example 22. (3*R*,5*S*)-3-Amino-5-(2-boronoethyl)-1-((*S*)-2,5-diaminopentanoyl)piperidine -3-carboxylic acid trihydrochloride.




Step A. (3*R*,5*S*)-1-((*S*)-5-(((Benzyloxy)carbonyl)amino)-2-((*tert*-butoxycarbonyl)amino)pentanoyl)-5-(2-boronoethyl)-3-((*tert*-butoxycarbonyl)amino)piperidine-3-carboxylic acid.



[00318] The title compound was obtained according to step (K) of Example 1, using (3*R*,5*S*)-5-(2-boronoethyl)-3-((*tert*-butoxycarbonyl)amino)piperidine-3-carboxylic acid (100 mg, 0.32 mmol), Boc-*L*-Orn(Cbz)-OSu (190 mg, 0.41 mmol) and DMF (2 mL). The crude product was purified by column chromatography on silica gel using DCM/MeOH (50:1 to 2:1) to give 95 mg (45%) of the corresponding product as a colorless glass. ESI+MS: m/z = 665.25 ($M+1$)⁺; ESI-MS: m/z = 663.25 ($M-1$)⁻.

Step B. (3*R*,5*S*)-3-Amino-1-((*S*)-2-amino-5-(((benzyloxy)carbonyl)amino)pentanoyl)-5-(2-boronoethyl)piperidine-3-carboxylic acid dihydrochloride.




[00319] The title compound was obtained according to step (L) of Example 1, using (3*R*,5*S*)-1-((*S*)-5-(((benzyloxy)carbonyl)amino)-2-((*tert*-butoxycarbonyl)amino)pentanoyl)-5-(2-boronoethyl)-3-((*tert*-butoxycarbonyl)amino)piperidine-3-carboxylic acid (95 mg, 0.14 mmol) and 4M HCl in EtOAc (6 mL). The desired product was obtained as a white solid (95 mg, 45%). ESI+MS: m/z = 464.95 ($M+1$)⁺; ESI-MS: m/z = 462.95 ($M-1$)⁻. ¹H NMR (700 MHz, 300K, Deuterium Oxide) δ 7.59 – 7.34 (m, 5H), 5.16 (s, 2H), 4.55 – 4.44 (m, 1H), 3.87 – 3.73 (m, 1H), 3.34 – 3.12 (m, 2H), 2.96 – 2.67 (m, 3H), 2.59 – 2.31 (m, 1H), 2.04 – 1.80 (m, 2H), 1.69 – 1.55 (m, 2H), 1.51 – 1.29 (m, 4H), 0.92 – 0.69 (m, 2H).


Step C. (3*R*,5*S*)-3-Amino-5-(2-boronoethyl)-1-((*S*)-2,5-diaminopentanoyl)piperidine-3-carboxylic acid trihydrochloride.

[00320] (3*R*,5*S*)-3-Amino-1-((*S*)-2-amino-5-(((benzyloxy)carbonyl)amino)pentanoyl)-5-(2-boronoethyl) piperidine-3-carboxylic acid dihydrochloride (76 mg, 0.14 mmol) was dissolved in 4 mL of MeOH and flushed with argon. Next, 3 mg of 10% Pd/C (wet) was added and the resulting mixture was stirred under hydrogen atmosphere (balloon) overnight. In the next step, the reaction mixture was filtered through the pad of Celite and the filtrate was concentrated. The crude product was purified by preparative HPLC (0.1 -1% of acetonitrile in water) to give (after acidification with 2M HCl and subsequent lyophilization) 23.8 mg (34%) of the corresponding product as a white solid (7 : 3 mixture of rotamers in D₂O solution at room temperature, based on NMR). ESI+MS: $m/z = 330.85$ ($M+1$)⁺; ESI-MS: $m/z = 328.85$ ($M-1$)⁻. ¹H NMR (700 MHz, 300K, Deuterium Oxide) δ 4.92 (dt, $J = 13.0, 1.8$ Hz, 0.7H), 4.64 (dd, $J = 6.9, 5.2$ Hz, 0.7H), 4.60 (t, $J = 5.5$ Hz, 0.3H), 4.50 (dd, $J = 13.0, 4.3$ Hz, 0.3H), 4.26 (d, $J = 13.5$ Hz, 0.3H), 3.89 (dd, $J = 13.6, 4.1$ Hz, 0.7H), 3.40 (d, $J = 13.5$ Hz, 0.3H), 3.15 – 3.04 (m, 2.7H), 2.99 – 2.87 (m, 1H), 2.54 – 2.42 (m, 1H), 2.23 – 2.12 (m, 0.7H), 2.10 – 1.94 (m, 2.3H), 1.89 – 1.77 (m, 1.7H), 1.77 – 1.69 (m, 0.3H), 1.56 – 1.30 (m, 3H), 0.99 – 0.74 (m, 2H).

Example 23. (3*R*,5*S*)-1-(*D*-Alanyl)-3-amino-5-(2-boronoethyl)piperidine-3-carboxylic acid dihydrochloride.



Step A. (3*R*,5*S*)-5-(2-Boronoethyl)-1-((*tert*-butoxycarbonyl)-*D*-alanyl)-3-((*tert*-butoxycarbonyl)amino)piperidine-3-carboxylic acid.



5

[00321] The title compound was obtained according to step (K) of Example 1, using (3*R*,5*S*)-5-(2-boronoethyl)-3-((*tert*-butoxycarbonyl)amino)piperidine-3-carboxylic acid (0.1 g, 0.32 mmol), Boc-*D*-Ala-OSu (0.13 g, 0.41 mmol) and DMF (2 mL). The crude product was purified by column chromatography on silica gel using DCM/MeOH (80:1 to 0:1) to give 80 mg (52%) of the corresponding product as a colorless film (5 : 2 mixture of rotamers in CD₃OD solution at room temperature, based on NMR). ESI+MS: *m/z* = 488.05 (*M*+1)⁺; ESI-MS: *m/z* = 486.05 (*M*-1)⁻. ¹H NMR (700 MHz, 300 K, Methanol-*d*₄) δ 5.05 (m, 0.7H), 4.97 (m, 0.3H), 4.63 – 4.41 (m, 2.7H), 3.99 – 3.90 (m, 0.3H), 3.73 – 3.59 (m, 1H), 3.04 – 2.92 (m, 1H), 2.41 – 2.15 (m, 2H), 1.57 – 1.36 (m, 18H), 1.22 – 1.35 (m, 5H), 0.95 – 0.74 (m, 2H).

15


Step B. (3*R*,5*S*)-1-(*D*-Alanyl)-3-amino-5-(2-boronoethyl)piperidine-3-carboxylic acid dihydrochloride.

[00322] The title compound was obtained according to step (L) of Example 1, using (3*R*,5*S*)-5-(2-boronoethyl)-1-((*tert*-butoxycarbonyl)-*D*-alanyl)-3-((*tert*-butoxycarbonyl)amino)piperidine-3-carboxylic acid (70 mg, 0.13 mmol) and 4M HCl in EtOAc (5 mL). The crude product was purified by preparative HPLC (0.1 -1% of acetonitrile in water) to give (after acidification with 2M HCl and subsequent lyophilization) 39 mg, (73%) of the corresponding product as a white solid (4 : 1 mixture of rotamers in D₂O solution at room temperature,


20

based on NMR). ESI+MS: $m/z = 287.85$ ($M+1$)⁺; ESI-MS: $m/z = 267.85$ ($M-18-1$)⁻. ¹H NMR (700 MHz, 300 K, Deuterium Oxide) δ 4.87 (dt, $J = 13.3, 2.0$ Hz, 0.8H), 4.54 (q, $J = 7.1$ Hz, 1H), 4.46 – 4.40 (m, 0.2H), 4.23 (dt, $J = 13.3, 2.0$ Hz, 0.2H), 3.87 – 3.81 (m, 0.8H), 3.40 (d, $J = 13.9$ Hz, 0.2H), 2.92 (d, $J = 13.4$ Hz, 0.8H), 2.84 (dd, $J = 14.1, 12.1$ Hz, 0.8H), 2.48 – 2.40 (m, 1H), 2.35 (dd, $J = 14.1, 12.1$ Hz, 0.2H), 2.04 – 1.97 (m, 0.8H), 1.68 – 1.58 (m, 0.2H), 1.56 – 1.48 (m, 1H), 1.46 – 1.29 (m, 5H), 0.83 – 0.72 (m, 2H).

Example 24. (3*R*,5*S*)-3-amino-5-(2-boronoethyl)-1-(1-methyl-*D*-tryptophyl)piperidine-3-carboxylic acid dihydrochloride.



Step A. (3*R*,5*S*)-5-(2-Boronoethyl)-1-(*N*^{*t*}-(*tert*-butoxycarbonyl)-1-methyl-*D*-tryptophyl)-3-((*tert*-butoxycarbonyl)amino)piperidine-3-carboxylic acid.




[00323] The title compound was obtained according to step (K) of Example 1, using (3*R*,5*S*)-5-(2-boronoethyl)-3-((*tert*-butoxycarbonyl)amino)piperidine-3-carboxylic acid (0.1 g, 0.32 mmol), 1-Me-Boc-*D*-Trp-OSu (0.17 g, 0.41 mmol) and DMF (2 mL). Stirred at room temperature for 24 h and then at 70 °C for 2 days. The crude product was purified by column

chromatography on silica gel using DCM/MeOH (50:1 to 15:1) to give 100 mg (51%) of the corresponding product as an off-white solid. ESI+MS: $m/z = 617.15$ ($M+1$)⁺.

Step B. (3*R*,5*S*)-3-Amino-5-(2-boronoethyl)-1-(1-methyl-*D*-tryptophyl)piperidine-3-carboxylic acid dihydrochloride.


[00324] The title compound was obtained according to step (L) of Example 1, using (3*R*,5*S*)-5-(2-boronoethyl)-1-(*N*¹-(*tert*-butoxycarbonyl)-1-methyl-*D*-tryptophyl)-3-((*tert*-butoxycarbonyl)amino)piperidine-3-carboxylic acid (100 mg, 0.16 mmol) and 4M HCl in EtOAc (5 mL). The crude product was purified by preparative HPLC (0.1 -5% of acetonitrile in water) to give (after acidification with 2M HCl and subsequent lyophilization) 70 mg, (89%) of the corresponding product as a white solid (3.3 : 1 mixture of rotamers in D₂O solution at room temperature, based on NMR). ESI+MS: $m/z = 417.00$ ($M+1$)⁺. ¹H NMR (700 MHz, 300 K, Deuterium Oxide) δ 7.68 (d, $J = 7.9$ Hz, 1H), 7.49 – 7.45 (m, 0.6H), 7.44 (d, $J = 8.0$ Hz, 1H), 7.30 – 7.24 (m, 1.3H), 7.23 – 7.18 (m, 1.3H), 7.16 (t, $J = 7.5$ Hz, 0.3H), 7.02 (s, 1H), 4.97 – 4.89 (m, 2H), 4.76 (dd, $J = 9.2, 5.2$ Hz, 0.3H), 4.31 – 4.26 (m, 0.3H), 3.80 (d, $J = 14.2$ Hz, 0.3H), 3.76 (s, 1H), 3.72 (s, 3H), 3.40 (dd, $J = 14.6, 5.2$ Hz, 0.3H), 3.35 (dd, $J = 14.4, 4.6$ Hz, 1H), 3.27 – 3.23 (m, 0.3H), 3.21 (dd, $J = 14.4, 11.0$ Hz, 1H), 3.07 (dd, $J = 13.3, 4.0$ Hz, 1H), 2.73 (d, $J = 13.3$ Hz, 1H), 2.40 (t, $J = 12.4$ Hz, 1H), 2.30 – 2.23 (m, 1.3H), 2.12 (d, $J = 13.9$ Hz, 0.3H), 1.84 (t, $J = 12.6$ Hz, 0.3H), 1.57 – 1.49 (m, 0.3H), 1.30 – 1.16 (m, 1H), 1.09 (t, $J = 12.8$ Hz, 1H), 0.70 (t, $J = 8.2$ Hz, 0.6H), 0.56 – 0.44 (m, 2H), 0.04 (ddd, $J = 15.9, 11.9, 3.9$ Hz, 1H), -0.02 – -0.12 (m, 1H), -0.21 (tt, $J = 12.5, 4.0$ Hz, 1H).

Example 25. (3*R*,5*S*)-3-Amino-1-((*S*)-2-aminopentanoyl)-5-(2-boronoethyl)piperidine-3-carboxylic acid dihydrochloride.



5

Step A. (3*R*,5*S*)-5-(2-Boronoethyl)-3-((*tert*-butoxycarbonyl)amino)-1-((*S*)-2-((*tert*-butoxycarbonyl)amino)pentanoyl)piperidine-3-carboxylic acid.



10

[00325] The title compound was obtained according to step (K) of Example 1, using (3*R*,5*S*)-5-(2-boronoethyl)-3-((*tert*-butoxycarbonyl)amino)piperidine-3-carboxylic acid (0.1 g, 0.32 mmol), Boc-*L*-Nva-OSu (0.13 g, 0.41 mmol) and DMF (2 mL). The crude product was purified by column chromatography on silica gel using DCM/MeOH (80:1 to 0:1) to give 64 mg (39%) of the corresponding product as a white solid (5 : 2 mixture of rotamers in CD₃OD solution at room temperature, based on NMR). ESI+MS: $m/z = 516.05$ ($M+1$)⁺; ESI-MS: $m/z = 514.10$ ($M-1$)⁻. ¹H NMR (700 MHz, 300 K, Methanol-*d*₄) δ 5.13 – 5.02 (m, 0.7H), 4.67 – 4.56 (m, 0.7H), 4.55 – 4.50 (m, 0.3H), 4.43 – 4.35 (m, 1H), 4.23 – 4.13 (m, 0.3H), 3.97 – 3.89 (m, 1H), 2.79 – 2.59 (m, 2H), 2.41 – 2.34 (m, 0.7H), 2.31 – 2.25 (m, 0.3H), 1.81 – 1.67 (m, 1H), 1.60 – 1.53 (m, 2H), 1.49 – 1.40 (m, 18H), 1.40 – 1.25 (m, 4H), 0.96 (t, $J = 7.4$ Hz, 3H), 0.91 – 0.71 (m, 2H).


20

Step B. (3*R*,5*S*)-3-Amino-1-((*S*)-2-aminopentanoyl)-5-(2-boronoethyl)piperidine-3-carboxylic acid dihydrochloride.


- 5 **[00326]** The title compound was obtained according to step (L) of Example 1, (3*R*,5*S*)-5-(2-boronoethyl)-3-((*tert*-butoxycarbonyl)amino)-1-((*S*)-2-((*tert*-butoxycarbonyl)amino)pentanoyl) piperidine-3-carboxylic acid (58 mg, 0.11 mmol) and 4M HCl in EtOAc (7 mL). The crude product was purified by preparative HPLC (0.1 -1% of acetonitrile in water) to give (after acidification with 2M HCl and subsequent lyophilization) 21
- 10 mg (49%) of the corresponding product as a white solid (9 : 1 mixture of rotamers in D₂O solution at room temperature, based on NMR). ESI+MS: $m/z = 315.85$ ($M+1$)⁺; 297.75 ($M-18+1$)⁺; ESI-MS: $m/z = 295.85$ ($M-18-1$)⁻. ¹H NMR (700 MHz, 300 K, Deuterium Oxide) δ 4.88 (d, $J = 13.2$ Hz, 0.9H), 4.48 (dd, $J = 7.7, 4.7$ Hz, 0.9H), 4.40 (dd, $J = 7.9, 3.9$ Hz, 0.1H), 4.36 (dd, $J = 13.3, 4.4$ Hz, 0.1H), 4.22 (d, $J = 13.8$ Hz, 0.1H), 3.81 (dd, $J = 13.6, 4.4$ Hz, 0.9H), 3.41 (d, $J = 13.8$ Hz, 0.1H), 2.94 – 2.85 (m, 1.8H), 2.46 – 2.40 (m, 1.1H), 2.10 – 1.97 (m, 0.9H), 1.96 – 1.85 (m, 0.1H), 1.85 – 1.69 (m, 2H), 1.49 – 1.29 (m, 5H), 0.90 (t, $J = 7.3$ Hz, 3H), 0.84 – 0.72 (m, 2H).
- 15

Example 26. (3*R*,5*S*)-1-(*L*-AsparaginyI)-3-amino-5-(2-boronoethyl)piperidine-3-

20 **carboxylic acid dihydrochloride.**



Step A. (3*R*,5*S*)-5-(2-Boronoethyl)-1-((*tert*-butoxycarbonyl)-*L*-asparaginy)-3-((*tert*-butoxycarbonyl)amino)piperidine-3-carboxylic acid.



5

[00327] The title compound was obtained according to step (K) of Example 1, using (3*R*,5*S*)-5-(2-boronoethyl)-3-((*tert*-butoxycarbonyl)amino)piperidine-3-carboxylic acid (0.114 g, 0.36 mmol), Boc-*L*-Asn-OSu (0.154 g, 0.47 mmol) and DMF (2 mL). The crude product was purified by column chromatography on silica gel using CHCl₃/MeOH (10:1 to 3:1) to give 60 mg (31 %) of the corresponding product as a white solid. ESI+MS: *m/z* = 531.15 (M+1)⁺; ESI-MS: *m/z* = 529.05 (M-1)⁻. ¹H NMR (700 MHz, 300 K, Methanol-*d*₄) δ 5.40-5.18 (m, 1H), 4.63-4.48 (m, 1H), 4.29 (bs, 1H), 3.35 (bs, 1H), 2.94 – 2.81 (m, 1H), 2.81 – 2.61 (m, 2H), 2.58 – 2.32 (m, 1H), 2.25-2.13 (m, 1H), 1.64 – 1.22 (m, 22H), 0.85 – 0.70 (m, 1H).


15 Step B. (3*R*,5*S*)-1-(*L*-Asparaginy)-3-amino-5-(2-boronoethyl)piperidine-3-carboxylic acid dihydrochloride.

[00328] The title compound was obtained according to step (L) of Example 1, using (3*R*,5*S*)-5-(2-boronoethyl)-1-((*tert*-butoxycarbonyl)-*L*-asparaginy)-3-((*tert*-butoxycarbonyl)amino) piperidine-3-carboxylic acid (60 mg, 0.11 mmol) and 4M HCl in EtOAc (3 mL). The crude product was purified by preparative HPLC (0.1 -1% of acetonitrile in water) to give (after acidification with 2M HCl and subsequent lyophilization) 7 mg (16%) of the corresponding product as a white solid (5 : 2 mixture of rotamers in D₂O solution at room temperature, based on NMR). ESI+MS: *m/z* = 330.85 (M+1)⁺; ESI-MS: *m/z* = 328.85 (M-1)⁻.


20

¹H NMR (700 MHz, 300 K, Deuterium Oxide) δ 4.94 (d, J = 13.3 Hz, 1H), 4.88 (dd, J = 8.9, 4.1 Hz, 1H), 4.48 (d, J = 9.6 Hz, 0.2H), 4.42 – 4.26 (m, 0.2H), 3.90 (dd, J = 13.6, 4.2 Hz, 1H), 3.46 (d, J = 13.6 Hz, 0.2H), 3.26 – 2.90 (m, 3H), 2.86 (dd, J = 16.9, 8.9 Hz, 1H), 2.53 (t, J = 13.4 Hz, 1H), 2.24 – 2.08 (m, 1H), 1.90-1.85 (m, 0.2H), 1.62 – 1.47 (m, 2H), 1.43 (tdd, J = 13.6, 11.0, 7.5 Hz, 1H), 0.87 (ttd, J = 15.6, 9.8, 5.2 Hz, 2H).

Example 27. (3*R*,5*S*)-3-Amino-5-(2-boronoethyl)-1-(methylglycyl)piperidine-3-carboxylic acid dihydrochloride.



Step A. (3*R*,5*S*)-5-(2-Boronoethyl)-1-(*N*-(*tert*-butoxycarbonyl)-*N*-methylglycyl)-3-((*tert*-butoxycarbonyl)amino)piperidine-3-carboxylic acid.



[00329] The title compound was obtained according to step (K) of Example 1, using (3*R*,5*S*)-5-(2-boronoethyl)-3-((*tert*-butoxycarbonyl)amino)piperidine-3-carboxylic acid (0.10 g, 0.32 mmol), Boc-Sar-OSu (91 mg, 0.32 mmol), TEA (49 μ L, 0.35 mmol) and DMF (2 mL). Next day, DMF was evaporated. The residue was diluted with EtOAc (30 mL) and washed with 1M KHSO₄ (1 x 20 mL), H₂O (1 x 20 mL), brine (1 x 20 mL), dried over MgSO₄ and

concentrated to give 119 mg (77%) of the corresponding product as a yellowish solid.

ESI+MS: $m/z = 488.05$ ($M+1$)⁺; ESI-MS: $m/z = 485.95$ ($M-1$)⁻. ¹H NMR (700 MHz, 300 K, Methanol-*d*₄) δ 4.65 – 4.48 (m, 2H), 4.43 – 4.34 (m, 1H), 4.32 – 4.25 (m, 1H), 2.92 – 2.83 (m, 4H), 2.30 – 2.22 (m, 1H), 1.51 – 1.43 (m, 19H), 1.40 – 1.28 (m, 4H), 0.89 – 0.78 (m, 2H).

5


Step B. (3*R*,5*S*)-3-Amino-5-(2-boronoethyl)-1-(methylglycyl)piperidine-3-carboxylic acid dihydrochloride.

[00330] The title compound was obtained according to step (L) of Example 1, using

10 (3*R*,5*S*)-5-(2-boronoethyl)-1-(*N*-(*tert*-butoxycarbonyl)-*N*-methylglycyl)-3-((*tert*-butoxycarbonyl)amino)piperidine-3-carboxylic acid (110 mg, 0.23 mmol) and 3.6 M HCl in EtOAc (5 mL). The crude product was purified by preparative HPLC (0.1 -1% of acetonitrile in water) to give (after acidification with 2M HCl and subsequent lyophilization) 40 mg (49%) of the corresponding product as a white foam (3 : 2 mixture of rotamers in D₂O solution at
15 room temperature, based on NMR). ESI+MS: $m/z = 287.85$ ($M+1$)⁺; ESI-MS: $m/z = 267.90$ ($M-18-1$)⁻. ¹H NMR (700 MHz, 300 K, Deuterium Oxide) δ 4.79 – 4.76 (m, 0.6H), 4.48 – 4.39 (m, 0.4H), 4.20 – 4.00 (m, 2.4H), 3.68 (dd, $J = 13.8, 4.2$ Hz, 0.6H), 3.26 (d, $J = 13.8$ Hz, 0.4H), 2.95 (d, $J = 13.3$ Hz, 0.6H), 2.83 – 2.66 (m, 3.6H), 2.42 – 2.29 (m, 1.4H), 2.05 – 1.98 (m, 0.6H), 1.73 – 1.66 (m, 0.4H), 1.48 – 1.24 (m, 3H), 0.82 – 0.73 (m, 2H).

20

Example 28. (2-((3*S*,5*R*)-1-(*L*-Alanyl)-5-amino-5-(methoxycarbonyl)piperidin-3-yl)ethyl)boronic acid dihydrochloride.




5

[00331] To a solution of (3*R*,5*S*)-1-(*L*-alanyl)-3-amino-5-(2-boronoethyl)piperidine-3-carboxylic acid dihydrochloride (82 mg, 0.23 mmol) in toluene (1 mL) and methanol (0.4 mL) was added trimethylsilyldiazomethane 2M solution in Et₂O (173 μL, 0.34 mmol). The mixture was stirred at room temperature overnight. The solvents were evaporated. The crude product was purified by preparative HPLC (0.1 -10% of acetonitrile in water) to give (after acidification with 2M HCl and subsequent lyophilization) 6.4 mg (8%) of the corresponding product as a white solid (9 : 1 mixture of rotamers in D₂O solution at room temperature, based on NMR). ESI+MS: *m/z* = 301.90 (*M*+1)⁺. ¹H NMR (700 MHz, 300K, Deuterium Oxide) δ 4.95 (dt, *J* = 13.3, 2.0 Hz, 0.9H), 4.59 (q, *J* = 7.1 Hz, 0.9H), 4.54 (q, *J* = 7.0 Hz, 0.1H), 4.48 (d, *J* = 13.7 Hz, 0.1H), 4.33 (d, *J* = 13.7 Hz, 0.1H), 3.92 – 3.85 (m, 3.9H), 3.46 (d, *J* = 13.8 Hz, 0.1H), 3.07 – 2.89 (m, 1.9H), 2.53 (dd, *J* = 28.5, 13.1 Hz, 1H), 2.02 (dt, *J* = 11.4, 5.2 Hz, 0.9H), 1.87 – 1.74 (m, 0.1H), 1.63 – 1.48 (m, 5H), 1.43 (ddt, *J* = 13.6, 9.8, 6.7 Hz, 1H), 0.97 – 0.78 (m, 2H).

15

Example 29. (3*R*,5*S*)-1-(*L*-Arginyl)-3-amino-5-(2-(4-carboxy-4-(carboxymethyl)-6-oxo-1,3,2-dioxaborinan-2-yl)ethyl)piperidine-3-carboxylic acid trihydrochloride.




5

[00332] To a solution of (3*R*,5*S*)-1-(*L*-arginyl)-3-amino-5-(2-boronoethyl)piperidine-3-carboxylic acid trihydrochloride (20 mg, 0.04 mmol) in methanol (1 mL), citric acid was added (9 mg, 0.04 mmol) and resulting mixture was stirred at room temperature for 2 h. Reaction was concentrated to dryness to give 26 mg (98%) of corresponding product as a white solid.


10 ^1H NMR (700 MHz, 300 K, DMSO- d_6) δ 9.03 – 8.78 (m, 3H), 8.41 – 8.17 (m, 3H), 8.02 – 7.79 (m, 1H), 7.57 – 6.86 (m, 3H), 4.90 – 4.82 (m, 1H), 4.66 – 4.50 (m, 1H), 4.31 – 4.19 (m, 1H), 3.93 – 3.86 (m, 1H), 3.60 – 3.53 (m, 2H), 3.20 – 3.06 (m, 2H), 2.99 – 2.87 (m, 1H), 2.88 – 2.72 (m, 1H), 2.69 – 2.56 (m, 2H), 2.56 – 2.53 (m, 1H), 2.43 – 2.15 (m, 3H), 1.95 – 1.63 (m, 3H), 1.62 – 1.39 (m, 3H), 1.35 – 1.04 (m, 2H), 0.41 – 0.14 (m, 2H).

15 **[00333]** The intermediate for the preparation of Examples 1 – 29 can be alternatively obtained as described below.



Ex. no 1 - 29

Step A. Methyl (2*R*,4*R*)-4-hydroxyproline-2-carboxylate hydrochloride.




5

[00334] *cis*-4-Hydroxy-*D*-proline hydrochloride (200 g, 1.19 mol) was dissolved in MeOH (2 L) in four-neck flask (equipped with mechanical stirrer, reflux condenser, dropping funnel

and septum) and was cooled to 0 °C. Thionyl chloride (95.8 mL, 1.31 mol) was added dropwise to the reaction mixture for 1.5 h (maintain a temperature 0 °C). The reaction mixture was warmed to room temperature for 1 h and heated to reflux for 1 h. The reaction mixture was cooled to room temperature (overnight), transferred to round-bottom-flask and concentrated. The gel-like residue was evaporated with CHCl₃ (3 x 1 L) and dried under high vacuum for 1 h at 50 °C (water bath). The residue was crumbled with spatula, suspended in Et₂O (1 L) and placed in ultrasound bath for 40 minutes (2 x 20 minutes). The white solid was filtered, washed with Et₂O (2 x 0.5 L) and dried under high vacuum for 4 h at 50 °C (water bath) to give 234.6 g of the crude product that was used in the next step without further purification. ESI+MS *m/z* = 146 (*M*+1)⁺; ¹H NMR (700 MHz, D₂O) δ 4.75 (d, *J* = 3.1 Hz, 1H), 4.74 (d, *J* = 3.0 Hz, 1H), 4.70 (qt, *J* = 4.2, 1.6 Hz, 2H), 3.92 (s, 7H), 3.57 – 3.50 (m, 5H), 2.59 (ddd, *J* = 14.4, 10.1, 4.2 Hz, 3H), 2.51 – 2.47 (m, 2H).


Step B. Methyl (2*R*,4*R*)-1-benzyl-4-hydroxypyrrolidine-2-carboxylate.



[00335] Methyl (2*R*,4*R*)-4-hydroxypyrrolidine-2-carboxylate hydrochloride (1.19 mol) was suspended in CHCl₃ (2 L) in four-neck flask equipped with mechanical stirrer, reflux condenser, dropping funnel and septum and was cooled to 0 °C. DIPEA (520 mL, 2.98 mol) was added dropwise at 0 °C and the reaction mixture was warmed to room temperature. Benzyl bromide (141.7 mL, 1.19 mol) was added dropwise for 1 h. The reaction mixture was heated to reflux (75 °C, oil bath temp.) for 1 h and cooled to room temperature (water bath with crushed ice). Water (1 L) was added to the reaction mixture and layers were separated. Organic layer was washed with water (1 x 1 L), 1M NaOH (1 x 1 L), brine (1 x 1 L), dried over

MgSO₄, filtered and concentrated under reduced pressure to give 233.4 g (83%, after 2 steps) of the desired as a pale orange oil. ESI+MS $m/z = 235.95$ ($M+1$)⁺; ¹H NMR (700 MHz, CDCl₃) δ 7.32 – 7.23 (m, 4H), 4.24 (m, 1H), 3.86 (d, $J = 13.1$ Hz, 1H), 3.71 (d, $J = 13.1$ Hz, 1H), 3.63 (s, 1H), 3.34 (dd, $J = 10.1, 3.8$ Hz, 1H), 3.11 (d, $J = 10.7$ Hz, 1H), 3.01 (dt, $J = 9.9, 1.6$ Hz, 1H), 2.63 (dd, $J = 10.1, 3.8$ Hz, 1H), 2.37 (ddd, $J = 14.2, 10.0, 5.7$ Hz, 1H), 1.95 (m, 1H).


Step C. (3*R*,5*R*)-1-Benzyl-5-(hydroxymethyl)pyrrolidin-3-ol.



[00336] To a solution of methyl (2*R*,4*R*)-1-benzyl-4-hydroxypyrrolidine-2-carboxylate obtained as above (90 g, 0.38 mol) in dry THF (0.9 L) was slowly added NaBH₄ (44 g, 1.16 mol) at room temperature. The reaction mixture was heated to reflux and methanol (180 mL) was added dropwise over 1.5 h with effervescence being observed. The reaction mixture was cooled to room temperature and quenched with 1M NaOH (240 mL, dropped over 15 min). Inorganic contaminations were precipitated. The layers were separated and the white solid was dissolved in water (250 ml) and washed with Et₂O (3 x 200 mL). The combined organic layers were dried over MgSO₄, filtered and concentrated to give 75.3 g (95%) of (3*R*,5*R*)-1-benzyl-5-(hydroxymethyl)pyrrolidin-3-ol as a colorless oil that solidified in the fridge. ESI+MS: $m/z = 207.95$ ($M+1$)⁺; ¹H NMR (700 MHz, Chloroform-*d*) δ 7.35 – 7.28 (m, 4H), 7.26 – 7.22 (m, 1H), 4.19 (t, $J = 4.9$ Hz, 1H), 3.93 (d, $J = 13.2$ Hz, 1H), 3.60 – 3.54 (m, 1H), 3.50 (d, $J = 13.2$ Hz, 1H), 3.40 (d, $J = 11.0$ Hz, 1H), 3.01 (dd, $J = 10.3, 2.1$ Hz, 1H), 2.90 – 2.83 (m, 1H), 2.77 (bs, 2H), 2.46 (dd, $J = 10.2, 3.8$ Hz, 1H), 2.35 (ddd, $J = 14.3, 10.3, 5.9$ Hz, 1H), 1.82 – 1.75 (m, 1H).

Step D. (3*R*,5*R*)-1-benzyl-5-vinylpiperidin-3-ol.

5



*Preparation of salt: (3*R*,5*R*)-1-benzyl-3-hydroxy-1-azabicyclo[3.1.0]hexan-1-ium*

10 trifluoromethanesulfonate:

[00337] To a solution of (3*R*,5*R*)-1-benzyl(5-hydroxymethyl)-pyrrolidin-3-ol (96.55 g, 0.466 mol) and DIPEA (162 mL, 0.932 mol) in dry DCM (450 mL) was added dropwise triflic anhydride (86 mL, 0.512 mol) for over 40 min, under Ar. The temperature of the reaction was maintained from -30 °C to -10 °C. After the addition was completed the reaction mixture was stirred at -25 °C for 20 min to achieved ca. 95% of conversion. TLC: CHCl₃/MeOH (9:1) + MVP. (Total consumption of substrate observed on LC-MS with ELSD).


Ring expansion:

[00338] To a suspension of CuCl (6.92 g, 0.07 mol) in dry THF (250 mL) was added dropwise vinylmagnesium chloride 1.7 M in THF (1100 mL, 1.86 mol) for over 60 min, under Ar. The temperature of the reaction mixture was maintained from -40 °C to -25 °C. To this mixture was transferred the cold solution of freshly prepared (as above) (3*R*,5*R*)-1-benzyl-3-hydroxy-1-azabicyclo[3.1.0]hexan-1-ium trifluoromethanesulfonate *via* cannula for over 50

20

min, under Ar. The temperature of the reaction was maintained from -35 °C to -10 °C. The resulting mixture was stirred at -30 °C for 60 min. Then the reaction mixture was quenched by the addition of 1M NaOH_{aq} (1300 mL) and 4M NaOH_{aq} (300 mL). The organic solvents were evaporated under reduced pressure (at 30 °C, water bath). The aqueous residue was treated with Et₂O (ca. 500 mL). The suspension that was formed was filtered through a Celite. The solid was washed with Et₂O (ca. 1000 mL). The filtrate (organic and aqueous layer) was separated. The aqueous layer was washed with Et₂O (1 x 300 mL). The combined organic layers were dried over MgSO₄, filtered and concentrated under reduced pressure to give 108 g of the crude product as an orange oil. The crude product was treated with 4M HCl in dioxane (180 mL), then ca. 50 mL of dioxane was evaporated under reduced pressure. The solid was filtered off and washed with acetone (ca. 120 mL) and dried under vacuum to give 45 g (38%) of (3*R*,5*R*)-1-benzyl-5-vinylpiperidin-3-ol hydrochloride as a beige solid. To a suspension of hydrochloride salt in H₂O (200 mL) was added 4M NaOH_{aq} (to pH 12) and the mixture was washed with DCM (2 x 400 mL). The combined organic layers were dried over MgSO₄, filtered and concentrated under reduced pressure to give 38.2 g (38%) of (3*R*,5*R*)-1-benzyl-5-vinylpiperidin-3-ol as a yellow oil that solidified in the fridge. The crude compound can be alternatively purified by flash chromatography on silica gel using hexane/AcOEt (8:1 to 1:1) as an eluent to afford pure (3*R*,5*R*)-1-benzyl-5-vinylpiperidin-3-ol in 50% yield. ESI+MS: *m/z* = 217.95 (M+1)⁺; ¹H NMR (700 MHz, Chloroform-*d*) δ 7.36 – 7.31 (m, 4H), 7.29 – 7.29 (m, 1H), 5.75 (ddd, *J* = 17.1, 10.5, 6.5 Hz, 1H), 5.15 – 4.95 (m, 2H), 3.84 (tt, *J* = 9.6, 4.1 Hz, 1H), 3.62 (d, *J* = 13.1 Hz, 1H), 3.54 (d, *J* = 13.1 Hz, 1H), 3.07 – 2.99 (m, 1H), 2.83 (ddt, *J* = 11.1, 3.6, 1.5 Hz, 1H), 2.39 (dtdt, *J* = 7.9, 6.5, 5.2, 3.8 Hz, 1H), 2.10 (dtd, *J* = 12.2, 4.0, 1.9 Hz, 1H), 1.87 – 1.76 (m, 2H), 1.14 (q, *J* = 11.6 Hz, 1H).


Step E. (*R*)-1-benzyl-5-vinylpiperidin-3-one.



[00339] *N*-chlorosuccinimide (NCS) (44.7 g, 0.335 mol) was suspended in dry toluene (0.5 L) and it was cooled to 0 °C. A solution of dimethyl sulfide (41 mL, 0.558 mol) in toluene (0.5 L) was added dropwise to the reaction mixture and it was stirred for 30 minutes at 0 °C.


Next, the mixture was cooled to -20 °C and a solution of (3*R*,5*R*)-1-benzyl-5-vinylpiperidin-3-ol (48.5 g, 0.223 mol) in toluene (0.5 L) was added dropwise to the reaction mixture and it was stirred for 2 h at -20 °C. A solution of DIPEA (117 mL, 0.67 mol) in toluene (0.2 L) was added dropwise and the reaction mixture was warmed slowly (over ca. 1 h) to room temperature. The progress of the reaction was performed using UPLC/MS [ESI+MS m/z = 233.95 ($M+18$)⁺] and TLC (Hex:EtOAc 1:5). After full consumption of the substrate, the reaction mixture was cooled to 0 °C. Saturated NaHCO₃ (2 L) and Et₂O (0.5 L) were added and it was stirred for 10 minutes. Layers were separated and water phase was extracted with Et₂O (3 x 0.5 L). Combined organic layers were washed with brine (1 L), dried over MgSO₄, filtered and concentrated. The crude product was used to the next step without any further purification. ESI+MS m/z = 233.95 ($M+18$)⁺. ¹H NMR (700 MHz, 300 K, Chloroform-*d*) δ 7.37 – 7.26 (m, 5H), 5.76 (ddd, J = 17.2, 10.6, 6.7 Hz, 1H), 5.10 – 5.03 (m, 2H), 3.66 – 3.56 (m, 2H), 3.19 (dt, J = 14.4, 1.6 Hz, 1H), 2.95 (ddt, J = 11.5, 3.3, 1.5 Hz, 1H), 2.80 (d, J = 14.4 Hz, 1H), 2.78 – 2.71 (m, 1H), 2.53 (dd, J = 15.4, 5.1 Hz, 1H), 2.29 (dd, J = 11.5, 9.6 Hz, 1H), 2.20 (ddd, J = 15.4, 11.0, 0.9 Hz, 1H).

Step F. (3*R*,5*R*)-3-amino-1-benzyl-5-vinylpiperidine-3-carbonitrile.



[00340] To the solution of (*R*)-1-benzyl-5-vinylpiperidin-3-one (0.223 mol) in aqueous ethanol (96%, 300 mL) was added acetone cyanohydrine (25 mL, 0.268 mol) followed by aqueous ammonia (25%, 300 mL) was added. The mixture was stirred at 60 °C (oil bath temperature) under autoclave conditions for 3 days. After cooling of the reaction mixture to room temperature ethanol was evaporated under reduced pressure. The biphasic mixture was obtained. The layers were separated. The aqueous layer was washed with diethyl ether (3 x 150 mL) and DCM (50 mL). The combined organic layers were washed with brine (50 mL), dried over Na₂SO₄ and concentrated under reduced pressure to give 54.6 g of the crude product as a pale brown oil. The crude product as a mixture of diastereoisomers 6.5 : 1 (based on ¹H NMR) was used to the next steps without any further purification. ESI+MS: *m/z* = 242.00 (*M*+1)⁺.

Step G. *N*-((3*R*,5*R*)-1-Benzyl-3-cyano-5-vinylpiperidin-3-yl)acetamide.



[00341] To a solution of (3*R*,5*R*)-3-amino-1-benzyl-5-vinylpiperidine-3-carbonitrile obtained above (54.6 g, 0.22 mol) in DCM (800 mL) were added TEA (78 mL, 0.56 mol) and acetic anhydride (23 mL, 0.24 mol). The mixture was stirred at room temperature for 3 h. After this time TEA (12 mL, 0.09 mol) and acetic anhydride (4 mL, 0.04 mol) were added. The resulting mixture was stirred at room temperature overnight. The mixture was diluted

with DCM (100 mL) and washed with 5% NaHCO₃ (2x 300 mL). The aqueous layer was extracted with DCM (200 mL). The combined organic layers were washed with brine (200 mL), dried over MgSO₄ and concentrated *in vacuo*. The crude product was purified by column chromatography on silica gel using CH₃Cl/acetone (1:0 to 100:1) to give 35.0 g (55%,
 5 after 3 steps) of the corresponding product as a pale yellow foam (single major diastereoisomer with enantiomeric excess *ee* > 99.9 %). ESI+MS: *m/z* = 284.05 (M+1)⁺; ESI-MS: *m/z* = 282.00 (M-1)⁻. ¹H NMR (700 MHz, 300K, Chloroform-*d*) δ 7.36 – 7.31 (m, 4H), 7.28 – 7.24 (m, 1H), 5.66 (ddd, *J* = 17.2, 10.5, 6.5 Hz, 1H), 5.55 (s, 1H), 5.13 – 4.91 (m, 2H), 3.68 – 3.56 (m, 3H), 2.90 (d, *J* = 11.2 Hz, 1H), 2.80 – 2.71 (m, 1H), 2.49 (d, *J* = 12.8 Hz, 1H),
 10 2.08 (d, *J* = 11.1 Hz, 1H), 1.98 (s, 3H), 1.97 – 1.90 (m, 1H), 1.51 – 1.41 (m, 1H).

[00342] *Ee* > 99.9 %. Enantiomeric excess (*ee*) was measured using chiral HPLC:

Column: Phenomenex Lux® 5µm Cellulose 4 (150 x 4.6 mm); Elution system: from 5 to 10% (iPrOH:EtOH 4:1) in Hexane for 20 minutes; Flow rate: 1 mL/min; Detector: ELSD/UV (210 nm); Retention times: *t*_{R1} = 6.72 min, *t*_{R2} = 12.05 min. See Figures 1 and 2. Respective

15 integration results are shown in Tables 3 and 4, below:


Table 3. Racemic *N*-((3*R*,5*R*)-1-Benzyl-3-cyano-5-vinylpiperidin-3-yl)acetamide

Peak No.	Ret. Time (min.)	Area (mV*min.)	Height (mV)	Rel. Area (%)	Rel. Height (%)
1	6.722	85.408	285.567	52.61	61.09
2	12.053	76.942	181.865	47.39	38.91

Table 4. Enantiomerically enriched *N*-((3*R*,5*R*)-1-Benzyl-3-cyano-5-vinylpiperidin-3-yl)acetamide

Peak No.	Ret. Time (min.)	Area (mV*min.)	Height (mV)	Rel. Area (%)	Rel. Height (%)
1	6.742	146.708	482.843	100.00	100.00

Step H. (2-((3*S*,5*R*)-5-acetamido-1-benzyl-5-cyanopiperidin-3-yl)ethyl)boronic acid.



5 [00343] Bis(1,5-cyclooctadiene)diiridium (I) dichloride (1.05 g, 1.58 mmol) and 1,2-bis(diphenylphosphino)ethane (1.25 g, 3.15 mmol) were dissolved in DCM (195 mL) and stirred at room temperature for 15 min. Then *N*-((3*R*,5*R*)-1-benzyl-3-cyano-5-vinylpiperidin-3-yl)acetamide (29.8 g, 105 mmol) in DCM (120 mL) was added and the mixture was stirred at room temperature for 30 min. The mixture was cooled to 0 °C and 4,4,5,5-tetramethyl-1,3,2-dioxaborolane (21.2 mL, 147 mmol) was added over 15 min. The resulting mixture was stirred at room temperature for 48 h and then 4,4,5,5-tetramethyl-1,3,2-dioxaborolane (3.0 mL, 21 mmol) was added. The mixture was stirred for 4 h. The reaction was diluted with DCM (70 mL) and washed with 5% NaHCO₃ (200 mL) and brine (150 mL). The organic layer was dried over MgSO₄ and concentrated *in vacuo* to give 51.5 g of the corresponding product


10 as an orange foam. ESI+MS: *m/z* = 411.95 (*M*+1)⁺. Crude *N*-((3*R*,5*S*)-1-benzyl-3-cyano-5-(2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)ethyl)piperidin-3-yl)acetamide (51.5 g, 105 mmol) was suspended in Et₂O (40 mL) and hexane (325 mL). 1M HCl (250 mL) and phenylboronic acid (13.44 g, 110 mmol) were added. The reaction mixture was stirred vigorously for 1 h (precipitate formed). The reaction mixture was filtered and the filtrate was

20 transferred to separatory funnel. Layers were separated. The aqueous layer was washed with hexane (3 x 300 mL) and alkalized with 4M NaOH to pH ≈ 12 (flask was cooled in ice-water bath). The aqueous layer contained an oily precipitation was washed with Et₂O (3 x 300 mL). After decantation the aqueous layer was washed again with Et₂O (2 x 150 mL). The oily residue was treated with a mixture of 1M NaOH (100 mL) and DCM (250 mL) and

25 sonicated to obtain almost clear biphasic mixture. The layers were separated. The organic


layer was washed with water (50 mL) and 1M NaOH (10 mL). The combined all aqueous layers were washed with Et₂O (3 x 200 mL), acidified with concentrate aqueous HCl to pH ≈ 3 and subsequent carefully alkalized with solid NaHCO₃ to pH ≈ 8. The aqueous layer was extracted with EtOAc (4 x 400 mL). The combined organic layers were dried over MgSO₄,
 5 filtered and concentrated to afford (2-((3*S*,5*R*)-5-acetamido-1-benzyl-5-cyanopiperidin-3-yl)ethyl)boronic acid as a white foam (29.17 g, 84 %). ESI+MS: *m/z* = 329.85 (*M*+1)⁺. ¹H NMR (700 MHz, 300 K, Methanol-*d*₄) δ 7.38 – 7.34 (m, 3H), 7.33 – 7.29 (m, 2H), 3.68 – 3.62 (m, 2H), 3.57 (d, *J* = 13.5 Hz, 1H), 2.99 – 2.95 (m, 1H), 2.49 (dt, *J* = 12.7, 1.8 Hz, 1H), 1.93 (s, 3H), 1.91 – 1.88 (m, 1H), 1.87 (d, *J* = 11.0 Hz, 1H), 1.67 (t, *J* = 11.0 Hz, 1H), 1.32 (dddd, *J* = 20.8, 13.7, 9.7, 6.8 Hz, 2H), 1.11 (t, *J* = 12.6 Hz, 1H), 0.83 – 0.73 (m, 2H).

Step I. (3*R*,5*S*)-3-Amino-1-benzyl-5-(2-boronoethyl)piperidine-3-carboxylic acid dihydrochloride.



[00344] A mixture of (2-((3*S*,5*R*)-5-acetamido-1-benzyl-5-cyanopiperidin-3-yl)ethyl)boronic acid (28.43 g, 86.36 mmol) and 12M HCl (224 mL) was heated at 120 °C for 5 h. The reaction mixture was concentrated under reduced pressure. The residue was dissolved in
 20 H₂O (150 mL) and washed with Et₂O (2 x 100 mL). Next, aqueous layer was alkalized with NaHCO_{3(s)} and washed with Et₂O (2 x 100 mL). The aqueous solution was used to the next step.

Step J. (3*R*,5*S*)-1-benzyl-5-(2-boronoethyl)-3-((*tert*-butoxycarbonyl)amino)piperidine-3-carboxylic acid.



5

[00345] To an alkaline solution of (3*R*,5*S*)-3-amino-1-benzyl-5-(2-boronoethyl)piperidine-3-carboxylic acid in H₂O was added solid Na₂CO₃ to pH = 9, acetone (250 mL) and di-*tert*-butyl dicarbonate (50.89 g, 233 mmol). The resulting mixture was stirred at room


temperature overnight. Inorganic contaminations were precipitated using acetone (500 mL)

10 and filtered off. Solid was washed with acetone (5 x 50 mL). Acetone was evaporated under reduced pressure and solid that was precipitated was filtered off, washed with Et₂O (3 x 40 mL) and dried under high vacuum to give 24.04 g (69%) of the corresponding product as a white solid. The aqueous layer was washed with Et₂O (2 x 100 mL) followed by neutralized with 1M HCl (to pH = 7) and concentrated under reduced pressure to a volume of 50 mL.

15 The residue was left in the refrigerator overnight. The precipitated solid was filtered off, washed with Et₂O (2 x 100 mL) and dried under high vacuum to give 6.64 g (19%) of the corresponding product as a white solid. Total yield: 30.68 g (88 %, after two steps).

ESI+MS: *m/z* = 407.10 (M+1)⁺; ESI-MS: *m/z* = 405.15 (M-1)⁻. ¹H NMR (700 MHz, 300 K, Deuterium Oxide) δ 7.63 – 7.52 (m, 5H), 4.70 – 4.58 (m, 1H), 4.06 (d, *J* = 13.1 Hz, 1H), 3.85
20 – 3.73 (m, 1H), 3.69 (d, *J* = 11.9 Hz, 1H), 2.87 – 2.60 (m, 2H), 2.12 – 2.07 (m, 1H), 1.99 – 1.88 (m, 1H), 1.54 – 1.29 (m, 9H), 1.11 (s, 3H), 0.90 – 0.73 (m, 2H).

Step K. (3*R*,5*S*)-5-(2-boronoethyl)-3-((*tert*-butoxycarbonyl)amino)piperidine-3-carboxylic acid.




5


[00346] To a solution of (3*R*,5*S*)-1-benzyl-5-(2-boronoethyl)-3-((*tert*-butoxycarbonyl)amino)piperidine-3-carboxylic acid (30.68 g, 75.51 mmol) in MeOH (350 mL) was added 20% Pd(OH)₂/C (1 g), under argon. The mixture was stirred overnight under hydrogen atmosphere (from balloon). The reaction mixture was filtered through a pad of Celite that was next washed with MeOH (10 x 100 mL). The filtrate was concentrated *in vacuo* to give 22.66 g (95%) of the corresponding product as a white solid. ESI+MS: *m/z* = 317.00 (M+1)⁺; ESI-MS: *m/z* = 315.05 (M-1)⁻. ¹H NMR (700 MHz, 300 K, Deuterium Oxide) δ 4.01 (dt, *J* = 12.1, 1.6 Hz, 1H), 3.45 (dd, *J* = 12.3, 4.1 Hz, 1H), 2.79 (d, *J* = 12.1 Hz, 1H), 2.64 (t, *J* = 12.4 Hz, 1H), 2.12 (bs, 1H), 1.83 (bs, 1H), 1.49 – 1.34 (m, 12H), 0.88 – 0.76 (m, 2H).

15

Example 30. (2*S*,3*R*,5*S*)-1-(*L*-alanyl)-3-amino-5-(2-boronoethyl)-2-methylpiperidine-3-carboxylic acid dihydrochloride.




20



Step A. Ethyl allylalaninate.

5




[00347] To a solution of allylamine hydrochloride (7.75 g, 82.86 mmol) and TEA (23 mL, 165.72 mmol) in acetonitrile (60 mL) ethyl 2-bromopropionate (15g, 82.86 mmol) was added.

The mixture was stirred at 90°C overnight. The solvent was evaporated. The residue was diluted with 5% NaHCO₃ (50 mL) and extracted with EtOAc (2x 50 mL). The combined organic layers were dried over MgSO₄ and concentrated *in vacuo* to give 13g (100%) of the corresponding product as a pale yellow oil. ESI+MS: m/z = 158.00 (M+1)⁺.

5


Step B. Ethyl *N*-allyl-*N*-(*tert*-butoxycarbonyl)alaninate.



- 10 **[00348]** To a solution of ethyl allylalaninate (13 g, 82.86 mmol) in DCM (200 mL) were added TEA (11 mL, 82.86 mmol) and di-*tert*-butyl dicarbonate (18 g, 82.86 mmol). The resulting mixture was stirred at room temperature overnight. The mixture was diluted with DCM (100 mL) and washed with 1 M HCl (100 mL). The organic layer was dried over MgSO₄ and concentrated *in vacuo*. The crude product was purified by column
- 15 chromatography on silica gel using hexane/EtOAc (50:1 to 15:1) to give 17 g (80%) of the corresponding product as a colorless oil. ESI+MS: m/z = 258.05 (M+1)⁺. ¹H NMR (250 MHz, 300K, Chloroform-*d*) δ 5.95 – 5.70 (m, 1H), 5.32 – 4.99 (m, 2H), 4.62 – 4.37 (m, 0.5H), 4.15 (qd, *J* = 7.1, 3.8 Hz, 2H), 4.05 – 3.83 (m, 2H), 3.74 – 3.60 (m, 0.5H), 1.46 – 1.38 (m, 12H), 1.26 (t, *J* = 7.1 Hz, 3H).

20


Step C. *N*-Allyl-*N*-(*tert*-butoxycarbonyl)alanine.



[00349] To a solution of ethyl *N*-allyl-*N*-(*tert*-butoxycarbonyl)alaninate (17 g, 66 mmol) in EtOH (132 mL) was added 1M NaOH (132 mL). The mixture was stirred at room temperature for 2.5 h. EtOH was evaporated. The aqueous layer was acidified by 2M HCl to pH=2 and extracted with Et₂O (3 x 70 mL). The combined organic layers were dried over MgSO₄ and concentrated *in vacuo* to give 15g (99%) of the corresponding product as a colorless oil. ESI+MS: *m/z* = 251.95 (M+23)⁺; ESI-MS: *m/z* = 228.05 (M-1)⁻. ¹H NMR (250 MHz, 300K, Chloroform-*d*) δ 5.84 (ddt, *J* = 16.3, 10.6, 5.9 Hz, 1H), 5.29 – 4.91 (m, 2H), 4.59 – 4.37 (m, 0.5H), 4.16 – 3.84 (m, 2H), 3.88 – 3.64 (m, 0.5H), 1.48 – 1.39 (m, 12H).

10


Step D. *tert*-Butyl allyl(1-(methoxy(methyl)amino)-1-oxopropan-2-yl)carbamate.



15 [00350] To a solution of *N*-allyl-*N*-(*tert*-butoxycarbonyl)alanine (15 g, 65 mmol) in DCM (150 mL) were added DIPEA (24 mL, 137 mmol), *N,O*-dimethylhydroxyamine (6.6 g, 68 mmol) and HATU (26 g, 68 mmol). The resulting mixture was stirred at room temperature overnight. The mixture was diluted with DCM (75 mL) and washed with 1M NaOH (75 mL), 1M HCl (75 mL) and brine (75 mL). The organic layer was dried over MgSO₄ and

20 concentrated *in vacuo*. The crude product was purified by column chromatography on silica gel using hexane/EtOAc (20:1 to 4:1) to give 17.8 g (100%) of the corresponding product as a colorless oil. ESI+MS: *m/z* = 273.05 (M+1)⁺. ¹H NMR (250 MHz, 300K, Chloroform-*d*) δ 5.81 (ddd, *J* = 21.4, 10.0, 5.0 Hz, 1H), 5.30 – 4.71 (m, 3H), 3.92 – 3.77 (m, 2H), 3.74 (s, 3H), 3.15 (s, 3H), 1.44 (s, 9H), 1.31 (d, *J* = 7.2 Hz, 3H).

Step E. *tert*-Butyl allyl(3-oxopent-4-en-2-yl)carbamate.




5

[00351] To a solution of *tert*-butyl allyl(1-(methoxy(methyl)amino)-1-oxopropan-2-yl)carbamate (10 g, 36.7 mmol) in dry THF (50 mL) at -78°C under Ar was added vinyl magnesium bromide 1M solution in THF (147 mL, 147 mmol) dropwise. The mixture was allowed to warm to -20 °C over 2 h. Then the reaction mixture was poured onto 3M HCl (chilled) (100 mL) and extracted with Et₂O (2x 100 mL). The combined organic layers were dried over MgSO₄ and concentrated *in vacuo* to give 8.8g (100%) of the corresponding product as a pale yellow oil. ESI+MS: *m/z* = 262.10 (M+23)⁺. ¹H NMR (250 MHz, Chloroform-*d*) δ 6.71 – 6.44 (m, 1H), 6.35 (dd, *J* = 17.3, 1.9 Hz, 1H), 5.99 – 5.56 (m, 2H), 5.32 – 4.69 (m, 3H), 4.19 – 3.49 (m, 2H), 1.58 – 1.20 (m, 12H).

15


Step F. *tert*-Butyl 2-methyl-3-oxo-3,6-dihydropyridine-1(2*H*)-carboxylate.



[00352] To a solution of *tert*-butyl allyl(3-oxopent-4-en-2-yl)carbamate (8.8 g, 36.7 mmol) in DCM (1200 mL) was added Grubbs catalyst 2nd generation (1.56 g, 1.84 mmol). The

mixture was stirred at room temperature overnight. The solvent was evaporated. The crude product was purified by column chromatography on silica gel using hexane/EtOAc (60:1 to 8:1) to give 5.16 g (66%) of the corresponding product as an orange oil. ESI+MS: m/z = 235.10 ($M+23$)⁺. ¹H NMR (700 MHz, 300K, Chloroform-*d*) δ 6.98 (s, 1H), 6.09 (dddd, J = 10.3, 2.7, 1.9, 0.5 Hz, 1H), 4.77 – 4.56 (m, 2H), 3.82 (d, J = 21.2 Hz, 1H), 1.48 (s, 9H), 1.26 (d, J = 7.2 Hz, 3H).


Step G. *tert*-Butyl 2-methyl-3-oxo-5-vinylpiperidine-1-carboxylate.



[00353] To a flask charged with CuBr x Me₂S complex (0.75 g, 3.66 mmol) and dry THF (100 mL) were added HMPA (17 mL, 97.6 mmol) and vinylmagnesium bromide 1M solution in THF (85 mL, 85.4 mmol) at -78 °C under Ar. The reaction mixture was stirred for 15 min followed by a solution of *tert*-butyl 2-methyl-3-oxo-3,6-dihydropyridine-1(2*H*)-carboxylate (5.16 g, 24.4 mmol) and chlorotrimethylsilane (15.4 mL, 122 mmol) in THF (65 mL) was added dropwise for over 30 min. The reaction mixture was stirred for 2 h at -78 °C and subsequently overnight at room temperature. After the reaction was completed, 80 mL of saturated aqueous NH₄Cl solution was added, and then the layers were separated. The organic layer was washed with NH₄Cl (3 x 30 mL). The aqueous layer was diluted with H₂O (100 mL) and washed with Et₂O (2 x 40 mL). The combined organic layers were dried over MgSO₄ and concentrated *in vacuo*. The crude product was purified by column chromatography on silica gel using hexane/EtOAc (100:1 to 15:1) to give 4.34 g (74%) of the corresponding product as a orange oil (7 : 3 mixture of diastereoisomers in CDCl₃ solution at room temperature, based on NMR). ESI+MS: m/z = 183.90 ($M-56+1$)⁺. ¹H NMR (700 MHz,

300K, Chloroform-*d*) δ 5.85 – 5.77 (m, 0.7H), 5.77 – 5.69 (m, 0.3H), 5.16 – 5.05 (m, 2H), 4.54 (bs, 0.7H), 4.28 (bs, 0.3H), 3.88 (d, J = 13.5 Hz, 1H), 3.35 (dd, J = 13.5, 4.6 Hz, 0.7H), 2.87 – 2.76 (m, 1H), 2.68 (dddd, J = 13.2, 11.6, 6.5, 3.3 Hz, 0.3H), 2.63 – 2.53 (m, 1H), 2.48 (ddt, J = 16.0, 7.2, 1.0 Hz, 0.7H), 2.34 (dd, J = 16.0, 11.8 Hz, 0.3H), 1.47 (s, 3H), 1.46 (s, 6H), 1.31 (d, J = 7.2 Hz, 2H), 1.29 (d, J = 7.2 Hz, 1H).


Step H. *tert*-Butyl (2*S*,3*R*,5*R*)-3-acetamido-3-(*tert*-butylcarbamoyl)-2-methyl-5-vinylpiperidine-1-carboxylate.



[00354] To a solution of *tert*-butyl 2-methyl-3-oxo-5-vinylpiperidine-1-carboxylate (3.3 g, 13.8 mmol), and ammonium acetate (4.25 g, 55.2 mmol) in 2,2,2-trifluoroethanol (44 mL), *tert*-butyl isocyanide (3 mL, 27.6 mmol) was added dropwise and the resulting mixture was stirred at room temperature overnight. After the reaction was completed, the solvent was evaporated under reduced pressure and the residue was diluted with EtOAc (60 mL) and water (25 mL). The separated aqueous layer was washed with EtOAc (3 x 20 mL). The combined organic layers were dried over MgSO_4 , filtered and concentrated *in vacuo*. The crude product was purified by column chromatography on silica gel using hexane/EtOAc (50:1 to 1:3) to give 3 g (mixture of diastereoisomers 7:3). The mixture of diastereoisomers was crystallized from EtOAc to give 1.34g as white solid (one single diastereoisomer). The racemic mixture was separated for its enantiomer using a chiral preparative HPLC method (Lux® 5 μm Cellulose-4 (21.2 x 250 mm)) with propan-2-ol and n-hexane (gradient: 8 - 30%) as an eluent and ELSD detection. Retention time of *tert*-butyl (2*S*,3*R*,5*R*)-3-acetamido-3-(*tert*-butylcarbamoyl)-2-methyl-5-vinylpiperidine-1-carboxylate in preparative HPLC was in the range from 3.1 to 5.5 min. Retention time of *tert*-butyl (2*R*,3*S*,5*S*)-3-acetamido-3-(*tert*-

butylcarbamoyl)-2-methyl-5-vinylpiperidine-1-carboxylate in preparative HPLC was in the range from 7.7 to 10.5 min. The enantiomeric excess for both enantiomers was determined with the use of chiral analytical HPLC method with ELSD detection with Lux® 5 μ m Cellulose-4 (4.6 x 150 mm) column using 10% propan-2-ol in n-hexane as eluent for 10 min.


- 5 The first desired enantiomer *tert*-butyl (2*S*,3*R*,5*R*)-3-acetamido-3-(*tert*-butylcarbamoyl)-2-methyl-5-vinylpiperidine-1-carboxylate (0.64 g, 12%, white solid) with the retention time of 3.6 min and the second undesired enantiomer *tert*-butyl (2*R*,3*S*,5*S*)-3-acetamido-3-(*tert*-butylcarbamoyl)-2-methyl-5 vinylpiperidine-1-carboxylate (0.61 g, 12%, white solid) at 8.7 min, each with enantiomeric excess of approximately 98% ee or higher.
- 10 ESI+MS: $m/z = 382.00$ ($M+1$)⁺; ESI-MS: $m/z = 380.00$ ($M-1$)⁻. ¹H NMR (700 MHz, 300K, Chloroform-*d*) δ 7.11 (bs, 1H), 5.67 (ddd, $J = 17.4, 10.6, 6.0$ Hz, 1H), 5.53 (bs, 1H), 5.35 (bs, 1H), 5.14 – 5.02 (m, 2H), 4.13 – 3.84 (m, 1H), 2.68 – 2.56 (m, 1H), 2.40 – 2.18 (m, 2H), 1.94 (s, 3H), 1.48 (s, 9H), 1.33 (s, 9H), 1.28 – 1.24 (m, 1H), 1.11 (d, $J = 6.8$ Hz, 3H).
- 15 Step I. (2*S*,3*R*,5*R*)-3-Acetamido-*N*-(*tert*-butyl)-2-methyl-5-vinylpiperidine-3-carboxamide hydrochloride.



- 20 **[00355]** The title compound was obtained according to step (E) of Example 1, using *tert*-butyl (2*S*,3*R*,5*R*)-3-acetamido-3-(*tert*-butylcarbamoyl)-2-methyl-5-vinylpiperidine-1-carboxylate (0.59 g, 1.54 mmol) and 4M HCl in EtOAc (20 mL). The desired product was obtained as a white solid (0.49 g, 100%). ESI+MS: $m/z = 281.95$ ($M+1$)⁺; ESI-MS: $m/z = 280.00$ ($M-1$)⁻. ¹H NMR (700 MHz, Chloroform-*d*) δ 10.45 (bs, 1H), 8.75 (bs, 1H), 8.52 (s, 1H), 6.88 (s, 1H), 5.65 (ddd, $J = 17.1, 10.5, 6.5$ Hz, 1H), 5.24 – 5.11 (m, 2H), 4.74 (d, $J = 8.3$
- 25

Hz, 1H), 3.17 (d, $J = 12.7$ Hz, 1H), 2.82 (q, $J = 12.4$ Hz, 1H), 2.58 – 2.49 (m, 1H), 2.15 (d, $J = 12.7$ Hz, 1H), 2.10 (s, 3H), 2.10 – 2.02 (m, 3H), 1.37 (d, $J = 7.1$ Hz, 3H), 1.34 (s, 9H).

Step J. (2*S*,3*R*,5*R*)-3-Acetamido-1-benzyl-*N*-(*tert*-butyl)-2-methyl-5-vinylpiperidine-3-carboxamide.



[00356] The title compound was obtained according to step (F) of Example 1, using

(2*S*,3*R*,5*R*)-3-acetamido-*N*-(*tert*-butyl)-2-methyl-5-vinylpiperidine-3-carboxamide

hydrochloride (0.49 g, 1.54 mmol), benzaldehyde (187 μ L, 1.85 mmol), sodium

triacetoxyborohydride (1.63 g, 7.70 mmol) and DCE (16 mL). The desired product was

obtained as a white foam (395 mg, 68%). ESI+MS: $m/z = 372.15$ ($M+1$)⁺; ESI-MS: $m/z =$

370.05 ($M-1$)⁻. ¹H NMR (700 MHz, 300K, Chloroform-*d*) δ 8.67 (s, 1H), 7.39 – 7.27 (m, 5H),


5.60 (ddd, $J = 17.1, 10.7, 6.3$ Hz, 1H), 5.40 (s, 1H), 5.02 – 4.88 (m, 2H), 4.24 (br s, 1H), 3.76

(d, $J = 13.2$ Hz, 1H), 3.48 (d, $J = 13.2$ Hz, 1H), 2.62 (dd, $J = 11.7, 4.6$ Hz, 1H), 2.44 (dq, $J =$

11.8, 5.8 Hz, 1H), 2.15 (t, $J = 11.0$ Hz, 1H), 1.98 (s, 3H), 1.87 (dd, $J = 12.5, 4.2$ Hz, 1H), 1.45

– 1.39 (m, 1H), 1.35 (s, 9H), 1.05 (d, $J = 6.6$ Hz, 3H).


Step K. (2*S*,3*R*,5*S*)-3-Acetamido-1-benzyl-*N*-(*tert*-butyl)-2-methyl-5-(2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)ethyl)piperidine-3-carboxamide.



5


[00357] The title compound was obtained according to step (G) of Example 1, using (2*S*,3*R*,5*R*)-3-acetamido-1-benzyl-*N*-(*tert*-butyl)-2-methyl-5-vinylpiperidine-3-carboxamide (395 mg, 1.06 mmol), dppe (25 mg, 0.064 mmol), bis(1,5-cyclooctadiene)diiridium(I) dichloride (21 mg, 0.032 mmol), 4,4,5,5-tetramethyl-1,3,2-dioxaborolane (230 μ L, 1.59 mmol) and DCM (20 mL). The crude product was purified by column chromatography on silica gel (hexane: EtOAc, 2:1 to 0:1) to give 488 mg (92%) of the corresponding product as a white foam. ESI+MS: m/z = 500.15 ($M+1$)⁺. ¹H NMR (700 MHz, 300K, Chloroform-*d*) δ 8.80 (s, 1H), 7.33 – 7.27 (m, 5H), 5.34 (s, 1H), 4.24 (q, J = 6.6 Hz, 1H), 3.75 (d, J = 13.3 Hz, 1H), 3.43 (d, J = 13.2 Hz, 1H), 2.63 (dd, J = 11.6, 4.5 Hz, 1H), 1.97 (s, 3H), 1.97 – 1.88 (m, 1H), 1.83 (dd, J = 12.4, 4.0 Hz, 1H), 1.66 (dq, J = 12.8, 6.7 Hz, 1H), 1.32 (s, 12H), 1.28 – 1.22 (m, 2H), 1.19 (s, 9H), 1.18 – 1.09 (m, 1H), 1.01 (d, J = 6.7 Hz, 3H), 0.72 – 0.65 (m, 1H), 0.61 (ddd, J = 16.1, 9.7, 6.8 Hz, 1H).

Step L. (2*S*,3*R*,5*S*)-3-Amino-1-benzyl-5-(2-boronoethyl)-2-methylpiperidine-3-carboxylic acid dihydrochloride.



[00358] The title compound was obtained according to step (H) of Example 1, using (2*S*,3*R*,5*S*)-3-acetamido-1-benzyl-*N*-(*tert*-butyl)-2-methyl-5-(2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)ethyl)piperidine-3-carboxamide (440 mg, 0.88 mmol) and 12M HCl_(aq) (8 mL). The desired product was obtained as a pale yellow foam (346 mg, 100%). ESI+MS: $m/z = 320.80$ ($M+1$)⁺; ESI-MS: $m/z = 318.95$ ($M-1$)⁻. ¹H NMR (700 MHz, 300K, Deuterium Oxide) δ 7.58 (s, 5H), 4.53 (d, $J = 13.4$ Hz, 1H), 4.41 (d, $J = 13.4$ Hz, 1H), 3.86 (q, $J = 7.0$ Hz, 1H), 3.41 (dd, $J = 12.8, 4.7$ Hz, 1H), 3.03 (t, $J = 12.7$ Hz, 1H), 2.18 (dd, $J = 13.5, 4.5$ Hz, 1H), 2.07 (tt, $J = 11.3, 5.6$ Hz, 1H), 1.78 (t, $J = 13.2$ Hz, 1H), 1.55 – 1.41 (m, 5H), 0.87 – 0.70 (m, 2H).


Step M. (2*S*,3*R*,5*S*)-1-Benzyl-5-(2-boronoethyl)-3-((*tert*-butoxycarbonyl)amino)-2-methylpiperidine-3-carboxylic acid.



[00359] The title compound was obtained according to step (I) of Example 1, using (2*S*,3*R*,5*S*)-3-Amino-1-benzyl-5-(2-boronoethyl)-2-methylpiperidine-3-carboxylic acid dihydrochloride (340 mg, 0.86 mmol), di-*tert*-butyl dicarbonate (560 mg, 2.57 mmol), 1M NaOH_(aq) (4 mL) and acetone (10 mL). The desired product was obtained as a white solid (360 mg, 99%). ESI+MS: $m/z = 420.95$ ($M+1$)⁺; ESI-MS: $m/z = 419.00$ ($M-1$)⁻. ¹H NMR (700


MHz, Methanol- d_4) δ 7.55 – 7.46 (m, 5H), 4.48 – 4.41 (m, 1H), 4.35 – 4.27 (m, 1H), 4.17 (d, J = 13.4 Hz, 1H), 3.87 – 3.75 (m, 1H), 3.36 – 3.28 (m, 1H), 2.98 – 2.80 (m, 1H), 1.89 – 1.78 (m, 1H), 1.48 – 1.30 (m, 2H), 1.27 – 1.21 (m, 4H), 1.03 (s, 9H), 0.81 – 0.67 (m, 2H).

- 5 Step N. (2*S*,3*R*,5*S*)-5-(2-boronoethyl)-3-((*tert*-butoxycarbonyl)amino)-2-methylpiperidine-3-carboxylic acid.



- 10 **[00360]** The title compound was obtained according to step (J) of Example 1, using (2*S*,3*R*,5*S*)-1-benzyl-5-(2-boronoethyl)-3-((*tert*-butoxycarbonyl)amino)-2-methylpiperidine-3-carboxylic acid (360 g, 0.86 mmol), 20% Pd(OH)₂/C (30 mg) and MeOH (6 mL). The desired product was obtained as a white solid (282 mg, 100%). ESI+MS: m/z = 330.85 ($M+1$)⁺; ESI-MS: m/z = 328.80 ($M-1$)⁻. ¹H NMR (700 MHz, 300K, Deuterium Oxide) δ 4.36 (p, J = 8.5, 7.9 Hz, 1H), 4.10 – 4.02 (m, 1H), 3.24 (d, J = 12.8 Hz, 1H), 2.81 (t, J = 10.9 Hz, 1H), 1.95 (t, J = 12.3 Hz, 1H), 1.83 – 1.72 (m, 1H), 1.55 – 1.49 (m, 1H), 1.44 – 1.39 (m, 1H), 1.31 (d, J = 6.8 Hz, 3H), 1.22 (s, 9H), 0.91 – 0.73 (m, 2H).
- 15

- Step O. (2*S*,3*R*,5*S*)-5-(2-Boronoethyl)-1-((*tert*-butoxycarbonyl)-*L*-alanyl)-3-((*tert*-butoxycarbonyl)amino)-2-methylpiperidine-3-carboxylic acid.
- 20




[00361] The title compound was obtained according to step (K) of Example 1, using (2*S*,3*R*,5*S*)-5-(2-boronoethyl)-3-((*tert*-butoxycarbonyl)amino)-2-methylpiperidine-3-carboxylic acid (183 mg, 0.55 mmol), Boc-*L*-Ala-OSu (206 g, 0.72 mmol), and DMF (2.5 mL). The crude was purified by column chromatography on silica gel using CHCl₃/MeOH (80:1 to 2:1) to give 181 mg (65%) of the corresponding product as a white solid. ESI+MS: *m/z* = 501.95 (M+1)⁺; ESI-MS: *m/z* = 500.00 (M-1)⁻. ¹H NMR (700 MHz, Methanol-*d*₄) δ 5.61 (q, *J* = 7.5 Hz, 1H), 5.14 – 5.02 (m, 1H), 4.46 – 4.37 (m, 1H), 3.71 – 3.65 (m, 1H), 2.74 (t, *J* = 11.7 Hz, 1H), 2.29 – 2.21 (m, 1H), 2.18 – 2.12 (m, 1H), 2.06 (d, *J* = 10.1 Hz, 1H), 1.44 (s, 9H), 1.43 (s, 9H), 1.41 – 1.25 (m, 1H), 1.22 (d, *J* = 6.9 Hz, 3H), 1.07 (d, *J* = 7.1 Hz, 3H), 0.83 – 0.74 (m, 2H).

Step P. (2*S*,3*R*,5*S*)-1-(*L*-alanyl)-3-amino-5-(2-boronoethyl)-2-methylpiperidine-3-carboxylic acid dihydrochloride.


[00362] The title compound was obtained according to step (L) of Example 1, using (2*S*,3*R*,5*S*)-5-(2-boronoethyl)-1-((*tert*-butoxycarbonyl)-*L*-alanyl)-3-((*tert*-butoxycarbonyl)amino)-2-methylpiperidine-3-carboxylic acid (88 mg, 0.18 mmol) and 4M HCl in EtOAc (6 mL). The crude product was purified by preparative HPLC (0.1 -1% of acetonitrile in water) to give (after acidification with 2M HCl and subsequent lyophilization) 35.3 mg (54%) of the corresponding product as a white solid (9 : 1 mixture of rotamers in D₂O solution at room temperature, based on NMR). ESI+MS: *m/z* = 301.85 (M+1)⁺. ¹H NMR (700 MHz, Deuterium Oxide) δ 5.12 (q, *J* = 7.1 Hz, 0.9H), 4.44 (q, *J* = 7.0 Hz, 0.9H), 4.39 (dq, *J* = 14.1, 7.0 Hz, 0.1H), 4.33 (dd, *J* = 13.8, 4.7 Hz, 0.1H), 3.58 (dd, *J* = 14.0, 4.6 Hz, 1H), 2.97 (dd, *J* = 14.1, 12.2 Hz, 0.9H), 2.55 – 2.45 (m, 0.1H), 2.23 – 2.13 (m, 1H), 1.96 (dt, *J* = 11.8, 5.5 Hz, 0.9H), 1.91 – 1.84 (m, 0.1H), 1.56 (t, *J* = 12.7 Hz, 1H), 1.52 – 1.40 (m, 4H), 1.38 – 1.31 (m, 1H), 1.23 (d, *J* = 7.1 Hz, 3H), 0.85 – 0.72 (m, 2H).

Example 31. (2*S*,3*R*,5*S*)-1-(*L*-Arginyl)-3-amino-5-(2-boronoethyl)-2-methylpiperidine-3-carboxylic acid trihydrochloride.



5

Step A. (2*S*,3*R*,5*S*)-1-(*N*^ω,*N*^{ω'}-Bis((benzyloxy)carbonyl)-*N*2-(*tert*-butoxycarbonyl)-*L*-arginyl)-5-(2-boronoethyl)-3-((*tert*-butoxycarbonyl)amino)-2-methylpiperidine-3-carboxylic acid.



10


[00363] The title compound was obtained according to step (K) of Example 1, using (2*S*,3*R*,5*S*)-5-(2-boronoethyl)-3-((*tert*-butoxycarbonyl)amino)-2-methylpiperidine-3-carboxylic acid (100 mg, 0.30 mmol), Boc-*L*-Arg(Cbz)₂-OSu (252 mg, 0.39 mmol) and DMF (2 mL).

The crude product was purified by column chromatography on silica gel using CHCl₃/MeOH

15 (80:1 to 6:1) to give 75 mg (27%) of the corresponding product as a white solid. ESI+MS: $m/z = 855.15$ ($M+1$)⁺; ESI-MS: $m/z = 853.20$ ($M-1$)⁻. ¹H NMR (700 MHz, 300K, Methanol-*d*₄) δ 7.50 – 7.19 (m, 10H), 5.35 – 5.18 (m, 2H), 5.15 – 5.03 (m, 2H), 4.46 – 4.35 (m, 1H), 4.13 – 3.86 (m, 2H), 3.66 – 3.54 (m, 1H), 1.84 – 1.55 (m, 5H), 1.51 – 1.37 (m, 19H), 1.36 – 1.25 (m, 5H), 1.22 – 1.15 (m, 2H), 1.02 – 0.97 (m, 1H), 0.96 – 0.85 (m, 2H).

20

Step B. (2*S*,3*R*,5*S*)-3-Amino-1-((*E*)- *N*^ω,*N*^{ω'}-bis((benzyloxy)carbonyl)-*L*-arginyl)-5-(2-boronoethyl)-2-methylpiperidine-3-carboxylic acid dihydrochloride.



5

[00364] The title compound was obtained according to step (L) of Example 1, using (2*S*,3*R*,5*S*)-1-((*N*^ω,*N*^{ω'}-bis((benzyloxy)carbonyl)-*N*2-(*tert*-butoxycarbonyl)-*L*-arginyl)-5-(2-boronoethyl)-3-((*tert*-butoxycarbonyl)amino)-2-methylpiperidine-3-carboxylic acid (75 mg, 0.09 mmol) and 4M HCl in EtOAc (5 mL). The desired product was obtained as a pale yellow foam (63 mg, 100%). ESI+MS: *m/z* = 655.25 (*M*+1)⁺. ¹H NMR (700 MHz, 300K, Methanol-*d*₄) δ 7.53 – 7.25 (m, 10H), 5.41 – 5.11 (m, 5H), 4.11 (dq, *J* = 14.5, 7.2 Hz, 1H), 3.96 – 3.85 (m, 2H), 3.66 – 3.55 (m, 1H), 2.28 (dd, *J* = 13.0, 4.8 Hz, 1H), 1.92 – 1.82 (m, 2H), 1.82 – 1.72 (m, 2H), 1.59 – 1.14 (m, 7H), 0.97 – 0.72 (m, 3H).


15 Step C. (2*S*,3*R*,5*S*)-1-(*L*-arginyl)-3-amino-5-(2-boronoethyl)-2-methylpiperidine-3-carboxylic acid trihydrochloride.


[00365] (2*S*,3*R*,5*S*)-3-amino-1-((*E*)- *N*^ω,*N*^{ω'}-bis((benzyloxy)carbonyl)-*L*-arginyl)-5-(2-boronoethyl)-2-methylpiperidine-3-carboxylic acid dihydrochloride (63 mg, 0.09 mmol) was dissolved in 2 mL of MeOH and flushed with argon. Next, 3 mg of Pd/C (wet, 10%) was added and the resulting mixture was stirred under hydrogen atmosphere (balloon) overnight. In the next step, the reaction mixture was filtered through the pad of Celite and concentrated. The crude product was purified by preparative HPLC (0.1 -1% of acetonitrile in water) to give (after acidification with 2M HCl and subsequent lyophilization) 13.6 mg (32%) of the

corresponding product as a white solid (9 : 1 mixture of rotamers in D₂O solution at room temperature, based on NMR). ESI+MS: $m/z = 387.00$ (M+1)⁺; ESI-MS: $m/z = 384.90$ (M-1)⁻.

¹H NMR (700 MHz, 300K, Deuterium Oxide) δ 5.28 (q, $J = 7.1$ Hz, 0.9H), 4.63 (t, $J = 6.0$ Hz, 0.9H), 4.55 (t, $J = 5.1$ Hz, 0.1H), 4.51 (dd, $J = 6.7, 5.3$ Hz, 0.1H), 4.42 (dd, $J = 13.8, 4.7$ Hz, 0.1H), 3.70 (dd, $J = 14.0, 4.6$ Hz, 0.9H), 3.38 – 3.18 (m, 2H), 3.08 (dd, $J = 13.9, 11.8$ Hz, 0.9H), 2.67 – 2.55 (m, 0.1H), 2.34 (d, $J = 13.6$ Hz, 1H), 2.17 – 1.85 (m, 3H), 1.82 – 1.60 (m, 3.1H), 1.54 (ddt, $J = 13.0, 10.3, 6.4$ Hz, 0.9H), 1.49 – 1.40 (m, 1H), 1.35 (dd, $J = 7.2, 1.2$ Hz, 3H), 0.97 – 0.74 (m, 2H).


10 **Example 32. (3*R*,5*R*)-1-(*L*-Alanyl)-3-amino-5-(2-boronoethyl)piperidine-3-carboxylic acid dihydrochloride.**





Step A. *tert*-Butyl 3-oxo-3,6-dihydropyridine-1(2*H*)-carboxylate.

5




[00366] To a solution of *tert*-butyl 3-hydroxy-3,6-dihydropyridine-1(2*H*)-carboxylate (10 g, 50.19 mmol) in DCM (200 mL) was added Dess-Martin periodinane (25.55 g, 60.2 mmol).

10 After stirring for 1.5 h additional amount of Dess-Martin periodinane (2.50 g, 12.54 mmol) was added together with DCM (50 mL). The reaction mixture was stirred for additional 1.5 h; then 750 mL of hexane was added and stirring was continued for 10 min. The solid that

precipitated was filtered off. The filtrate was concentrated and treated with a fresh portion of hexane (500 mL), filtered and concentrated *in vacuo* to give 10.01 g (100%) of *tert*-butyl 3-oxo-3,6-dihydropyridine-1(2*H*)-carboxylate as a pale orange solid. ESI+MS: $m/z = 142.20$ ($M - 56 + 1$)⁺. ¹H NMR (700 MHz, 300 K, DMSO-*d*₆) δ 7.22 (bs, 1H), 6.10 (dt, $J = 10.3, 2.3$ Hz, 1H), 4.18 (bs, 1H), 4.01 (bs, 1H), 1.42 (s, 9H).

Step B. *tert*-Butyl 3-oxo-5-vinylpiperidine-1-carboxylate.




[00367] To a flask charged with CuBr x Me₂S complex (0.78 g, 3.8 mmol) and dry THF (125 mL) were added HMPA (17.60 mL, 101.40 mmol) and vinylmagnesium bromide 1M solution in THF (88.72 mL, 88.72 mmol) at -78 °C under Ar. The reaction mixture was stirred for 15 min followed by a solution of *tert*-butyl 3-oxo-3,6-dihydropyridine-1(2*H*)-carboxylate (5 g, 25.35 mmol) and chlorotrimethylsilane (16.08 mL, 126.75 mmol) in THF (75 mL) was added dropwise for over 30 min. The reaction mixture was stirred for 2 h at -78 °C and subsequently overnight at RT. After the reaction was completed, 60 mL of saturated aqueous NH₄Cl solution was added, and then the layers were separated. The organic layer was washed with NH₄Cl (3 x 30 mL). The aqueous layer was diluted with H₂O (100 mL) and washed with AcOEt (2 x 40 mL). The combined organic layers were washed with brine (20 mL), dried over MgSO₄ and concentrated *in vacuo*. The crude product was purified by silica gel column chromatography using hexane/EtOAc (1:0 to 1:4) as an eluent. The desired product was obtained as a colorless oil. Yield: 4.23 g (74 %). ESI+MS: $m/z = 170.15$ ($M - 56 + 1$)⁺. ¹H NMR (700 MHz, 300 K, chloroform-*d*) δ 5.77 (ddd, $J = 17.0, 10.5, 6.3$ Hz, 1H), 5.15

– 5.10 (m, 2H), 4.09 (d, $J = 18.0$ Hz, 1H), 4.05 – 3.72 (m, 2H), 3.21 (bs, 1H), 2.78 – 2.71 (m, 1H), 2.61 (dd, $J = 16.3, 4.7$ Hz, 1H), 2.37 (dd, $J = 16.2, 10.0$ Hz, 1H), 1.46 (s, 9H).

Step C. *tert*-Butyl 3-hydroxy-3-(trichloromethyl)-5-vinylpiperidine-1-carboxylate.


5



[00368] To flask with *tert*-butyl 3-oxo-5-vinylpiperidine-1-carboxylate (406 mg, 1.80 mol), malonic acid (187 mg, 1.80 mol) were added. Reaction was stirred overnight at RT. Next, reaction mixture was poured with AcOEt (50 mL), H₂O (2 mL) and was washed with brine (3 x 10 mL). Organic solution containing product was dried over MgSO₄, filtered and concentrated in vacuo. Product was purified by silica gel column chromatography starting from 100% *n*-hexane and ending at AcOEt/*n*-hexane, 1:4. Product was obtained as mixture of four stereoisomers (the mixture of two diastereoisomers and two enantiomers). The correlation between enantiomeric mixture of the two sets of diastereoisomers was determined by LCMS (major 70%, lower retention time C18-column and minor 30%, higher retention time C18-column). The *tert*-butyl-3-hydroxy-3-(trichloromethyl)-5-vinylpiperidine-1-carboxylate was obtained in (279 mg, 45%) amount as a colorless oil. Peak 1 (70%) ESI+MS: $m/z = 244.05$ ($M+1$ -Boc)⁺ and peak 2 (30%) ESI+MS: $m/z = 244.00$ ($M+1$ -Boc)⁺.


20

Step D. 3-Azido-1-(*tert*-butoxycarbonyl)-5-vinylpiperidine-3-carboxylic acid.



[00369] To flask with *tert*-butyl-3-hydroxy-3-(trichloromethyl)-5-vinylpiperidine-1-carboxylate (270 mg, 0.78 mol), 1,4-dioxane was poured and next a solution of NaN₃ (254 mg, 3.91 mol) and NaOH (157 mg, 3.91 mol) in H₂O (5 mL) was added. After reaction was complete, 1,4-dioxane was evaporated and reaction was quenched with saturated NH₄Cl and contaminations were extracted with DCM (3 x 10 mL). The water layer was acidified in flask equipped with septum and next degassed under vacuum through flask with 4M NaOH. Product was extracted with DCM (5 x 30 mL). Combined organic layer was washed with brine, dried over MgSO₄, filtered and concentrated *in vacuo*. Product 3-azido-1-(*tert*-butoxycarbonyl)-5-vinylpiperidine-3-carboxylic acid was obtained in (179 mg, 77%) amount as an light yellow oil. ESI-MS: *m/z* =295.10 (M-1)⁻.


Step E. 3-Benzyl 1-(*tert*-butyl) (3*R*,5*S*)-3-azido-5-vinylpiperidine-1,3-dicarboxylate and 3-benzyl 1-(*tert*-butyl) (3*S*,5*R*)-3-azido-5-vinylpiperidine-1,3-dicarboxylate.



[00370] To flask with 3-azido-1-(*tert*-butoxycarbonyl)-5-vinylpiperidine-3-carboxylic acid (265 mg, 0.89 mmol), CH₃CN (4 mL), Cs₂CO₃ (157 mg, 1.79 mmol) and benzyl bromide (117 μL, 0.98 mmol) were added. Reaction was stirred overnight at RT. Product was purified by silica gel column chromatography starting from 100% n-hexane and ending at EtOAc/n-


hexane, 1:4. At these level the enantiomeric mixture of two sets of diastereoisomers was separated by silica gel column chromatography. The major diastereoisomer (140 mg) was separated into its enantiomer using a chiral preparative HPLC method (LumiSep Chiralcel AD column) with propan-2-ol and n-hexane (isocratic, 1%) as an eluent and ELSD detection.

- 5 Retention time of 3-benzyl 1-(*tert*-butyl) (3*R*,5*S*)-3-azido-5-vinylpiperidine-1,3-dicarboxylate in preparative HPLC was in the range from 17.3 to 20.1 min. Retention time of 3-benzyl 1-(*tert*-butyl) (3*S*,5*R*)-3-azido-5-vinylpiperidine-1,3-dicarboxylate in preparative HPLC was in the range from 22.5 to 28.3 min. The enantiomeric excess for both enantiomers was determined with the use of chiral analytical HPLC method with ELSD detection with
- 10 RegisPack (5 μ m, 4.6 x 250 mm) column using 2% propan-2-ol in n-hexane as eluent for 15 min. The first enantiomer 3-benzyl 1-(*tert*-butyl) (3*R*,5*S*)-3-azido-5-vinylpiperidine-1,3-dicarboxylate (26 mg, 19%, colorless oil) with the retention time of 8.1 min and the second desired enantiomer 3-benzyl 1-(*tert*-butyl) (3*S*,5*R*)-3-azido-5-vinylpiperidine-1,3-dicarboxylate (31 mg, 22%, colorless oil) at 9.2 min, each with an enantiomeric excess of approximately
- 15 98%. ESI+MS: m/z = 409.20 ($M+23$)⁺. ¹H NMR (700 MHz, 300 K, Chloroform-*d*) δ 7.41 – 7.32 (m, 5H), 5.64 (ddd, J = 17.1, 10.5, 6.3 Hz, 1H), 5.13 – 5.03 (s, 2H), 5.09 (dd, J = 22.1, 13.9 Hz, 2H), 4.45 – 4.23 (m, 2H), 3.12 – 2.91 (m, 1H), 2.55 – 2.32 (m, 2H), 2.09 – 2.00 (m, 1H), 1.68 (t, J = 13.0 Hz, 1H), 1.48 (s, 9H).
- 20 Step F. 3-Benzyl 1-(*tert*-butyl) (3*R*,5*R*)-3-azido-5-(2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)ethyl)piperidine-1,3-dicarboxylate.



[00371] A mixture of dppe (1.60 mg, 0.004 mmol) and bis(1,5-cyclooctadiene)diiridium(I) dichloride (1.30 mg, 0.002 mmol) in DCM (0.5 mL) was flushed with argon (bubbling). Subsequently, the separately prepared solution of 4,4,5,5-tetramethyl-1,3,2-dioxaborolane (15 μ L, 0.097 mmol) and 3-benzyl 1-(*tert*-butyl) (3*R*,5*S*)-3-azido-5-vinylpiperidine-1,3-dicarboxylate (25 mg, 0.065 mmol) in 0.5 mL of dry DCM was added successively at room temperature. The resulting mixture was stirred at room temperature overnight. After that time the reaction mixture was diluted with DCM (10 mL) and washed with 5% NaHCO₃ (1x 10 mL) and brine (1x 10 mL). The organic layer was dried over MgSO₄, filtered and concentrated *in vacuo*. The crude product was purified by column chromatography on silica gel using Hex/EtOAc (50:1 to 10:1) to give 25 mg (75%) of the corresponding product as a colorless oil. ESI+MS: $m/z = 415.25$ (M-100+1)⁺; ESI-MS: $m/z = 559.25$ (M+45)⁻. ¹H NMR (700 MHz, 300 K, Chloroform-*d*) δ 7.41 – 7.30 (m, 5H), 5.23 (br s, 2H), 4.41 – 4.06 (m, 2H), 2.99 (d, $J = 81.2$ Hz, 1H), 2.17 (br s, 1H), 2.06 (br s, 1H), 1.71 (br s, 1H), 1.47 (s, 9H), 1.27 (br s, 3H), 1.23 (s, 12H), 0.78 (t, $J = 8.2$ Hz, 2H).


Step G. Benzyl (3*R*,5*R*)-3-azido-5-(2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)ethyl)piperidine-3-carboxylate hydrochloride.



[00372] To a solution of 3-benzyl 1-(*tert*-butyl) (3*R*,5*R*)-3-azido-5-(2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)ethyl)piperidine-1,3-dicarboxylate (25 mg, 0.047 mmol) in AcOEt (1 mL) 4M HCl in AcOEt (1 mL) was added and the resulting mixture was stirred at room temperature for 1 h. Then the reaction mixture was concentrated under reduced pressure to

give 22 mg (99%) of the corresponding product as a colorless oil. ESI+MS: m/z = 415.20 ($M+1$)⁺. ¹H NMR (700 MHz, 300 K, Chloroform-*d*) δ 7.44 – 7.32 (m, 5H), 7.11 (s, 1H), 5.27 – 5.21 (m, 2H), 3.54 – 5.49 (m, 1H), 3.38 (d, J = 12.4 Hz, 1H), 3.12 (d, J = 12.0 Hz, 1H), 2.44 (br s, 1H), 2.32 (d, J = 14.0 Hz, 1H), 2.17 (br s, 1H), 1.40 – 1.25 (m, 3H), 1.24 (s, 12H), 0.88 – 0.75 (m, 2H).


Step H. Benzyl (3*R*,5*R*)-3-azido-1-((*tert*-butoxycarbonyl)-*L*-alanyl)-5-(2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)ethyl)piperidine-3-carboxylate.



[00373] To a solution of benzyl (3*R*,5*R*)-3-azido-5-(2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)ethyl)piperidine-3-carboxylate hydrochloride (22 mg, 0.048 mmol) in DCM (0.8 mL) DIPEA (21 μ L, 0.12 mmol) and Boc-*L*-Ala-OH (9.1 mg, 0.048 mmol) were added. Then to the reaction mixture TBTU (17 mg, 0.053 mmol) was added and stirred at room temperature overnight. The reaction was washed with 1M HCl (1x 2 mL), 1M NaOH (1x 2 mL) and brine (1x 2 mL). The organic layer was dried over MgSO₄, filtered and concentrated in *vacuo*. The crude product was purified by column chromatography on silica gel using Hex/EtOAc (10:1 to 3:1) to give 10 mg (36%) of the corresponding product as a colorless oil. ESI+MS: m/z = 586.35 ($M+1$)⁺; 608.35 ($M+23$)⁺. (5 : 2 mixture of rotamers in CDCl₃ solution at room temperature, based on NMR). ¹H NMR (700 MHz, 300 K, Chloroform-*d*) δ 7.42 – 7.32 (m, 5H), 7.11 (s, 1H), 5.58 (dd, J = 50.1, 7.8 Hz, 1H), 5.24 (s, 2H), 4.83 (d, J = 14.0 Hz, 0.7H), 4.71 – 4.56 (m, 1.3H), 3.91 (d, J = 13.8 Hz, 0.7H), 3.75 (d, J = 14.3 Hz, 0.3H), 3.31 (d, J = 14.1 Hz, 0.3H), 2.85 (d, J = 13.9 Hz, 0.7H), 2.64 (dd, J = 13.7, 11.8 Hz, 0.7H), 2.35 –


2.29 (m, 0.3H), 2.16 - 2.11 (m, 1H), 1.84 – 1.68 (m, 1H), 1.43 (s, 9H), 1.35 (d, $J = 6.9$ Hz, 3H), 1.24 (s, 2H), 1.23 (s, 12H), 0.81 (t, $J = 8.0$ Hz, 2H).

Step I. Benzyl (3*R*,5*R*)-1-(*L*-alanyl)-3-azido-5-(2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)ethyl)piperidine-3-carboxylate hydrochloride.



[00374] To a benzyl (3*R*,5*R*)-3-azido-1-((*tert*-butoxycarbonyl)-*L*-alanyl)-5-(2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)ethyl)piperidine-3-carboxylate (8 mg, 0.014 mmol) was added 4M HCl in AcOEt (1 mL) and the resulting mixture was stirred at room temperature for 1 h. Then the reaction mixture was concentrated under reduced pressure to give 7.1 mg (99%) of the corresponding product as a colorless film. ESI+MS: $m/z = 486.30$ ($M+1$)⁺. ¹H NMR (700 MHz, 300 K, Chloroform-*d*) δ 8.53 (br s, 3H), 7.39 (d, $J = 25.8$ Hz, 5H), 5.27 (br s, 2H), 4.75 – 4.55 (m, 2H), 3.86 – 3.56 (m, 2H), 2.37 – 2.07 (m, 2H), 1.88 – 1.80 (m, 1H), 1.28 – 1.25 (m, 6H), 1.22 (s, 12H), 0.90 – 0.72 (m, 2H).

Step J. (2-((3*R*,5*R*)-1-(*L*-Alanyl)-5-azido-5-((benzyloxy)carbonyl)piperidin-3-yl)ethyl)boronic acid hydrochloride.



[00375] To a suspension of benzyl (3*R*,5*R*)-1-(*L*-alanyl)-3-azido-5-(2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)ethyl)piperidine-3-carboxylate hydrochloride (6 mg, 0.012 mmol) and phenylboronic acid (1.4 mg, 0.012 mmol) in H₂O (1 mL) was added 2N HCl (0.25 mL) and hexane (1.5 mL) and the mixture was stirred for 30 min at room temperature. The reaction mixture was separated and to the aqueous layer phenylboronic acid (0.3 mg, 0.002 mmol) and hexane were added and the reaction was stirred for additional 30 min. Next, the layers were separated and the aqueous layer was washed with Et₂O (2 x 3 mL) and concentrated under reduced pressure to give 5 mg (99%) of the corresponding product as a colorless oil.

ESI+MS: $m/z = 404.15$ ($M+1$)⁺. (3 : 2 mixture of rotamers in D₂O solution at room temperature, based on NMR). ¹H NMR (700 MHz, 300 K, Deuterium Oxide) δ 7.54 – 7.45 (m, 5H), 5.39 – 5.34 (m, 2H), 4.66 – 4.55 (m, 1H), 4.55 – 4.44 (m, 1H), 3.84 – 3.77 (m, 2H), 3.68 (d, $J = 14.5$ Hz, 0.4H), 3.20 (d, $J = 13.9$ Hz, 0.6H), 2.93 (dd, $J = 14.0, 11.5$ Hz, 0.6H), 2.53 – 2.46 (m, 0.4H), 2.39 (dd, $J = 13.9, 2.8$ Hz, 0.4H), 2.32 – 2.26 (m, 0.6H), 1.88 – 1.73 (m, 2H), 1.56 (d, $J = 7.0$ Hz, 2H), 1.47 (d, $J = 7.1$ Hz, 1H), 1.45 – 1.31 (m, 1H), 0.90 – 0.85 (m, 2H).


Step K. (3*R*,5*R*)-1-(*L*-Alanyl)-3-amino-5-(2-boronoethyl)piperidine-3-carboxylic acid dihydrochloride.

[00376] To a solution of (2-((3*R*,5*R*)-1-(*L*-alanyl)-5-azido-5-((benzyloxy)carbonyl)piperidine-3-yl)ethyl)boronic acid hydrochloride (4.5 mg, 0.01 mmol), in H₂O/AcOEt (0.5 mL : 50 μ L) mixture under argon 1 mg 10% Pd/C (wet) was added. The mixture was degassed, charged with H₂, and stirred overnight at room temperature. The mixture was filtered through a pad of Celite, washed with H₂O (2 x 10 mL) and to the filtrate was added 2 drops of 2M HCl and concentrated *in vacuo*. The residue was dissolved in H₂O (2 mL), frozen and lyophilized to give 2.3 mg (63%) of the corresponding product as a white foam. ESI+MS: $m/z = 288.15$

(M+1)⁺; ESI-MS: m/z = 286.05 (M-1)⁻. ¹H NMR (700 MHz, 300 K, Deuterium Oxide) δ 4.68 – 4.52 (m, 2H), 3.95 – 3.78 (m, 1H), 3.39 – 3.28 (m, 1H), 2.96 (t, *J* = 12.8 Hz, 1H), 2.26 – 2.15 (m, 1H), 2.00 – 1.88 (m, 1H), 1.62 – 1.58 (m, 2H), 1.55 – 1.47 (m, 3H), 1.37 – 1.22 (m, 1H), 0.90 – 0.85 (m, 2H).


5

Example 33. (3*S*,5*S*)-1-(*L*-Alanyl)-3-amino-5-(2-boronoethyl)piperidine-3-carboxylic acid dihydrochloride.



10

Step A. 3-Benzyl 1-(*tert*-butyl) (3*S*,5*S*)-3-azido-5-(2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)ethyl)piperidine-1,3-dicarboxylate.




15

[00377] The title compound was obtained according to step (F) of Example 32, using 3-benzyl 1-(*tert*-butyl) (3*S*,5*R*)-3-azido-5-vinylpiperidine-1,3-dicarboxylate (30 mg, 0.078 mmol), dppe (2 mg, 0.005 mmol), bis(1,5-cyclooctadiene)diiridium(I) dichloride (1.6 mg, 0.0023 mmol), 4,4,5,5-tetramethyl-1,3,2-dioxaborolane (18 μL, 0.116 mmol) and DCM (1 mL). The crude product was purified by column chromatography on silica gel using Hex/EtOAc (50:1 to 10:1) to give 32 mg (80%) of the corresponding product as a colorless oil. ESI+MS: m/z = 415.25 (M-100+1)⁺; ESI-MS: m/z = 559.20 (M+45)⁻. ¹H NMR (700 MHz,


20

300 K, Chloroform-*d*) δ 7.42 – 7.32 (m, 5H), 5.23 (bs, 2H), 4.45 – 4.04 (m, 2H), 3.08 – 2.89 (m, 1H), 2.18 (d, J = 19.5 Hz, 1H), 2.06 (d, J = 15.7 Hz, 1H), 1.71 (bs, 1H), 1.47 (s, 9H), 1.24 (bs, 3H), 1.23 (s, 12H), 0.79 (t, J = 8.2 Hz, 2H).

- 5 Step B. Benzyl (3*S*,5*S*)-3-azido-5-(2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)ethyl)piperidine-3-carboxylate hydrochloride.




- 10 **[00378]** The title compound was obtained according to step (G) of Example 32, using 3-benzyl 1-(*tert*-butyl) (3*S*,5*S*)-3-azido-5-(2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)ethyl)piperidine-1,3-dicarboxylate (31 mg, 0.06 mmol), EtOAc (1 mL) and 4M HCl in EtOAc (1 mL). The reaction mixture was concentrated under reduced pressure to give 26 mg (96%) of the corresponding product as white solid. ESI+MS: m/z = 415.20 ($M+1$)⁺. ¹H NMR (700
- 15 MHz, 300 K, Chloroform-*d*) δ 7.42 – 7.33 (m, 5H), 7.11 (s, 1H), 5.28 – 5.19 (m, 2H), 3.58 – 5.49 (m, 1H), 3.38 (d, J = 13.1 Hz, 1H), 3.12 (d, J = 12.9 Hz, 1H), 2.44 (t, J = 11.8 Hz, 1H), 2.31 (d, J = 14.2 Hz, 1H), 2.16 (bs, 1H), 1.51 – 1.42 (m, 1H), 1.41 – 1.32 (m, 1H), 1.30 – 1.25 (m, 1H), 1.23 (s, 12H), 0.90 – 0.75 (m, 2H).
- 20 Step C. Benzyl (3*S*,5*S*)-3-azido-1-((*tert*-butoxycarbonyl)-*L*-alanyl)-5-(2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)ethyl)piperidine-3-carboxylate.




[00379] The title compound was obtained according to step (H) of Example 32, using benzyl (3*S*,5*S*)-3-azido-5-(2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)ethyl)piperidine-3-carboxylate hydrochloride (25.5 mg, 0.057 mmol), DIPEA (24 μ L, 0.14 mmol), Boc-*L*-Ala-OH (10.7 mg, 0.057 mmol), TBTU (20 mg, 0.062 mmol) and DCM (1 mL). The crude product was purified by column chromatography on silica gel using hexane: AcOEt (10:1 to 2:1) to give 20.5 mg (62%) of the corresponding product as a colorless oil. ESI+MS: m/z = 586.35 ($M+1$)⁺; 608.35 ($M+23$)⁺. (3 : 2 mixture of rotamers in CDCl₃ solution at room temperature, based on NMR). ¹H NMR (700 MHz, 300 K, Chloroform-*d*) δ 7.42 – 7.34 (m, 5H), 7.11 (s, 1H), 5.57 (d, J = 7.6 Hz, 0.6H), 5.29 (d, J = 8.5 Hz, 0.4H), 5.26 – 5.20 (m, 2H), 4.80 (d, J = 13.8 Hz, 0.6H), 4.72 – 4.67 (m, 0.4H), 4.65 – 4.59 (m, 0.6H), 4.58 – 4.53 (m, 0.4H) 3.89 (dd, J = 24.3, 13.8 Hz, 1H), 3.33 (d, J = 14.0 Hz, 0.4H), 2.86 (d, J = 13.9 Hz, 0.6H), 2.61 (dd, J = 13.5, 11.7 Hz, 0.6H), 2.31 (d, J = 14.7 Hz, 0.4H), 2.16 (d, J = 11.1 Hz, 0.6H), 2.12 (dd, J = 13.2, 11.7 Hz, 0.4H), 1.81 (bs, 0.6H), 1.68 (br s, 0.4H), 1.43 (d, J = 18.7 Hz, 9H), 1.29 (d, J = 6.8 Hz, 3H), 1.26 – 1.24 (m, 2H), 1.23 (s, 12H), 0.86 – 0.74 (m, 2H).

Step D. Benzyl (3*S*,5*S*)-1-(*L*-alanyl)-3-azido-5-(2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)ethyl)piperidine-3-carboxylate hydrochloride.



[00380] The title compound was obtained according to step (I) of Example 32, using benzyl (3*S*,5*S*)-3-azido-1-((*tert*-butoxycarbonyl)-*L*-alanyl)-5-(2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)ethyl)piperidine-3-carboxylate (19 mg, 0.032 mmol), 4M HCl in AcOEt (2 mL). The reaction mixture was concentrated under reduced pressure to give 17 mg (99%) of the corresponding product as a colorless film. ESI+MS: $m/z = 486.30$ ($M+1$)⁺. ¹H NMR (700 MHz, 300 K, Chloroform-*d*) δ 8.59 (br s, 1H), 8.37 (bs, 2H), 7.42 – 7.33 (m, 5H), 5.24 (bs, 2H), 4.78 – 4.38 (m, 2H), 3.82 – 3.35 (m, 3H), 2.29 – 2.14 (m, 2H), 1.56 – 1.42 (m, 1H), 1.35 – 1.28 (m, 3H) 1.22 (s, 12H), 1.18 – 1.12 (m, 2H), 0.85 – 0.77 (m, 2H).

Step E. (2-((3*S*,5*S*)-1-(*L*-Alanyl)-5-azido-5-((benzyloxy)carbonyl)piperidin-3-yl)ethyl)boronic acid hydrochloride.



[00381] The title compound was obtained according to step (J) of Example 32, using benzyl (3*S*,5*S*)-1-(*L*-alanyl)-3-azido-5-(2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)ethyl)piperidine-3-carboxylate hydrochloride (15 mg, 0.029 mmol), phenylboronic acid (4.2 mg, 0.034 mmol), H₂O (1.5 mL), 2N HCl (0.25 mL) and hexane (2 mL). The final compound was obtained as a colorless oil (11.6 mg, 92%). ESI+MS: $m/z = 404.20$ ($M+1$)⁺. (5 : 2 mixture of rotamers in D₂O solution at room temperature, based on NMR). ¹H NMR (700 MHz, 300 K, Deuterium Oxide) δ 7.55 – 7.47 (m, 5H), 5.38 – 5.32 (m, 2H), 4.60 – 4.53 (m, 1.3H), 4.50 – 4.42 (m, 0.7H), 3.83 (dd, $J = 14.3, 5.1$ Hz, 1H), 3.74 (d, $J = 9.6$ Hz, 1H), 3.62 (d, $J = 14.2$ Hz, 0.3H), 3.22 (d, $J = 13.9$ Hz, 0.7H), 2.98 (dd, $J = 13.8, 11.6$ Hz, 0.7H), 2.55 –

2.50 (m, 0.3H), 2.42 (d, $J = 14.1$ Hz, 0.3H), 2.26 (d, $J = 13.8$ Hz, 0.7H), 1.87 – 1.71 (m, 2H), 1.63 (d, $J = 6.9$ Hz, 1H), 1.53 (d, $J = 7.0$ Hz, 2H), 1.44 – 1.36 (m, 1H), 0.92 – 0.80 (m, 2H).

Step F. (3S,5S)-1-(L-Alanyl)-3-amino-5-(2-boronoethyl)piperidine-3-carboxylic acid

5 dihydrochloride.

[00382] The title compound was obtained according to step (K) of Example 32, using (2-((3S,5S)-1-(L-alanyl)-5-azido-5-((benzyloxy)carbonyl)piperidin-3-yl)ethyl)boronic acid

hydrochloride (11 mg, 0.025 mmol), Pd/C (2 mg), H₂O (1 mL) and AcOEt (0.1 mL). To the

10 filtrate was added 2 drops of 2M HCl and concentrated *in vacuo*. The residue was dissolved in H₂O (2 mL), frozen and lyophilized to give 6.8 mg (76%) of the corresponding product as a white foam. ESI+MS: $m/z = 288.15$ ($M+1$)⁺; 270.20 ($M-18+1$)⁺; ESI-MS: $m/z = 286.05$ ($M-1$)⁻. ¹H NMR (700 MHz, 300 K, Deuterium Oxide) δ 4.74 – 4.70 (m, 1H), 4.61 (q, $J = 7.1$ Hz, 1H), 3.94 – 3.86 (m, 1H), 3.36 (d, $J = 14.5$ Hz, 1H), 3.10 – 3.03 (m, 1H), 2.32 – 2.23 (m, 1H), 2.03
15 – 1.92 (m, 1H), 1.85 – 1.77 (m, 1H), 1.61 – 1.46 (m, 4H), 1.47 – 1.40 (m, 1H), 0.91 – 0.78 (m, 2H).

Human arginase inhibition assay

[00383] The inhibitory activities of the compounds of the invention were assessed using

20 recombinant human arginase 1 and 2. Both enzymes were biosynthesized using a prokaryotic expression system (*E. coli*) and purified by fast protein liquid chromatography (FPLC). The compounds were screened in 96-well plates at the total reaction volume of 100 μ L. Briefly, recombinant enzymes were incubated with the tested compounds for 1 h at 37 °C in the reaction buffer (100 mM sodium phosphate buffer, 130 mM NaCl, 1 mg/mL BSA, pH 7.4) containing substrate (10 mM L-arginine hydrochloride) and cofactor (200 μ M MnCl₂).
25 The assay is based on the detection of urea, which is generated during the conversion of L-arginine into L-ornithine catalyzed by ARG1 or ARG2. The colorimetrically detectable




product was developed by adding a mixture of reagent A (4 mM oPA, 50 mM boric acid, 1 M sulfuric acid, 0.03% Brij-35) and reagent B (4 mM NED, 50 mM boric acid, 1 M sulfuric acid, 0.03% Brij-35) in equal proportions. The absorbance for each well was measured at 515 nm and the enzyme inhibition was calculated. The urea production in the absence of any tested compound was considered as maximal enzyme activity. The absorbance at the absence of arginase (background) was subtracted from all the values. Normalized values were analyzed using GraphPad Prism 7.0 software by plotting inhibition curves and determining the IC₅₀ values.








[00384] The IC₅₀ values were calculated using GraphPad Prism and divided into the









following classes: A = 1-249 nM; B = 250-499 nM; C = 500-999 nM; D = 1-10 μ M; E >10 μ M.









The inhibitory activity toward humane arginase 1 of the hydrochloride salts of the exemplary compounds according to the invention is presented in Table 5.








Table 5. Arginase 1 Inhibitory Activity

Example No.	Compound Structure	Activity Class (ARG I)
1		B
2		E
3		A

Example No.	Compound Structure	Activity Class (ARG I)
4	 x 2HCl	B
5	 x 2HCl	B
6	 x 2HCl	A
7	 x 3HCl	A
8	 x 2HCl	C
9	 x 2HCl	C
10	 x2HCl	B









Example No.	Compound Structure	Activity Class (ARG I)
11	 x 2 HCl	A
12	 x 2 HCl	B
13	 x 3 HCl	A
14	 x 2 HCl	C
15	 x 2 HCl	C
16	 x 2 HCl	B
17	 x 2 HCl	B
18	 x 2 HCl	B

Example No.	Compound Structure	Activity Class (ARG I)
19	 x 2HCl	C
20	 x 3HCl	A
21	 x 2HCl	B
22	 x 3HCl	B
23	 x 2HCl	D
24	 x 2HCl	C
25	 x 2HCl	B
26	 x 2HCl	B

Example No.	Compound Structure	Activity Class (ARG I)
27	 x 2HCl	B
28	 x 2HCl	E
29	 x 3HCl	A
30	 x 2HCl	A
31	 x 3HCl	B
32	 x 2HCl	E
33	 x 2HCl	E

The inhibitory activity toward humane arginase 2 of the hydrochloride salts of the selected exemplary compounds according to the invention is presented in Table 6.

Table 6. Arginase 2 Inhibitory Activity


Example No.	Compound Structure	Activity Class (ARG II)
1		C
3		C
6		C
7		C
11		D
13		C
20		B
30		C

*Evaluation of pharmacokinetic (PK) and pharmacodynamic (PD) properties***Example 34. Pharmacokinetic and Pharmacodynamic Studies**

PK/PD studies were performed using BALB/c mice or Sprague-Dawley rats. The compounds
5 were tested after intravenous and oral (intragastric) administration at doses of 3 mg/kg or 10
mg/kg, respectively. Saline solution (suitable for infusions) was used as vehicle. Blood
samples were collected from the animals to EDTA tubes in relevant time-points (3 samples
per time-point), usually up to 24 h following the administration. The concentrations of the
tested compounds and L-arginine were determined in blood plasma by LC-MS method. The
10 pharmacokinetic parameters ($C_{\max}$, $t_{\max}$, AUC, CL, V_{ss} , $t_{1/2}$, F) were determined by a non-
compartmental method using standard equations in MS Excel software. Results are shown
in Figures 3–6.

WHAT IS CLAIMED IS:

1. A compound of the Formula (I):



wherein:

R^1 is selected from the group consisting of H, straight-chain or branched (C_1-C_6) alkyl, $HC(O)-$, and (C_1-C_6) alkyl- $C(O)-$;

R^2 and R^3 are each independently selected from hydrogen, straight-chain or branched (C_1-C_6) alkyl or (C_1-C_6) alkyl- $C(O)-$,

or R^2 and R^3 taken together with the boron atom and oxygen atoms to which they are bound form a 4-, 5-, 6- or 7- membered ring that is fully saturated, or partially saturated,

or R^2 and R^3 taken together with the boron atom and oxygen atoms to which they are bound form a diester of the boronic acid and polyalcohols selected from: pinanediol, mannitol, glycerol, xylitol, sorbitol, or erythritol,

or R^2 and R^3 taken together with the boron atom and oxygen atoms to which they are bound form an anhydride or mixed ester-anhydride of the boronic acid and hydroxy acids or di-carboxylic acids selected from: iminodiacetic acid or *N*-methyliminodiacetic acid or oxalic acid or tartaric acid or citric acid or malic acid or malonic acid or mandelic acid or glycolic acid or lactic acid or 3-hydroxypropionic acid;

R⁴ is selected from the group consisting of H, straight-chain and branched (C₁-C₆)alkyl;


R⁵ is selected from the group consisting of H, F, methyl, ethyl, propyl, isopropyl, -CH₂NH₂, -CH₂NHCH₃, -CH₂NHCH₂CH₃, -CH₂NHCH(CH₃)₂, -CH₂N(CH₃)₂, -CH₂N(CH₃)CH₂CH₃, -CH₂N(CH₂CH₃)₂, -CH₂N(CH₃)CH(CH₃)₂, -CH₂-azetidiny, -CH₂-pyrrolidiny, and -CH₂-piperidiny;

R⁶ is selected from the amino acid side chains of Gly, Ala, Val, Ser, Phe, Lys, Thr, Met, Tyr, His, Asp, Glu, Asn, Gln, Cys, Sec, Ile, Leu, Arg, Orn, Cit, Trp, 1-Me-Trp and Nva; and

R⁷ and R⁸ are each independently selected from hydrogen and methyl, or, when R⁷ is H, R⁶ and R⁸ together with the nitrogen atom carrying R⁸ form pyrrolidine ring (proline side chain);

or a pharmaceutically acceptable salt thereof.

2. A compound according to claim 1, having the Formula (Ia):



wherein:


R⁵ is selected from the group consisting of

H, -CH₃, -CH₂NH₂, -CH₂NHCH₃, -CH₂N(CH₃)₂, and -CH₂-pyrrolidiny; and

R⁶ is selected from the amino acid side chain of Gly, Ala, Val, Ser, Phe, Lys, Thr, Met, Tyr, His, Asp, Glu, Asn, Gln, Cys, Sec, Ile, Leu, Arg, Orn, Cit, Trp, 1-Me-Trp and Nva;

or a pharmaceutically acceptable salt thereof.

3. A compound according to claim 1, having the Formula (Ib):



wherein:

R⁶ is selected from the amino acid side chain of Gly, Ala, Val, Ser, Phe, Lys, Thr, Met,
 5 Tyr, His, Asp, Glu, Asn, Gln, Cys, Sec, Ile, Leu, Arg, Orn, Cit, Trp, 1-Me-Trp or
 Nva

or a pharmaceutically acceptable salt thereof.

4. A compound according to claim 1, wherein:

10 R⁵ is -CH₂NH₂ or -CH₂N(CH₃)₂ or -CH₂NHCH₃ or -CH₂N(CH₃)₂ or -CH₂N(CH₃)CH₂CH₃
 or -CH₂-pyrrolidinyl or -CH₂-azetidinyI or CH₂-piperidinyl.

5. A compound according to claim 1, wherein:

15 R⁶ is selected from the amino acid side chains of Gly, Ala, Val, Ser, Phe, Lys, Thr,
 Met, Tyr, His, Asp, Glu, Asn, Gln, Cys, Sec, Ile, Leu, Arg, Orn, Cit, Trp, 1-Me-
 Trp, and Nva.

6. A compound according to claim 1, wherein:

20 R⁶ is selected from the amino acid side chains of Gly, Ala, Val, Ser, Phe, Lys, Thr,
 Met, Tyr, His, Asp, Glu, Asn, Gln, Cys, Sec, Ile, Leu, Arg, Orn, Cit, Trp, and 1-Me-
 Trp.

7. A compound according to claim 1, wherein:

R¹ is H; R² is H; R³ is H; R⁴ is H; R⁷ is H; and R⁸ is H.

8. A compound according to claim 1, selected from the following compounds:

(3*R*,5*S*)-1-(*L*-alanyl)-3-amino-5-(2-boronoethyl)piperidine-3-carboxylic acid;

(3*S*,5*R*)-1-(*L*-alanyl)-3-amino-5-(2-boronoethyl)piperidine-3-carboxylic acid;

5 (3*R*,5*S*)-3-amino-5-(2-boronoethyl)-1-glycylpiperidine-3-carboxylic acid;

(3*R*,5*S*)-1-(*L*-proyl)-3-amino-5-(2-boronoethyl)piperidine-3-carboxylic acid;

(3*R*,5*S*)-1-(*L*-valyl)-3-amino-5-(2-boronoethyl)piperidine-3-carboxylic acid;

(3*R*,5*S*)-1-(*L*-seryl)-3-amino-5-(2-boronoethyl)piperidine-3-carboxylic acid;

(3*R*,5*S*)-1-(*L*-lysyl)-3-amino-5-(2-boronoethyl)piperidine-3-carboxylic acid;

10 (3*R*,5*S*)-1-(*L*-leucyl)-3-amino-5-(2-boronoethyl)piperidine-3-carboxylic acid;

(3*R*,5*S*)-1-(*L*-isoleucyl)-3-amino-5-(2-boronoethyl)piperidine-3-carboxylic acid; and

(3*R*,5*S*)-1-(*L*-tyrosyl)-3-amino-5-(2-boronoethyl)piperidine-3-carboxylic acid

(3*R*,5*S*)-1-(*L*-phenylalanyl)-3-amino-5-(2-boronoethyl)piperidine-3-carboxylic acid

(3*R*,5*S*)-1-(*L*-threonyl)-3-amino-5-(2-boronoethyl)piperidine-3-carboxylic acid

15 (3*R*,5*S*)-1-(*L*-histidyl)-3-amino-5-(2-boronoethyl)piperidine-3-carboxylic acid

(3*R*,5*S*)-1-(*L*-aspartyl)-3-amino-5-(2-boronoethyl)piperidine-3-carboxylic acid

(3*R*,5*S*)-1-(*L*-glutamyl)-3-amino-5-(2-boronoethyl)piperidine-3-carboxylic acid

(3*R*,5*S*)-1-(*L*-glutaminyl)-3-amino-5-(2-boronoethyl)piperidine-3-carboxylic acid

(3*R*,5*S*)-1-(*L*-methionyl)-3-amino-5-(2-boronoethyl)piperidine-3-carboxylic acid

20 (3*R*,5*S*)-1-(*L*-tryptophyl)-3-amino-5-(2-boronoethyl)piperidine-3-carboxylic acid

(3*R*,5*S*)-1-(*L*-cysteinyl)-3-amino-5-(2-boronoethyl)piperidine-3-carboxylic acid

(3*R*,5*S*)-1-(*L*-arginyl)-3-amino-5-(2-boronoethyl)piperidine-3-carboxylic acid

(3*R*,5*S*)-3-amino-1-((*S*)-2-amino-5-ureidopentanoyl)-5-(2-boronoethyl) piperidine-3-carboxylic acid

25 (3*R*,5*S*)-3-amino-5-(2-boronoethyl)-1-((*S*)-2,5-diaminopentanoyl)piperidine -3-carboxylic

(3*R*,5*S*)-1-(*D*-alanyl)-3-amino-5-(2-boronoethyl)piperidine-3-carboxylic acid

(3*R*,5*S*)-3-amino-5-(2-boronoethyl)-1-(1-methyl-D-tryptophyl)piperidine-3-carboxylic acid

(3*R*,5*S*)-3-amino-1-((*S*)-2-aminopentanoyl)-5-(2-boronoethyl)piperidine-3-carboxylic acid

5 (3*R*,5*S*)-1-(*L*-asparaginy)-3-amino-5-(2-boronoethyl)piperidine-3-carboxylic acid

(3*R*,5*S*)-3-amino-5-(2-boronoethyl)-1-(methylglycyl)piperidine-3-carboxylic acid

(2-((3*S*,5*R*)-1-(*L*-alanyl)-5-amino-5-(methoxycarbonyl)piperidin-3-yl)ethyl)boronic acid

(3*R*,5*S*)-1-(*L*-arginyl)-3-amino-5-(2-(4-carboxy-4-(carboxymethyl)-6-oxo-1,3,2-dioxaborinan-2-yl)ethyl)piperidine-3-carboxylic acid

10 (2*S*,3*R*,5*S*)-1-(*L*-alanyl)-3-amino-5-(2-boronoethyl)-2-methylpiperidine-3-carboxylic acid

(2*S*,3*R*,5*S*)-1-(*L*-Arginyl)-3-amino-5-(2-boronoethyl)-2-methylpiperidine-3-carboxylic acid

(3*R*,5*R*)-1-(*L*-alanyl)-3-amino-5-(2-boronoethyl)piperidine-3-carboxylic acid

15 (3*S*,5*S*)-1-(*L*-alanyl)-3-amino-5-(2-boronoethyl)piperidine-3-carboxylic acid

or a pharmaceutically acceptable salt thereof.

9. A pharmaceutical composition comprising (i) a therapeutically active amount of at least one compound as claimed in claim 1, or a pharmaceutically acceptable salt thereof;

20 and (ii) a pharmaceutically acceptable carrier, vehicle or excipient therefor.

10. A method for inhibiting arginase 1, arginase 2, or a combination thereof in a cell, comprising contacting the cell with at least one compound as claimed in claim 1, or a pharmaceutically acceptable salt thereof.

25

11. A method for the treatment of a disease or condition associated with expression or activity of arginase 1, arginase 2, or a combination thereof in a subject, comprising

administering to the subject a therapeutically effective amount of at least one compound as claimed in claim 1, or a pharmaceutically acceptable salt thereof.

12. Use of a compound according to claim 1, or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of a disease or condition associated with expression or activity of arginase 1, arginase 2, or a combination thereof.

13. A compound according to claim 1, or a pharmaceutically acceptable salt thereof for the treatment of a disease or condition associated with expression or activity of arginase 1, arginase 2, or a combination thereof.

14. A method according to claim 11, wherein the disease or condition is selected from the group consisting of cardiovascular disorders, pulmonary disorders, autoimmune disorders, immune disorders, hemolytic disorders, gastrointestinal disorders, sexual disorders, infections, cancers, and wound healing disorders.

15. A method according to claim 14, wherein the disease or condition is a cardiovascular disorder selected from the group consisting of systemic hypertension, pulmonary arterial hypertension (PAH), pulmonary arterial hypertension in high altitude, ischemia reperfusion (IR) injury, myocardial infarction, and atherosclerosis.

16. A method according to claim 15, wherein the disease or condition is pulmonary arterial hypertension (PAH).

17. A method according to claim 15, wherein the disease or condition is myocardial infarction or atherosclerosis.

18. A method according to claim 14, wherein the disease or condition is a pulmonary disorder selected from the group consisting of chemically-induced lung fibrosis, idiopathic pulmonary fibrosis, cystic fibrosis, chronic obstructive pulmonary disease (COPD), and asthma.

5

19. A method according to claim 14, wherein the disease or condition is an autoimmune disorder selected from the group consisting of encephalomyelitis, multiple sclerosis, anti-phospholipid syndrome 1, autoimmune hemolytic anemia, chronic inflammatory demyelinating polyradiculoneuropathy, dermatitis herpetiformis, dermatomyositis,

10 myasthenia gravis, pemphigus, rheumatoid arthritis, stiff-person syndrome, type 1 diabetes, ankylosing spondylitis, paroxysmal nocturnal hemoglobinuria (PNH), paroxysmal cold hemoglobinuria, severe idiopathic autoimmune hemolytic anemia, and Goodpasture's syndrome.

15 **20.** A method according to claim 14, wherein the disease or condition is an immune disorder selected from the group consisting of myeloid-derived suppressor cell (MDSC) mediated T-cell dysfunction, human immunodeficiency virus (HIV) infection, autoimmune encephalomyelitis, and ABO mismatch transfusion reaction.

20 **21.** A method according to claim 20, wherein the disease or condition is T-cell dysfunction mediated by myeloid-derived suppressor cells (MDSC).

22. A method according to claim 14, wherein the disease or condition is a hemolytic disorder selected from the group consisting of sickle-cell disease, thalassemias, hereditary
25 spherocytosis, stomatocytosis, microangiopathic hemolytic anemias, pyruvate kinase deficiency, infection-induced anemia, cardiopulmonary bypass, mechanical heart valve-induced anemia, and chemical-induced anemia.

23. A method according to claim 22, wherein the disease or condition is sickle-cell disease.

24. A method according to claim 14, wherein the disease or condition is a gastrointestinal disorder selected from the group consisting of gastrointestinal motility disorders, gastric cancers, inflammatory bowel disease, Crohn's disease, ulcerative colitis, and gastric ulcers.

25. A method according to claim 14, wherein the disease or condition is a sexual disorder selected from the group consisting of Peyronie's disease and erectile dysfunction.

26. A method according to claim 11, wherein the disease or condition is ischemia reperfusion (IR) injury selected from the group consisting of liver IR, kidney IR, and myocardial IR.

27. A method according to claim 14, wherein the disease or condition is a cancer selected from the group consisting of oesophagic, gastric, colon, ovary, breast, pancreatic, head-and-neck, bladder, and lung cancers, including squamous and non-small cell lung carcinoma, renal cell carcinoma, prostate carcinoma, multiple myeloma, neuroblastoma, glioblastoma, astrocytoma, mesothelioma and melanoma, B cell-, T cell-, and NK cell- lymphomas, acute and chronic, myeloid and lymphoid leukemia, gastroesophageal junction cancer, colorectal cancer, pancreatic cancer, liver cancer, breast cancer, lung cancers including non-small cell lung carcinoma, renal cell carcinoma, prostate carcinoma, multiple myeloma, acute and chronic leukemias, T cell, B cell and NK cell lymphomas, brain tumors including neuroblastoma, glioblastoma, and astrocytoma, squamous-cell carcinomas of the head and neck, melanoma, chronic lymphocytic leukemia, acute lymphoblastic leukemia, chronic myelogenous leukemia, acute myeloid leukemia, adrenocortical carcinoma, anal cancer, appendix cancer, atypical teratoid/rhabdoid tumor, basal cell carcinoma, bile duct cancer, bladder cancer, bone cancer, brain tumor, brain and spinal cord tumor, brain stem

glioma, central nervous system atypical teratoid/rhabdoid tumor, central nervous system embryonal tumors, breast cancer, bronchial tumors, Burkitt lymphoma, carcinoid tumor, carcinoma of unknown primary origin, central nervous system cancer, cervical cancer, childhood cancers, chordoma, chronic myeloproliferative disorders, colon cancer,

5 craniopharyngioma, cutaneous T-cell lymphoma, ductal carcinoma in situ, embryonal tumors, endometrial cancer, ependymoblastoma, ependymoma, esophageal cancer, esthesioneuroblastoma, Ewing sarcoma, extracranial germ cell tumor, extrahepatic bile duct cancer, eye cancer, fibrous histiocytoma of bone, gallbladder cancer, gastric cancer, gastrointestinal carcinoid tumor, gastrointestinal stromal tumors, germ cell tumor, extracranial

10 germ cell tumor, extragonadal germ cell tumor, ovarian germ cell tumor, gestational trophoblastic tumor, glioma, hairy cell leukemia, head and neck cancer, heart cancer, hepatocellular cancer, histiocytosis, Langerhans cell cancer, Hodgkin's lymphoma, hypopharyngeal cancer, intraocular melanoma, islet cell tumors, Kaposi sarcoma, kidney cancer, Langerhans cell histiocytosis, laryngeal cancer, lip and oral cavity cancer, lobular

15 carcinoma in situ, lymphoma, AIDS-related lymphoma, macroglobulinemia, male breast cancer, medulloblastoma, medulloepithelioma, Merkel cell carcinoma, malignant mesothelioma, metastatic squamous neck cancer, midline tract carcinoma involving NUT gene, mouth cancer, multiple endocrine neoplasia syndrome, plasma cell neoplasm, mycosis fungoides, myeloma, chronic myeloproliferative disorder, nasal cavity cancer, paranasal

20 sinus cancer, nasopharyngeal cancer, non-Hodgkin's lymphoma, oral cancer, oral cavity cancer, lip cancer, oropharyngeal cancer, osteosarcoma, ovarian cancer, papillomatosis, paraganglioma, paranasal sinus cancer, nasal cavity cancer, parathyroid cancer, penile cancer, pharyngeal cancer, pheochromocytoma, pineal parenchymal tumors of intermediate differentiation, pineoblastoma, pituitary tumor, plasma cell neoplasm, pleuropulmonary

25 blastoma, primary central nervous system lymphoma, rectal cancer, renal cell cancer, renal pelvis cancer, ureter cancer, transitional cell cancer, retinoblastoma, rhabdomyosarcoma, salivary gland cancer, sarcoma, Sézary syndrome, skin cancer, small cell lung cancer, small intestine cancer, soft tissue sarcoma, squamous cell carcinoma, squamous neck cancer with

occult primary, stomach cancer, supratentorial primitive neuroectodermal tumors, testicular cancer, throat cancer, thymoma, thymic carcinoma, thyroid cancer, transitional cell cancer of the renal pelvis and ureter, gestational trophoblastic tumor, unknown primary, unusual cancer of childhood, urethral cancer, uterine cancer, uterine sarcoma, Waldenströms

5 macroglobulinemia, and Wilms' tumor.

28. A method according to claim 11, wherein the disease or condition is selected from the group consisting of renal disease inflammation, psoriasis, leishmaniosis, neurodegenerative diseases, wound healing, human immunodeficiency virus (HIV) infection, hepatitis B virus
10 (HBV) infection, *Helicobacter pylori* infection, fibrotic disorders, arthritis, candidiasis, periodontal disease, keloids, adenotonsillar disease, African sleeping sickness, and Chagas' disease.

29. A method according to claim 14, wherein the disease or condition is a wound healing
15 disorder comprising infected and uninfected wound healing.

30. A method according to claim 11, wherein the at least one compound as claimed in claim 1 is administered simultaneously or sequentially with one or more other therapeutic agent(s) selected from the group consisting of steroids, membrane stabilizers, 5LO inhibitors,
20 leukotriene synthesis and receptor inhibitors, inhibitors of IgE isotype switching or IgE synthesis, IgG isotype switching or IgG synthesis, β -agonists, tryptase inhibitors, aspirin, COX inhibitors, methotrexate, anti-TNF drugs, rituximab, p38 inhibitors, PDE4 inhibitors, and antihistamines, immunotherapeutic agents, including checkpoint inhibitors such as PD-1, PD-L1, CTLA-4, LAG-3, TIM-3, TIGIT, VISTA inhibitors, IDO/TDO inhibitors, adenosine A2A
25 receptor antagonists, ectonucleotidase (CD73 and CD39) inhibitors, immunosuppressants, agents affecting interleukins, cytokines and chemokines, kinase inhibitors, chemotherapeutic agents including alkylating antineoplastic agents, antimetabolites, anti-microtubule agents, topoisomerase inhibitors, cytotoxic antibiotics or targeted therapies such as antibodies,

antibodies drug conjugates, cell-based immunotherapies, nanoparticles, anti-cancer vaccines, and radiotherapy.

31. A method according to claim 30, wherein the one or more additional

5 chemotherapeutic agents are selected from the group consisting of aminoglutethimide, amsacrine, anastrozole, asparaginase, AZD5363, Bacillus Calmette-Guerin vaccine (BCG), bicalutamide, bleomycin, bortezomib, buserelin, busulfan, camptothecin, capecitabine, carboplatin, carfilzomib, carmustine, chlorambucil, chloroquine, cisplatin, cladribine, clodronate, cobimetinib, colchicine, cyclophosphamide, cyproterone, cytarabine, 10 dacarbazine, dactinomycin, daunorubicin, demethoxyviridin, dexamethasone, dichloroacetate, dienestrol, diethylstilbestrol, docetaxel, doxorubicin, epirubicin, erlotinib, estradiol, estramustine, etoposide, everolimus, exemestane, filgrastim, fludarabine, fludrocortisone, fluorouracil, fluoxymesterone, flutamide, gemcitabine, genistein, goserelin, hydroxyurea, idarubicin, ifosfamide, imatinib, interferon, irinotecan, lenalidomide, letrozole, 15 leucovorin, leuprolide, levamisole, lomustine, lonidamine, mechlorethamine, medroxyprogesterone, megestrol, melphalan, mercaptopurine, mesna, metformin, methotrexate, miltefosine, mitomycin, mitotane, mitoxantrone, MK-2206, nilutamide, nocodazole, octreotide, olaparib, oxaliplatin, paclitaxel, pamidronate, pazopanib, pentostatin, perifosine, plicamycin, pomalidomide, porfimer, procarbazine, raltitrexed, rituximab, 20 rucaparib, selumetinib, sorafenib, streptozocin, sunitinib, suramin, talazoparib, tamoxifen, temozolomide, temsirolimus, teniposide, testosterone, thalidomide, thioguanine, thiotepa, titanocene dichloride, topotecan, trametinib, trastuzumab, tretinoin, veliparib, vinblastine, vincristine, vindesine, and vinorelbine.

25 **32.** A method according to claim 30, wherein the one or more additional

chemotherapeutic agents are selected from the group consisting of abagovomab, adecatumumab, afutuzumab, anatumomab mafenatox, apolizumab, avelumab, blinatumomab, catumaxomab, durvalumab, epratuzumab, inotuzumab ozogamicin,

intelumumab, ipilimumab, isatuximab, lambrolizumab, nivolumab, ocaratuzumab, olatumab, pembrolizumab, pidilizumab, ticilimumab, samalizumab, tremelimumab, and BMS-936559.


- 5 **33.** A method according to claim 30, wherein the one or more additional chemotherapeutic agents are selected from the group consisting of AB122, AB154, AB680, AB928, BMS-202, BMS-813160, BMS-986016, BMS-986205, BMS-986207, CA-170, CA-327, EOS200271, epacadostat, GDC-0919, LY3321367, 1-methyl-D-tryptophan, MGA012, MK-7684, OMP-313M32, PF-06840003, REGN2810, SHR-1210, and TSR-022.

10

34. A method according to claim 30, wherein the one or more additional chemotherapeutic agents are selected from the group consisting of atezolizumab, avelumab, durvalumab, ipilimumab, nivolumab, pembrolizumab, and pidilizumab.

- 15 **35.** A method according to claim 30, wherein the one additional chemotherapeutic agent is hydroxyurea.

36. A process for preparing a compound of Formula Ib:




20 or a precursor thereof, wherein:

R⁶ is selected from the amino acid side chain of Gly, Ala, Val, Ser, Phe, Lys, Thr, Met, Tyr, His, Asp, Glu, Asn, Gln, Cys, Sec, Ile, Leu, Arg, Orn, Cit, Trp; 1-Me-Trp and Nva;

or a pharmaceutically acceptable salt thereof;

comprising:


(a) reducing an ester of the formula




where

5 P_g is methyl substituted with 1, 2, or 3 phenyl groups, where each phenyl group is optionally substituted with 1, 2 or 3 groups independently selected from halogen, nitro, C_1 - C_6 alkoxy, or C_1 - C_6 alkyl;


10 R^E is C_1 - C_6 alkyl, C_3 - C_6 cycloalkyl, C_3 - C_6 cycloalkyl(C_1 - C_6)alkyl, or methyl substituted with 1, 2, or 3 phenyl groups, where each phenyl group is optionally substituted with 1, 2 or 3 groups independently selected from halogen, nitro, C_1 - C_6 alkoxy, or C_1 - C_6 alkyl to yield a protected hydroxymethylpyrrolidine of the formula:




15 (b) subjecting the protected hydroxymethylpyrrolidine to ring expansion conditions to produce a protected piperidine of the formula:




(c) oxidizing the protected piperidine to form an enantiomerically enriched product comprising a ketone of the formula:



(d) reacting the ketone with cyanide and an amine source to yield an α -cyanoamine of the formula:




5 (e) acylating the amino group of the α -cyanoamine to produce an acylated α -cyanoamine of the formula:



wherein R^N is C_2 - C_6 alkanoyl.

10 **37.** A process according to claim 36, further comprising


- (f) subjecting the acylated α -cyanoamine to hydroboration conditions; and
- (g) deprotecting the resulting cyclic boronate ester to produce a boronic acid of the formula:



15

38. A process according to claim 37, further comprising


- (h) hydrolyzing the acyl group to yield an α -amino acid with an unprotected amino group; and
- (i) protecting the amino group of the α -amino acid to generate a boronic acid of Formula B-1:

B-1

wherein R^N represents a nitrogen protecting group.

39. A process according to claim 38, further comprising reacting the compound of formula

10 B-1 with a compound of the formula:



wherein


L is a leaving group, such as *N*-hydroxysuccinimidyl or carboxylate or carbonate;

Pg^1 is a nitrogen protecting group;

15 R^6 represents a side chain of an amino acid selected from the group consisting of Gly, Ala, Val, Ser, Phe, Lys, Thr, Met, Tyr, His, Asp, Glu, Asn, Gln, Cys, Sec, Ile, Leu, Arg, Orn, Cit, Trp; 1-Me-Trp and Nva; and

R^7 is hydrogen or methyl.

20 40. A compound of Formula II:



II

wherein

R^{21} is hydrogen, C_1 - C_6 alkyl, or R^N , wherein R^N is a nitrogen protecting group; and

R^{22} is hydrogen, C_1 - C_6 alkyl, or Pg, wherein Pg is a nitrogen protecting group


5 which may be the same as or different than R^N .

41. A compound according to claim 40, wherein R^{22} is benzyl, 4-methylbenzyl, 4-methoxybenzyl, 4-bromobenzyl, 4-nitrobenzyl, 3-methylbenzyl, 2-methylbenzyl, 3,4-dimethoxybenzyl, 2,4,6-trimethylbenzyl, benzhydryl, or trityl.

10

42. A compound according to claim 40 or 41, wherein R^N is acetyl, benzyloxycarbonyl, or t-butoxycarbonyl.

43. A compound of Formula III:



15

III

wherein

R^{23} is hydrogen, C_1 - C_6 alkyl, or R^N , wherein R^N is a nitrogen protecting group; and

R^{24} is hydrogen, C_1 - C_6 alkyl, or Pg, wherein Pg is a nitrogen protecting group

20 which may be the same as or different than R^N .

44. A compound according to claim 43, wherein R^N is acetyl, benzyloxycarbonyl, or t-butoxycarbonyl.


45. A compound according to claim 43 or 44, wherein R^{24} is benzyl, 4-methylbenzyl, 4-methoxybenzyl, 4-bromobenzyl, 4-nitrobenzyl, 3-methylbenzyl, 2-methylbenzyl, 3,4-dimethoxybenzyl, 2,4,6-trimethylbenzyl, benzhydryl, or trityl.

AMENDED CLAIMS

received by the International Bureau on 27 August 2019 (27.08.2019)

WHAT IS CLAIMED IS:

1. A compound of the Formula (I):



wherein:

R¹ is selected from the group consisting of H, straight-chain or branched (C₁-C₆)alkyl, HC(O)-, and (C₁-C₆)alkyl-C(O)-;

R² and R³ are each independently selected from hydrogen, straight-chain or branched (C₁-C₆)alkyl or (C₁-C₆)alkyl-C(O)-,

or R² and R³ taken together with the boron atom and oxygen atoms to which they are bound form a 4-, 5-, 6- or 7- membered ring that is fully saturated, or partially saturated,

or R² and R³ taken together with the boron atom and oxygen atoms to which they are bound form a diester of the boronic acid and polyalcohols selected from: pinanediol, mannitol, glycerol, xylitol, sorbitol, or erythritol,

or R² and R³ taken together with the boron atom and oxygen atoms to which they are bound form an anhydride or mixed ester-anhydride of the boronic acid and hydroxy acids or di-carboxylic acids selected from: iminodiacetic acid or *N*-methyliminodiacetic acid or oxalic acid or tartaric acid or citric acid or malic acid or malonic acid or mandelic acid or glycolic acid or lactic acid or 3-hydroxypropionic acid;

R⁴ is selected from the group consisting of H, straight-chain and branched (C₁-C₆)alkyl;


R⁵ is selected from the group consisting of H, F, methyl, ethyl, propyl, isopropyl, -CH₂NH₂, -CH₂NHCH₃, -CH₂NHCH₂CH₃, -CH₂NHCH(CH₃)₂, -CH₂N(CH₃)₂, -CH₂N(CH₃)CH₂CH₃, -CH₂N(CH₂CH₃)₂, -CH₂N(CH₃)CH(CH₃)₂, -CH₂-azetidiny, -CH₂-pyrrolidiny, and -CH₂-piperidiny;

R⁶ is selected from the amino acid side chains of Gly, Ala, Val, Ser, Phe, Lys, Thr, Met, Tyr, His, Asp, Glu, Asn, Gln, Cys, Sec, Ile, Leu, Arg, Orn, Cit, Trp, 1-Me-Trp and Nva; and

R⁷ and R⁸ are each independently selected from hydrogen and methyl, or, when R⁷ is H, R⁶ and R⁸ together with the nitrogen atom carrying R⁸ form pyrrolidine ring (proline side chain);

or a pharmaceutically acceptable salt thereof.

2. A compound according to claim 1, having the Formula (Ia):



wherein:


R⁵ is selected from the group consisting of

H, -CH₃, -CH₂NH₂, -CH₂NHCH₃, -CH₂N(CH₃)₂, and -CH₂-pyrrolidiny; and

R⁶ is selected from the amino acid side chain of Gly, Ala, Val, Ser, Phe, Lys, Thr, Met, Tyr, His, Asp, Glu, Asn, Gln, Cys, Sec, Ile, Leu, Arg, Orn, Cit, Trp, 1-Me-Trp and Nva;

or a pharmaceutically acceptable salt thereof.

3. A compound according to claim 1, having the Formula (Ib):



wherein:

R⁶ is selected from the amino acid side chain of Gly, Ala, Val, Ser, Phe, Lys, Thr, Met,
 5 Tyr, His, Asp, Glu, Asn, Gln, Cys, Sec, Ile, Leu, Arg, Orn, Cit, Trp, 1-Me-Trp or
 Nva

or a pharmaceutically acceptable salt thereof.

4. A compound according to claim 1, wherein:

10 R⁵ is -CH₂NH₂ or -CH₂N(CH₃)₂ or -CH₂NHCH₃ or -CH₂N(CH₃)₂ or -CH₂N(CH₃)CH₂CH₃
 or -CH₂-pyrrolidinyl or -CH₂-azetidinyll or CH₂-piperidinyl.

5. A compound according to claim 1, wherein:

15 R⁶ is selected from the amino acid side chains of Gly, Ala, Val, Ser, Phe, Lys, Thr,
 Met, Tyr, His, Asp, Glu, Asn, Gln, Cys, Sec, Ile, Leu, Arg, Orn, Cit, Trp, 1-Me-
 Trp, and Nva.

6. A compound according to claim 1, wherein:

20 R⁶ is selected from the amino acid side chains of Gly, Ala, Val, Ser, Phe, Lys, Thr,
 Met, Tyr, His, Asp, Glu, Asn, Gln, Cys, Sec, Ile, Leu, Arg, Orn, Cit, Trp, and 1-Me-
 Trp.

7. A compound according to claim 1, wherein:

R¹ is H; R² is H; R³ is H; R⁴ is H; R⁷ is H; and R⁸ is H.

8. A compound according to claim 1, selected from the following compounds:

(3*R*,5*S*)-1-(*L*-alanyl)-3-amino-5-(2-boronoethyl)piperidine-3-carboxylic acid;

(3*S*,5*R*)-1-(*L*-alanyl)-3-amino-5-(2-boronoethyl)piperidine-3-carboxylic acid;

5 (3*R*,5*S*)-3-amino-5-(2-boronoethyl)-1-glycylpiperidine-3-carboxylic acid;

(3*R*,5*S*)-1-(*L*-prolyl)-3-amino-5-(2-boronoethyl)piperidine-3-carboxylic acid;

(3*R*,5*S*)-1-(*L*-valyl)-3-amino-5-(2-boronoethyl)piperidine-3-carboxylic acid;

(3*R*,5*S*)-1-(*L*-seryl)-3-amino-5-(2-boronoethyl)piperidine-3-carboxylic acid;

(3*R*,5*S*)-1-(*L*-lysyl)-3-amino-5-(2-boronoethyl)piperidine-3-carboxylic acid;

10 (3*R*,5*S*)-1-(*L*-leucyl)-3-amino-5-(2-boronoethyl)piperidine-3-carboxylic acid;

(3*R*,5*S*)-1-(*L*-isoleucyl)-3-amino-5-(2-boronoethyl)piperidine-3-carboxylic acid; and

(3*R*,5*S*)-1-(*L*-tyrosyl)-3-amino-5-(2-boronoethyl)piperidine-3-carboxylic acid

(3*R*,5*S*)-1-(*L*-phenylalanyl)-3-amino-5-(2-boronoethyl)piperidine-3-carboxylic acid

(3*R*,5*S*)-1-(*L*-threonyl)-3-amino-5-(2-boronoethyl)piperidine-3-carboxylic acid

15 (3*R*,5*S*)-1-(*L*-histidyl)-3-amino-5-(2-boronoethyl)piperidine-3-carboxylic acid

(3*R*,5*S*)-1-(*L*-aspartyl)-3-amino-5-(2-boronoethyl)piperidine-3-carboxylic acid

(3*R*,5*S*)-1-(*L*-glutamyl)-3-amino-5-(2-boronoethyl)piperidine-3-carboxylic acid

(3*R*,5*S*)-1-(*L*-glutaminy)-3-amino-5-(2-boronoethyl)piperidine-3-carboxylic acid

(3*R*,5*S*)-1-(*L*-methionyl)-3-amino-5-(2-boronoethyl)piperidine-3-carboxylic acid

20 (3*R*,5*S*)-1-(*L*-tryptophyl)-3-amino-5-(2-boronoethyl)piperidine-3-carboxylic acid

(3*R*,5*S*)-1-(*L*-cysteinyl)-3-amino-5-(2-boronoethyl)piperidine-3-carboxylic acid

(3*R*,5*S*)-1-(*L*-arginyl)-3-amino-5-(2-boronoethyl)piperidine-3-carboxylic acid

(3*R*,5*S*)-3-amino-1-((*S*)-2-amino-5-ureidopentanoyl)-5-(2-boronoethyl) piperidine-3-carboxylic acid

25 (3*R*,5*S*)-3-amino-5-(2-boronoethyl)-1-((*S*)-2,5-diaminopentanoyl)piperidine -3-carboxylic

(3*R*,5*S*)-1-(*D*-alanyl)-3-amino-5-(2-boronoethyl)piperidine-3-carboxylic acid

(3*R*,5*S*)-3-amino-5-(2-boronoethyl)-1-(1-methyl-D-tryptophyl)piperidine-3-carboxylic acid

(3*R*,5*S*)-3-amino-1-((*S*)-2-aminopentanoyl)-5-(2-boronoethyl)piperidine-3-carboxylic acid

5 (3*R*,5*S*)-1-(*L*-asparaginy)-3-amino-5-(2-boronoethyl)piperidine-3-carboxylic acid

(3*R*,5*S*)-3-amino-5-(2-boronoethyl)-1-(methylglycyl)piperidine-3-carboxylic acid

(2-((3*S*,5*R*)-1-(*L*-alanyl)-5-amino-5-(methoxycarbonyl)piperidin-3-yl)ethyl)boronic acid

(3*R*,5*S*)-1-(*L*-arginyl)-3-amino-5-(2-(4-carboxy-4-(carboxymethyl)-6-oxo-1,3,2-dioxaborinan-2-yl)ethyl)piperidine-3-carboxylic acid

10 (2*S*,3*R*,5*S*)-1-(*L*-alanyl)-3-amino-5-(2-boronoethyl)-2-methylpiperidine-3-carboxylic acid

(2*S*,3*R*,5*S*)-1-(*L*-Arginyl)-3-amino-5-(2-boronoethyl)-2-methylpiperidine-3-carboxylic acid

(3*R*,5*R*)-1-(*L*-alanyl)-3-amino-5-(2-boronoethyl)piperidine-3-carboxylic acid

15 (3*S*,5*S*)-1-(*L*-alanyl)-3-amino-5-(2-boronoethyl)piperidine-3-carboxylic acid

or a pharmaceutically acceptable salt thereof.

9. A pharmaceutical composition comprising (i) a therapeutically active amount of at least one compound as claimed in claim 1, or a pharmaceutically acceptable salt thereof;
20 and (ii) a pharmaceutically acceptable carrier, vehicle or excipient therefor.

10. A method for inhibiting arginase 1, arginase 2, or a combination thereof in a cell, comprising contacting the cell with at least one compound as claimed in claim 1, or a pharmaceutically acceptable salt thereof.

25

11. A method for the treatment of a disease or condition associated with expression or activity of arginase 1, arginase 2, or a combination thereof in a subject, comprising

administering to the subject a therapeutically effective amount of at least one compound as claimed in claim 1, or a pharmaceutically acceptable salt thereof.

12. Use of a compound according to claim 1, or a pharmaceutically acceptable salt

5 thereof in the manufacture of a medicament for the treatment of a disease or condition associated with expression or activity of arginase 1, arginase 2, or a combination thereof.

13. A compound according to claim 1, or a pharmaceutically acceptable salt thereof for the treatment of a disease or condition associated with expression or activity of arginase 1,

10 arginase 2, or a combination thereof.

14. A method according to claim 11, wherein the disease or condition is selected from the group consisting of cardiovascular disorders, pulmonary disorders, autoimmune disorders, immune disorders, hemolytic disorders, gastrointestinal disorders, sexual disorders,

15 infections, cancers, and wound healing disorders.

15. A method according to claim 14, wherein the disease or condition is a cardiovascular disorder selected from the group consisting of systemic hypertension, pulmonary arterial hypertension (PAH), pulmonary arterial hypertension in high altitude, ischemia reperfusion

20 (IR) injury, myocardial infarction, and atherosclerosis.

16. A method according to claim 15, wherein the disease or condition is pulmonary arterial hypertension (PAH).

25 **17.** A method according to claim 15, wherein the disease or condition is myocardial infarction or atherosclerosis.

18. A method according to claim 14, wherein the disease or condition is a pulmonary disorder selected from the group consisting of chemically-induced lung fibrosis, idiopathic pulmonary fibrosis, cystic fibrosis, chronic obstructive pulmonary disease (COPD), and asthma.

5

19. A method according to claim 14, wherein the disease or condition is an autoimmune disorder selected from the group consisting of encephalomyelitis, multiple sclerosis, anti-phospholipid syndrome 1, autoimmune hemolytic anemia, chronic inflammatory demyelinating polyradiculoneuropathy, dermatitis herpetiformis, dermatomyositis,

10 myasthenia gravis, pemphigus, rheumatoid arthritis, stiff-person syndrome, type 1 diabetes, ankylosing spondylitis, paroxysmal nocturnal hemoglobinuria (PNH), paroxysmal cold hemoglobinuria, severe idiopathic autoimmune hemolytic anemia, and Goodpasture's syndrome.

15 **20.** A method according to claim 14, wherein the disease or condition is an immune disorder selected from the group consisting of myeloid-derived suppressor cell (MDSC) mediated T-cell dysfunction, human immunodeficiency virus (HIV) infection, autoimmune encephalomyelitis, and ABO mismatch transfusion reaction.

20 **21.** A method according to claim 20, wherein the disease or condition is T-cell dysfunction mediated by myeloid-derived suppressor cells (MDSC).

22. A method according to claim 14, wherein the disease or condition is a hemolytic disorder selected from the group consisting of sickle-cell disease, thalassemias, hereditary
25 spherocytosis, stomatocytosis, microangiopathic hemolytic anemias, pyruvate kinase deficiency, infection-induced anemia, cardiopulmonary bypass, mechanical heart valve-induced anemia, and chemical-induced anemia.

23. A method according to claim 22, wherein the disease or condition is sickle-cell disease.

24. A method according to claim 14, wherein the disease or condition is a gastrointestinal disorder selected from the group consisting of gastrointestinal motility disorders, gastric cancers, inflammatory bowel disease, Crohn's disease, ulcerative colitis, and gastric ulcers.

25. A method according to claim 14, wherein the disease or condition is a sexual disorder selected from the group consisting of Peyronie's disease and erectile dysfunction.

26. A method according to claim 11, wherein the disease or condition is ischemia reperfusion (IR) injury selected from the group consisting of liver IR, kidney IR, and myocardial IR.

27. A method according to claim 14, wherein the disease or condition is a cancer selected from the group consisting of oesophagic, gastric, colon, ovary, breast, pancreatic, head-and-neck, bladder, and lung cancers, including squamous and non-small cell lung carcinoma, renal cell carcinoma, prostate carcinoma, multiple myeloma, neuroblastoma, glioblastoma, astrocytoma, mesothelioma and melanoma, B cell-, T cell-, and NK cell- lymphomas, acute and chronic, myeloid and lymphoid leukemia, gastroesophageal junction cancer, colorectal cancer, pancreatic cancer, liver cancer, breast cancer, lung cancers including non-small cell lung carcinoma, renal cell carcinoma, prostate carcinoma, multiple myeloma, acute and chronic leukemias, T cell, B cell and NK cell lymphomas, brain tumors including neuroblastoma, glioblastoma, and astrocytoma, squamous-cell carcinomas of the head and neck, melanoma, chronic lymphocytic leukemia, acute lymphoblastic leukemia, chronic myelogenous leukemia, acute myeloid leukemia, adrenocortical carcinoma, anal cancer, appendix cancer, atypical teratoid/rhabdoid tumor, basal cell carcinoma, bile duct cancer, bladder cancer, bone cancer, brain tumor, brain and spinal cord tumor, brain stem

glioma, central nervous system atypical teratoid/rhabdoid tumor, central nervous system embryonal tumors, breast cancer, bronchial tumors, Burkitt lymphoma, carcinoid tumor, carcinoma of unknown primary origin, central nervous system cancer, cervical cancer, childhood cancers, chordoma, chronic myeloproliferative disorders, colon cancer,

5 craniopharyngioma, cutaneous T-cell lymphoma, ductal carcinoma in situ, embryonal tumors, endometrial cancer, ependymoblastoma, ependymoma, esophageal cancer, esthesioneuroblastoma, Ewing sarcoma, extracranial germ cell tumor, extrahepatic bile duct cancer, eye cancer, fibrous histiocytoma of bone, gallbladder cancer, gastric cancer, gastrointestinal carcinoid tumor, gastrointestinal stromal tumors, germ cell tumor, extracranial

10 germ cell tumor, extragonadal germ cell tumor, ovarian germ cell tumor, gestational trophoblastic tumor, glioma, hairy cell leukemia, head and neck cancer, heart cancer, hepatocellular cancer, histiocytosis, Langerhans cell cancer, Hodgkin's lymphoma, hypopharyngeal cancer, intraocular melanoma, islet cell tumors, Kaposi sarcoma, kidney cancer, Langerhans cell histiocytosis, laryngeal cancer, lip and oral cavity cancer, lobular

15 carcinoma in situ, lymphoma, AIDS-related lymphoma, macroglobulinemia, male breast cancer, medulloblastoma, medulloepithelioma, Merkel cell carcinoma, malignant mesothelioma, metastatic squamous neck cancer, midline tract carcinoma involving NUT gene, mouth cancer, multiple endocrine neoplasia syndrome, plasma cell neoplasm, mycosis fungoides, myeloma, chronic myeloproliferative disorder, nasal cavity cancer, paranasal

20 sinus cancer, nasopharyngeal cancer, non-Hodgkin's lymphoma, oral cancer, oral cavity cancer, lip cancer, oropharyngeal cancer, osteosarcoma, ovarian cancer, papillomatosis, paraganglioma, paranasal sinus cancer, nasal cavity cancer, parathyroid cancer, penile cancer, pharyngeal cancer, pheochromocytoma, pineal parenchymal tumors of intermediate differentiation, pineoblastoma, pituitary tumor, plasma cell neoplasm, pleuropulmonary

25 blastoma, primary central nervous system lymphoma, rectal cancer, renal cell cancer, renal pelvis cancer, ureter cancer, transitional cell cancer, retinoblastoma, rhabdomyosarcoma, salivary gland cancer, sarcoma, Sézary syndrome, skin cancer, small cell lung cancer, small intestine cancer, soft tissue sarcoma, squamous cell carcinoma, squamous neck cancer with

occult primary, stomach cancer, supratentorial primitive neuroectodermal tumors, testicular cancer, throat cancer, thymoma, thymic carcinoma, thyroid cancer, transitional cell cancer of the renal pelvis and ureter, gestational trophoblastic tumor, unknown primary, unusual cancer of childhood, urethral cancer, uterine cancer, uterine sarcoma, Waldenströms

5 macroglobulinemia, and Wilms' tumor.

28. A method according to claim 11, wherein the disease or condition is selected from the group consisting of renal disease inflammation, psoriasis, leishmaniosis, neurodegenerative diseases, wound healing, human immunodeficiency virus (HIV) infection, hepatitis B virus
10 (HBV) infection, *Helicobacter pylori* infection, fibrotic disorders, arthritis, candidiasis, periodontal disease, keloids, adenotonsillar disease, African sleeping sickness, and Chagas' disease.

29. A method according to claim 14, wherein the disease or condition is a wound healing
15 disorder comprising infected and uninfected wound healing.

30. A method according to claim 11, wherein the at least one compound as claimed in claim 1 is administered simultaneously or sequentially with one or more other therapeutic agent(s) selected from the group consisting of steroids, membrane stabilizers, 5LO inhibitors,
20 leukotriene synthesis and receptor inhibitors, inhibitors of IgE isotype switching or IgE synthesis, IgG isotype switching or IgG synthesis, β -agonists, tryptase inhibitors, aspirin, COX inhibitors, methotrexate, anti-TNF drugs, rituximab, p38 inhibitors, PDE4 inhibitors, and antihistamines, immunotherapeutic agents, including checkpoint inhibitors such as PD-1, PD-L1, CTLA-4, LAG-3, TIM-3, TIGIT, VISTA inhibitors, IDO/TDO inhibitors, adenosine A2A
25 receptor antagonists, ectonucleotidase (CD73 and CD39) inhibitors, immunosuppressants, agents affecting interleukins, cytokines and chemokines, kinase inhibitors, chemotherapeutic agents including alkylating antineoplastic agents, antimetabolites, anti-microtubule agents, topoisomerase inhibitors, cytotoxic antibiotics or targeted therapies such as antibodies,

antibodies drug conjugates, cell-based immunotherapies, nanoparticles, anti-cancer vaccines, and radiotherapy.

31. A method according to claim 30, wherein the one or more additional

5 chemotherapeutic agents are selected from the group consisting of aminoglutethimide, amsacrine, anastrozole, asparaginase, AZD5363, Bacillus Calmette-Guerin vaccine (BCG), bicalutamide, bleomycin, bortezomib, buserelin, busulfan, camptothecin, capecitabine, carboplatin, carfilzomib, carmustine, chlorambucil, chloroquine, cisplatin, cladribine, clodronate, cobimetinib, colchicine, cyclophosphamide, cyproterone, cytarabine, 10 dacarbazine, dactinomycin, daunorubicin, demethoxyviridin, dexamethasone, dichloroacetate, dienestrol, diethylstilbestrol, docetaxel, doxorubicin, epirubicin, erlotinib, estradiol, estramustine, etoposide, everolimus, exemestane, filgrastim, fludarabine, fludrocortisone, fluorouracil, fluoxymesterone, flutamide, gemcitabine, genistein, goserelin, hydroxyurea, idarubicin, ifosfamide, imatinib, interferon, irinotecan, lenalidomide, letrozole, 15 leucovorin, leuprolide, levamisole, lomustine, lonidamine, mechlorethamine, medroxyprogesterone, megestrol, melphalan, mercaptopurine, mesna, metformin, methotrexate, miltefosine, mitomycin, mitotane, mitoxantrone, MK-2206, nilutamide, nocodazole, octreotide, olaparib, oxaliplatin, paclitaxel, pamidronate, pazopanib, pentostatin, perifosine, plicamycin, pomalidomide, porfimer, procarbazine, raltitrexed, rituximab, 20 rucaparib, selumetinib, sorafenib, streptozocin, sunitinib, suramin, talazoparib, tamoxifen, temozolomide, temsirolimus, teniposide, testosterone, thalidomide, thioguanine, thiotepa, titanocene dichloride, topotecan, trametinib, trastuzumab, tretinoin, veliparib, vinblastine, vincristine, vindesine, and vinorelbine.

25 **32.** A method according to claim 30, wherein the one or more additional

chemotherapeutic agents are selected from the group consisting of abagovomab, adecatumumab, afutuzumab, anatumomab mafenatox, apolizumab, avelumab, blinatumomab, catumaxomab, durvalumab, epratuzumab, inotuzumab ozogamicin,

intelumumab, ipilimumab, isatuximab, lambrolizumab, nivolumab, ocaratuzumab, olatumab, pembrolizumab, pidilizumab, ticilimumab, samalizumab, tremelimumab, and BMS-936559.


- 5 **33.** A method according to claim 30, wherein the one or more additional chemotherapeutic agents are selected from the group consisting of AB122, AB154, AB680, AB928, BMS-202, BMS-813160, BMS-986016, BMS-986205, BMS-986207, CA-170, CA-327, EOS200271, epacadostat, GDC-0919, LY3321367, 1-methyl-D-tryptophan, MGA012, MK-7684, OMP-313M32, PF-06840003, REGN2810, SHR-1210, and TSR-022.

10

- 34.** A method according to claim 30, wherein the one or more additional chemotherapeutic agents are selected from the group consisting of atezolizumab, avelumab, durvalumab, ipilimumab, nivolumab, pembrolizumab, and pidilizumab.

- 15 **35.** A method according to claim 30, wherein the one additional chemotherapeutic agent is hydroxyurea.

- 36.** A process for preparing a compound of Formula Ib:




- 20 or a precursor thereof, wherein:

R⁶ is selected from the amino acid side chain of Gly, Ala, Val, Ser, Phe, Lys, Thr, Met, Tyr, His, Asp, Glu, Asn, Gln, Cys, Sec, Ile, Leu, Arg, Orn, Cit, Trp; 1-Me-Trp and Nva;

or a pharmaceutically acceptable salt thereof;

comprising:


(a) reducing an ester of the formula




where

5 P_g is methyl substituted with 1, 2, or 3 phenyl groups, where each phenyl group is optionally substituted with 1, 2 or 3 groups independently selected from halogen, nitro, C_1 - C_6 alkoxy, or C_1 - C_6 alkyl;


R^E is C_1 - C_6 alkyl, C_3 - C_6 cycloalkyl, C_3 - C_6 cycloalkyl(C_1 - C_6)alkyl, or methyl substituted with 1, 2, or 3 phenyl groups, where each phenyl group is
10 optionally substituted with 1, 2 or 3 groups independently selected from halogen, nitro, C_1 - C_6 alkoxy, or C_1 - C_6 alkyl to yield a protected hydroxymethylpyrrolidine of the formula:




(b) subjecting the protected hydroxymethylpyrrolidine to ring expansion conditions to
15 produce a protected piperidine of the formula:




(c) oxidizing the protected piperidine to form an enantiomerically enriched product comprising a ketone of the formula:



(d) reacting the ketone with cyanide and an amine source to yield an α -cyanoamine of the formula:




5 (e) acylating the amino group of the α -cyanoamine to produce an acylated α -cyanoamine of the formula:



wherein R^N is C_2 - C_6 alkanoyl.

10 **37.** A process according to claim 36, further comprising


- (f) subjecting the acylated α -cyanoamine to hydroboration conditions; and
- (g) deprotecting the resulting cyclic boronate ester to produce a boronic acid of the formula:



15

38. A process according to claim 37, further comprising


- (h) hydrolyzing the acyl group and the cyano group to yield an α -amino acid with an unprotected amino group; and
- (i) protecting the amino group of the α -amino acid to generate a boronic acid of Formula B-1:

B-1

wherein R^N represents a nitrogen protecting group.

39. A process according to claim 38, further comprising

- (j) deprotecting the piperidine nitrogen of the compound of formula B-1 under hydrogenolytic conditions; and
- (k) amidating the intermediate with a compound of the formula:



wherein

L is a leaving group, such as *N*-hydroxysuccinimidyl or carboxylate or carbonate;

Pg^1 is a nitrogen protecting group;


R^6 represents a side chain of an amino acid selected from the group consisting of Gly, Ala,

Val, Ser, Phe, Lys, Thr, Met, Tyr, His, Asp, Glu, Asn, Gln, Cys, Sec, Ile, Leu, Arg,

Orn, Cit, Trp; 1-Me-Trp and Nva; and

R^7 is hydrogen or methyl.

40. A compound of Formula II:



II

wherein


R^{21} is hydrogen, C_1 - C_6 alkyl, or R^N , wherein R^N is a nitrogen protecting group; and

5 R^{22} is hydrogen, C_1 - C_6 alkyl, or Pg, wherein Pg is a nitrogen protecting group which may be the same as or different than R^N .

10 **41.** A compound according to claim 40, wherein R^{22} is benzyl, 4-methylbenzyl, 4-methoxybenzyl, 4-bromobenzyl, 4-nitrobenzyl, 3-methylbenzyl, 2-methylbenzyl, 3,4-dimethoxybenzyl, 2,4,6-trimethylbenzyl, benzhydryl, or trityl.

42. A compound according to claim 40 or 41, wherein R^N is acetyl, benzyloxycarbonyl, or t-butoxycarbonyl.

15 **43.** A compound of Formula III:



III

wherein

R^{23} is hydrogen, C_1 - C_6 alkyl, or R^N , wherein R^N is a nitrogen protecting group; and

20 R^{24} is hydrogen, C_1 - C_6 alkyl, or Pg, wherein Pg is a nitrogen protecting group which may be the same as or different than R^N .

44. A compound according to claim 43, wherein R^N is acetyl, benzyloxycarbonyl, or t-butoxycarbonyl.

45. A compound according to claim 43 or 44, wherein R^{24} is benzyl, 4-methylbenzyl, 4-methoxybenzyl, 4-bromobenzyl, 4-nitrobenzyl, 3-methylbenzyl, 2-methylbenzyl, 3,4-dimethoxybenzyl, 2,4,6-trimethylbenzyl, benzhydryl, or trityl.


Fig. 1

Fig. 2




Fig. 3

Pharmacokinetics
in Sprague-Dawley male rats
after IV administration (3 mg/kg)




Fig. 4

Pharmacokinetics
in Sprague-Dawley male rats
after PO administration (10 mg/kg)




Fig. 5

Arginine levels (PD effect)
in Sprague-Dawley male rats
after IV administration (3 mg/kg)





Fig. 6

Arginine levels (PD effect)
in Sprague-Dawley male rats
after PO administration (10 mg/kg)



INTERNATIONAL SEARCH REPORT

International application No

PCT/IB2019/052616

A. CLASSIFICATION OF SUBJECT MATTER

INV. C07K5/02 C07D211/60 C07F5/02
ADD.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

C07K C07D C07F

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-Internal, BIOSIS, CHEM ABS Data, EMBASE, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 2017/191130 A2 (ONCOARENDI THERAPEUTICS SA [PL]) 9 November 2017 (2017-11-09) examples 57-59 -----	1-45



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

20 June 2019

Date of mailing of the international search report

27/06/2019

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040,
Fax: (+31-70) 340-3016

Authorized officer

Schleifenbaum, A

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/IB2019/052616

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2017191130 A2	09-11-2017	AU 2017259887 A1	27-09-2018
		CA 3022482 A1	09-11-2017
		CL 2018003132 A1	22-02-2019
		CN 109415387 A	01-03-2019
		CO 2018013077 A2	30-04-2019
		EP 3452485 A2	13-03-2019
		KR 20190015250 A	13-02-2019
		PE 19242018 A1	11-12-2018
		SG 11201807974Q A	30-10-2018
		US 2017319536 A1	09-11-2017
		WO 2017191130 A2	09-11-2017
